Artificial Intelligence for Hard-to-Treat and Unknown-Origin Cancers

Authors:

Mehrdad Farrokhi
ERIS Research Institute

Niloofar Taheri
Shahroud University of Medical Sciences

Omid Fakharzadeh Moghadam
Mashhad University of Medical Sciences

Mahdi Armoon
K. N. Toosi University of Technology

Susan Samimi
Shiraz University of Medical Sciences

Narges Torkashvand
Tehran University of Medical Sciences

Saeed Motevalli
Yasuj University of Medical Sciences

Shabahang Moghaddasi Esfivashi
Northumbria University

Elham Sadat Mostafavi
Ferdowsi University of Mashhad

Sepideh Hassanpour Khodaei
Eastern Mediterranean University

Fatemeh Amini
Sichuan University

Zahra Taheri
Shiraz University

Sepide Javankiani
Tehran University of Medical Sciences

Amir Nasrollahizadeh
Tehran University of Medical Sciences

Reyhaneh Mahbubi Arani
Shahid Beheshti University of Medical Sciences

Oveis Ahmadzadeh
Kashan University of Medical Sciences

Kimia Kowsari
Azad University of Sari

Kourosh Shahraki
Zahedan University of Medical Sciences

Mahyar Noorbakhsh
Kashan University of Medical Sciences

Mohammad Bdaqli
University of Tabriz

Roozbeh Roohinezhad
Iran University of Medical Sciences

Arezoo Heidary
Qazvin Islamic Azad University

Kimia Baghebani
Jeonbuk National University

Farzaneh Kianifar
Iran University of Medical Sciences

Reza Mohajer Shirazi
Islamic Azad University of Tehran Medical Sciences

Mohammad Eslami
Shahid Beheshti University of Medical Sciences

Shahram Asgari
University of Georgia

Yousef Fekri Dabanloo
University of Georgia

Saman Abdollahpour
Shahid Beheshti University of Medical Sciences

Sanaz Amiri Marbini
University Medical Center Hamburg-Eppendorf

Seyed Ali Hashemi Kiapey
Mashhad University of Medical Sciences

Atena Talebpoor Amirhandeh
Shahid Beheshti University of Medical Sciences

Mohammad Yaghoubi
Azerbaijan Medical University

Neda Gorjizadeh
Tehran University of Medical Sciences

Book Details:

Publisher: PreferPub and Kindle

Publication Date: December 2025

Language: English

Dimensions: 5 x 0.39 x 8 inches

ISBN-13: 979-8277533666

Contents

Chapter

1. AI for Hard-to-Treat Hematologic Malignancies

2. AI for Hard-to-Treat Neurological Cancers

3. AI for Hard-to-Treat Gastrointestinal Cancers

4. AI for Hard-to-Treat Breast and Lung Cancers

5. AI for Hard-to-Treat Urogenital Cancers

6. AI for Hard-to-Treat Skin and Soft Tissue Cancers

7. AI for Hard-to-Treat Head and Neck Cancers

8. AI for Hard-to-Treat Oral Cancers

9. AI for Hard-to-Treat Bone and Musculoskeletal Cancers

10. AI for the Diagnosis and Treatment of Unknown-Origin Cancers

1. AI FOR HARD-TO-TREAT HEMATOLOGIC MALIGNANCIES

Background

Leukemia, commonly known as blood cancer, is a type of hematologic malignancy in which the bone marrow begins producing abnormal and dysfunctional blood cells, particularly white blood cells. These immature cells that lack normal immune function accumulate within the blood and bone marrow, replacing healthy cells and interfering with normal hematopoiesis. In general terms, leukemia refers to a group of cancers that originate from blood forming tissues including the bone marrow and the lymphatic system.

Leukemia may develop suddenly with rapid progression as seen in acute forms, or it may emerge gradually while following a slower clinical course as seen in chronic forms. Based on the origin of the malignant cell, whether myeloid or lymphoid, this disease is classified into four principal categories which are Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia.

Acute Lymphoblastic Leukemia occurs more frequently in children and is marked by the rapid proliferation of immature lymphocytes that

are unable to combat infections effectively. Even though this disease progresses aggressively, early diagnosis accompanied by appropriate treatment often results in a high rate of remission and long term recovery potential in many cases.

Acute Myeloid Leukemia, in contrast, generally appears in adults and arises from abnormal growth of myeloid cells that are responsible for producing red blood cells, white blood cells, and platelets. The clinical outcome of Acute Myeloid Leukemia is typically poorer than that of Acute Lymphoblastic Leukemia and treatment often involves intensive chemotherapy and occasionally bone marrow transplantation as a standard therapeutic approach.

Chronic Lymphocytic Leukemia occurs primarily in older adults and usually follows a slow and sometimes asymptomatic course for extended periods. It is often detected incidentally through routine blood examinations. Malignant lymphocytes in Chronic Lymphocytic Leukemia gradually accumulate in the blood and lymphatic tissues which, if left untreated, can lead to significant immune system dysfunction and susceptibility to infections.

Chronic Myeloid Leukemia is associated with the presence of a specific genetic alteration known as the Philadelphia chromosome which results in abnormal activation of proliferative signals and excessive production of myeloid cells. Although treatment of this disease was historically difficult,

the introduction of targeted therapies such as tyrosine kinase inhibitors has greatly improved survival outcomes and quality of life for affected patients.

In addition to the four major categories, rarer forms of leukemia also exist including Hairy Cell Leukemia, Promyelocytic Leukemia, and mixed phenotype leukemias. Promyelocytic Leukemia, a subtype of Acute Myeloid Leukemia, is defined by an excessive accumulation of promyelocytes in the bone marrow and severe coagulation disorders. Due to the possibility of life threatening bleeding, this subtype requires rapid diagnosis and urgent intervention to prevent mortality.

From a cellular and histopathological viewpoint, leukemias characteristically present as blasts which are immature undifferentiated cells with high proliferative potential. Their morphological characteristics are visible in peripheral blood smears or bone marrow biopsy samples. Cytochemical and immunophenotypic studies utilize specific molecular markers such as CD19 and CD10 in Acute Lymphoblastic Leukemia or CD33 and myeloperoxidase in Acute Myeloid Leukemia to support accurate diagnosis and classification. Precise molecular and genetic profiling is essential for determining prognosis and selecting effective treatment regimens. For instance, certain gene mutations in Acute Myeloid Leukemia can strongly influence therapeutic responses and overall clinical outcomes.

The prevalence of leukemia varies by age group. International health statistics indicate that leukemia is the most common cancer diagnosed in children under 15 years of age while chronic leukemias are more commonly observed in elderly populations. The incidence rate also tends to be slightly higher in males than in females. Reports from some regions suggest that leukemia rates are rising possibly due to environmental and industrial exposures, chemical contact, and improvements in detection systems.

Several classification systems have been developed to categorize leukemias based on morphological, immunophenotypic, and cytogenetic characteristics. The French American British classification was one of the earliest systems and defined subtypes of Acute Myeloid Leukemia from M0 to M7 based on cellular morphology. Modern classifications incorporate genetic abnormalities, specific chromosomal mutations, and the degree of cellular differentiation, allowing more precise disease categorization.

With advancements in genomic sequencing, medical imaging, and machine learning, more accurate leukemia classification is becoming increasingly vital not only for diagnostic accuracy but also for prognosis prediction, therapeutic planning, and implementation of personalized medicine. Artificial intelligence based methods such as bioinformatics modelling, RNA

sequencing analysis, and integration of laboratory data have recently enabled the development of sophisticated computational tools capable of detecting leukemia subgroups with high accuracy. These emerging technologies will be explained in later sections of this study.

Etiological and Predisposing Factors of Leukemia

Although leukemia originates from genetic and cellular abnormalities, its onset often results from a complex interaction between internal factors including genetic and epigenetic alterations and external influences such as environmental exposure, occupational hazards, lifestyle, and infectious agents. Understanding these contributing factors is essential for exploring disease mechanisms and designing predictive systems using artificial intelligence based methods.

Among the most significant genetic contributors are chromosomal abnormalities which are frequently observed in leukemia subtypes. The Philadelphia chromosome which is caused by a translocation between chromosomes 9 and 22 is a hallmark of Chronic Myeloid Leukemia and is responsible for continual activation of proliferative signalling pathways that stimulate uncontrolled cell growth.

Mutations in several genes including NPM1, FLT3, TP53, DNMT3A, and IDH1 or IDH2

appear frequently in patients with Acute Myeloid Leukemia and have considerable effects on prognosis and treatment responses. Some of these genetic alterations result in incomplete differentiation, enhanced resistance to cell death, and promotion of malignant proliferation. In children, inherited genetic syndromes such as Down syndrome, Bloom syndrome, Fanconi anemia, and neurofibromatosis markedly increase susceptibility to leukemia because of impaired DNA repair mechanisms.

Environmental and occupational exposures also play a major role in leukemia onset. Ionizing radiation, especially when exposure occurs during prenatal development or early childhood, is a well recognized risk factor. Workers frequently exposed to X rays or radioactive substances also face increased likelihood of disease development. Chemical substances including benzene, pesticides, and industrial solvents have been widely acknowledged as factors that can induce leukemia, particularly cases with myeloid origin.

Lifestyle habits influence leukemia risk as well. Cigarette smoking contains carcinogenic compounds capable of damaging hematopoietic stem cells and contributing to malignant transformation. Poor nutrition, reduced antioxidant intake, and consumption of foods containing synthetic preservatives increase oxidative stress which can disrupt DNA stability in

bone marrow cells.

Viral factors have gained increasing attention as certain viruses are linked with hematologic malignancies. Human T lymphotropic virus type 1 is definitively associated with Adult T cell Leukemia and may remain dormant for years prior to disease onset. Epstein Barr virus and several herpesvirus strains are believed to contribute to immune dysregulation and may predispose individuals to leukemia development under specific conditions.

Immunosuppression contributes significantly to leukemia susceptibility, particularly among organ transplant recipients or individuals with chronic immune dysfunction such as HIV infection. Exposure to chemotherapy or radiotherapy during prior cancer treatment may also lead to secondary leukemia which is a therapy related complication.

Recent research has turned its attention toward the gut microbiome and its role in hematologic malignancies. Alterations in beneficial microbial communities can impair immune regulation and promote chronic inflammation which in turn increases risk for malignant transformation in blood forming tissues.

Psychosocial influences have also been studied. Although a direct causal relationship is not fully established, chronic psychological stress may disrupt normal immune responses and therefore contribute indirectly to cancer development including leukemia.

The interaction between genetic vulnerability and environmental triggers is fundamental in leukemia pathogenesis. An individual carrying a predisposing mutation may only experience disease manifestation when exposed to a specific environmental factor. This concept forms the basis of many artificial intelligence based predictive models which estimate leukemia risk by integrating genetic, biological, demographic, and environmental data. Machine learning models that combine multi dimensional datasets have shown superior accuracy compared with analyses relying on isolated risk factors alone.

Recognizing and addressing these predisposing factors not only supports early diagnosis but also lays the foundation for targeted interventions, optimized preventive strategies, and development of personalized treatment planning. These elements will be further expanded upon in subsequent chapters focusing on artificial intelligence applications in leukemia diagnosis and management.

Clinical Manifestations and Diagnostic Methods of Leukemia

The clinical manifestations of leukemia are often gradual and nonspecific, and in the early stages may be mistaken for viral infections or simple anemias. This characteristic can delay diagnosis, particularly in chronic leukemias. Symptom presentation depends on the type of

leukemia, whether acute or chronic and myeloid or lymphoid, the rate of disease progression, the extent of bone marrow involvement, and the spread to other organs. Common general symptoms include severe fatigue, weakness, pallor, fever, night sweats, unexplained weight loss, bone and joint pain, abnormal bleeding, spontaneous bruising, recurrent infections, and lymphadenopathy.

In acute leukemias, symptoms appear suddenly within a few weeks, and the patient's condition can deteriorate rapidly. For instance, in Acute Lymphoblastic Leukemia, patients may present with fever, severe infections, and reduced levels of consciousness. In children with Acute Lymphoblastic Leukemia, the most common signs include anemia, gum bleeding, leg pain, and splenomegaly. In Acute Myeloid Leukemia, symptoms result from impaired bone marrow function and the accumulation of blasts. Patients may experience neutropenia, thrombocytopenia, and reduced red blood cell counts, which manifest as fever, bleeding, recurrent infections, and anemia.

In contrast, chronic leukemias are often discovered incidentally during routine blood tests. In Chronic Lymphocytic Leukemia, patients may remain asymptomatic for a long period, with the only abnormal finding being an elevated white blood cell count. As the disease progresses, splenomegaly, lymphadenopathy, night sweats,

and fatigue may develop. In Chronic Myeloid Leukemia, the hallmark symptom is splenomegaly, which can cause abdominal fullness or pain under the left rib cage. Additional symptoms such as weight loss, unexplained fever, and night sweats may also occur as the disease advances.

Diagnostic methods for leukemia involve a combination of clinical examinations, blood tests, bone marrow investigations, and molecular analyses. The first and simplest method is the complete blood count, in which abnormalities such as marked leukocytosis, reduced red blood cells and platelets, and the presence of immature cells can be detected. In acute leukemias, blasts in the peripheral blood are a key finding, although in some cases these blasts may only be identified in the bone marrow.

The next step is the peripheral blood smear, which allows examination of the morphological characteristics of blood cells. Through staining and microscopic evaluation, the presence of myeloid or lymphoid blasts can be confirmed. However, for definitive diagnosis, bone marrow aspiration or biopsy is essential. In this procedure, bone marrow tissue is obtained, usually from the pelvis, and subjected to microscopic, cytochemical, immunophenotypic, and genetic tests to achieve accurate classification.

Cytochemical tests include special stains such as myeloperoxidase, periodic acid Schiff, and Sudan

Black, which help in identifying the type of leukemia and the cellular lineage. For example, positive myeloperoxidase staining indicates a myeloid origin. One of the most precise diagnostic methods is immunophenotyping using flow cytometry. This technique evaluates specific surface and intracellular markers on cells, enabling accurate differentiation between leukemia types. Markers such as CD10, CD19, and terminal deoxynucleotidyl transferase are useful for Acute Lymphoblastic Leukemia, while CD13, CD33, and HLA DR are commonly applied for Acute Myeloid Leukemia.

Genetic and molecular studies have played a decisive role in diagnosis, classification, prognosis assessment, and treatment selection. Techniques such as karyotyping, fluorescence in situ hybridization, polymerase chain reaction, and next generation sequencing are widely used to identify chromosomal abnormalities, gene mutations, and genetic rearrangements in leukemia patients. For example, in Chronic Myeloid Leukemia, the detection of the t(9;22) translocation and the formation of the BCR ABL fusion gene confirms the diagnosis and guides targeted therapy.

Imaging also has important applications, particularly for evaluating splenomegaly, lymphadenopathy, or central nervous system involvement in aggressive leukemias. Magnetic resonance imaging and computed tomography

scans, and when necessary cerebrospinal fluid sampling, are recommended in complex cases. In children, lumbar puncture is performed to assess central nervous system involvement, and the cerebrospinal fluid is subjected to cytologic and molecular analysis in order to detect leukemic cells.

With the rapid advancement of technology, machine learning based approaches have recently been introduced as complementary tools in leukemia diagnosis. Using classification algorithms and computer vision, automated analysis of blood smears or molecular data has become possible. Studies have shown that deep learning models such as convolutional neural networks and ensemble methods can achieve very high accuracy in classifying normal blood cells versus blasts, representing a significant step toward rapid screening and reduction of human error in clinical practice.

In summary, early and accurate diagnosis of leukemia requires a multistep approach that integrates clinical, laboratory, cellular, and molecular data. Incorporating these datasets into artificial intelligence based systems enables the development of clinical decision support algorithms, which in recent years have attracted the attention of many research centers and hospitals. The following chapters will discuss the design and evaluation of these algorithms and their applications in leukemia modeling and

patient management.

Common Therapeutic Approaches for Leukemia

The treatment of leukemia depends on its type, whether acute or chronic and myeloid or lymphoid, as well as on the patient's age, overall health status, and the molecular and genetic characteristics of the malignant cells. Over recent decades, therapeutic strategies have evolved from classical chemotherapy toward targeted therapies, immunotherapy, bone marrow transplantation, and, more recently, gene therapy and chimeric antigen receptor T cell therapy. The primary goals of treatment are to eradicate malignant cells, restore normal bone marrow function, control symptoms, and prevent relapse.

Chemotherapy remains the first line and most common treatment for most types of leukemia, particularly acute forms. Cytotoxic agents such as cytarabine, daunorubicin, doxorubicin, vincristine, and methotrexate are used to eliminate proliferating malignant cells. In Acute Lymphoblastic Leukemia, therapy typically involves three major phases, namely induction, consolidation, and maintenance, which together may last for two to three years. In Acute Myeloid Leukemia, the standard regimen usually combines cytarabine with anthracyclines. While these regimens are effective, they can lead to severe immunosuppression, profound neutropenia, and

significant adverse effects that require careful monitoring and supportive care.

In Chronic Myeloid Leukemia, a major therapeutic breakthrough followed the discovery of the Philadelphia chromosome and the BCR ABL gene. This mutation produces a tyrosine kinase that drives uncontrolled cell proliferation. Imatinib was the first tyrosine kinase inhibitor specifically targeting this pathway and dramatically improved survival rates for patients. Subsequent agents such as dasatinib, nilotinib, and ponatinib have been developed to overcome drug resistance and secondary mutations, offering additional therapeutic options when initial treatment fails or intolerance occurs.

Targeted therapy involves drugs designed to specifically block molecular pathways or receptors in malignant cells while sparing normal tissues. In Acute Promyelocytic Leukemia, the combination of arsenic trioxide and all trans retinoic acid has largely replaced intensive chemotherapy, improving survival with fewer complications. Similarly, in Acute Myeloid Leukemia patients with FLT3 mutations, targeted agents such as midostaurin are administered alongside chemotherapy to significantly enhance treatment outcomes. The continued development of targeted therapies offers new hope for patients with specific genetic lesions.

Immunotherapy has emerged as a prominent treatment strategy in recent decades. Monoclonal

antibodies such as rituximab for Chronic Lymphocytic Leukemia with CD20 expression, blinatumomab for Acute Lymphoblastic Leukemia with CD19, and inotuzumab ozogamicin have shown substantial clinical benefit. These drugs bind to specific surface receptors on malignant cells and mediate immune destruction through various mechanisms. One of the most revolutionary therapies is chimeric antigen receptor T cell therapy, in which patient derived T cells are genetically reprogrammed to recognize and attack cancer cells. This approach has shown remarkable results in relapsed and refractory pediatric and young adult Acute Lymphoblastic Leukemia and is being studied for application in other leukemia types.

Bone marrow transplantation, also referred to as hematopoietic stem cell transplantation, remains a cornerstone therapy for refractory, relapsed, or high risk leukemias. Transplantation can be autologous, using the patient's own stem cells, or allogeneic, using cells from a donor. Allogeneic transplantation benefits from the graft versus leukemia effect, in which donor immune cells attack residual malignant cells. However, complications such as graft versus host disease, infections, and organ toxicity remain significant challenges. The timing of transplantation, patient age, disease severity, comorbidities, and donor availability are critical determinants of transplant success.

Radiotherapy plays a more limited but still important role in leukemia treatment. It may be employed in cases of central nervous system involvement, as part of conditioning regimens before bone marrow transplantation, or in rare cases of massive splenomegaly that cause pain or functional impairment. Careful dosing is required to minimize long term side effects, especially in children and young adults.

Supportive care is essential for improving quality of life and survival in leukemia patients. This includes blood and platelet transfusions, infection prophylaxis and prompt antimicrobial therapy, nutritional support, antifungal treatment, and careful monitoring of drug related complications. Growth factors such as granulocyte colony stimulating factor are used to shorten the duration of neutropenia, while antiemetics, analgesics, psychological support, and palliative care services form integral components of comprehensive leukemia management.

In recent years, technological advances have enhanced therapeutic development and personalization. Machine learning and artificial intelligence are increasingly applied to predict treatment responses, guide drug selection, and assist in drug design. Predictive algorithms based on clinical, genetic, and molecular data can help determine which patients are likely to respond to specific drugs or are at higher risk of relapse. These technologies have significantly influenced

the implementation of personalized medicine in leukemia and are expected to play an even larger role in future treatment planning.

Despite these remarkable advances, challenges remain, including the development of drug resistance, disease relapse, limited access to novel therapies in developing countries, and the high costs of targeted and cellular therapies. Therefore, interdisciplinary research involving clinicians, pharmacologists, molecular biologists, data scientists, and health policy experts is critical to further improving leukemia treatment outcomes and ensuring broader access to innovative therapies.

Diagnostic and Therapeutic Challenges in Leukemia

Despite significant advances in medical science, genetics, immunology, and imaging technologies, leukemia remains associated with major diagnostic and therapeutic challenges. The heterogeneous and complex nature of leukemia, its high genetic variability, differing treatment responses, and the development of drug resistance are among the main barriers to the full success of therapeutic interventions. One of the most critical challenges is delayed initial diagnosis, especially in chronic leukemias, because early symptoms are nonspecific and often mistaken for other conditions such as infections or anemia. This problem is more pronounced in developing

countries due to the lack of advanced laboratory facilities, limited access to specialized centers, and absence of routine screening programs.

In diagnostics, although tools such as blood smears, bone marrow aspiration, and molecular assays are widely available in many tertiary centers, identifying rare subtypes or differentiating leukemia from other hematologic malignancies can be difficult. For example, in mixed phenotype leukemias, cells may simultaneously display both lymphoid and myeloid features, requiring a combination of immunophenotyping, cytogenetics, and gene sequencing for precise diagnosis. Limited access to such advanced technologies in many treatment centers delays diagnosis and initiation of appropriate therapy. Furthermore, genetic abnormalities that are not detectable using conventional tools highlight the growing need for next generation sequencing and similar high resolution techniques, which remain costly and resource intensive.

In treatment, multiple challenges persist. Drug resistance is one of the most significant barriers to effective therapy. In Chronic Myeloid Leukemia, a considerable proportion of patients develop resistance to tyrosine kinase inhibitors such as imatinib due to mutations in the BCR ABL gene or additional molecular changes. This necessitates the use of second or third generation agents, which are expensive and not universally

accessible. In acute leukemias, both intrinsic and acquired resistance to chemotherapeutic agents such as cytarabine and daunorubicin has been observed, with mechanisms involving increased drug efflux, altered drug metabolism, and disruption of apoptotic pathways.

Another therapeutic challenge is selecting appropriate treatment regimens for elderly patients or those with significant comorbidities. Many anticancer drugs are highly toxic, and in patients with poor cardiac, hepatic, or renal function they may cause severe complications or early mortality. In such cases, balancing efficacy and tolerability is critical. Reduced intensity regimens or the use of less toxic hypomethylating agents in elderly Acute Myeloid Leukemia patients have been proposed, but responses are usually modest and of limited duration, necessitating continued research into better tolerated options.

Bone marrow transplantation, while effective in refractory and high risk leukemias, remains complicated due to the difficulty of finding suitable donors, risks such as graft versus host disease, and high financial costs. Lack of public awareness about stem cell donor registries, inadequate infrastructure, and limited transplant centers in many regions aggravate these problems and restrict access to potentially curative therapy.

Monitoring treatment response is also problematic. In many centers, evaluation still relies primarily on blast counts in blood

or bone marrow, which are insufficient to accurately predict relapse. Hence, the concept of minimal residual disease has gained prominence. Minimal residual disease assessment requires advanced technologies such as highly sensitive flow cytometry or quantitative polymerase chain reaction, which are unavailable in many facilities. The absence of minimal residual disease monitoring may result in suboptimal treatment decisions or failure to detect early relapse when additional interventions could be most effective.

Economic and social factors further influence access to effective therapy. The high costs of targeted therapies, immunotherapies, and advanced genetic testing place treatment out of reach for many patients, particularly in low income countries. Lack of comprehensive insurance coverage, inadequate pharmaceutical policies, and medication shortages also limit equal access to standard care.

From a psychosocial perspective, leukemia patients often suffer from anxiety, depression, and fear of death, which can affect treatment adherence and overall outcome. The absence of integrated psychosocial support alongside medical therapy represents a major gap in comprehensive cancer care. Inadequate patient and family education regarding the disease, treatment phases, potential side effects, and long term follow up requirements can reduce compliance and engagement with therapy.

In recent years, artificial intelligence and machine learning have shown promise in addressing some of these challenges. Clinical decision support systems can analyse clinical, genetic, imaging, and treatment response data simultaneously to suggest optimal therapeutic strategies and risk stratification. However, issues such as data quality, incomplete data, inconsistent formats, and lack of unified standards for data integration and model validation remain unresolved and must be addressed for widespread clinical adoption.

In conclusion, the diagnostic and therapeutic challenges of leukemia are multifaceted and complex. Better management requires interdisciplinary collaboration, infrastructure development, continuous professional training, investment in modern technologies, and the establishment of equitable access to care and innovative treatments.

Basic Concepts of Artificial Intelligence in Medical Sciences

Artificial intelligence refers to a set of methods and algorithms that are designed and implemented to mimic human cognitive abilities, including learning, reasoning, decision making, and problem solving. With the rapid growth of medical data volume and the increasing complexity of diagnostic and therapeutic processes, medicine has become one of the most important domains for the application of

artificial intelligence. In this context, artificial intelligence can act as an intelligent assistant to physicians in analyzing clinical data, predicting disease progression, detecting hidden patterns in images or laboratory results, and even designing personalized treatment plans.

In the scientific literature, artificial intelligence is generally divided into two broad categories, narrow artificial intelligence and general artificial intelligence. Narrow artificial intelligence refers to algorithms trained for a specific task such as image recognition, laboratory result prediction, or genetic data classification. General artificial intelligence refers to systems capable of reasoning comprehensively like humans, which remain at the theoretical and research stage. In medicine, current applications mostly fall into the narrow category and include machine learning, computer vision, natural language processing, and predictive modeling.

One of the key concepts in artificial intelligence is machine learning. Instead of following predefined rules, machine learning algorithms learn patterns from experience and data and thereby acquire predictive capability. Machine learning is generally divided into three categories, supervised learning, unsupervised learning, and reinforcement learning. In supervised learning, algorithms are trained on labeled datasets such as identifying cancerous cells in microscopic images or predicting laboratory outcomes from known

inputs. In unsupervised learning, the goal is to discover hidden structures or clusters in data such as identifying unknown patient subgroups based on gene expression profiles. In reinforcement learning, an intelligent agent interacts with its environment through trial and error, improving its decision making based on rewards and penalties.

Another fundamental concept is the artificial neural network, which is inspired by the structure of the human brain. These networks are composed of interconnected artificial neurons organized in layers. In medicine, artificial neural networks play an important role in disease diagnosis, medical image processing, genomic analysis, and modeling of complex clinical pathways. A more advanced form, deep learning, incorporates multiple hidden layers to extract increasingly complex and abstract features from raw data and has become a leading approach in many biomedical applications.

A widely used branch of deep learning in medicine is the convolutional neural network, particularly applied in analyzing medical images such as magnetic resonance imaging, computed tomography scans, X rays, and blood smear images. For example, in the automated diagnosis of leukemia cells from microscopic images, convolutional neural networks have in some cases achieved accuracy levels comparable to or higher than human specialists. These models can detect complex visual features such as cell shape, nuclear

texture, and staining patterns and use them for precise disease classification.

Beyond image analysis, textual data analysis is also vital in modern healthcare. Natural language processing, a branch of artificial intelligence, is designed to analyse and interpret human language. In medicine, natural language processing can automatically extract information from clinical records, physician notes, pathology reports, and scientific literature. This facilitates the identification of risk factors, medication histories, comorbidities, and laboratory findings from large amounts of unstructured data and enhances clinical research and decision making. Modern language models have demonstrated remarkable performance in natural language understanding and are expected to be increasingly integrated into health information systems.

Artificial intelligence is not limited to diagnosis and classification; it also plays a major role in prediction. Risk prediction models can integrate clinical, laboratory, genetic, and environmental data to estimate the likelihood of disease occurrence, progression, or relapse with high accuracy. For instance, in leukemia patients, artificial intelligence models can predict treatment response, risk of adverse effects, or survival outcomes. Such models are designed using algorithms like random forests, support vector machines, gradient boosting methods, and deep learning architectures.

Clinical decision support systems represent another practical product of artificial intelligence in medicine. By analyzing patient data, these systems provide physicians with recommendations that may include likely diagnoses, drug selection, optimal dosages, alerts about potential adverse events, or suggested follow up plans. Some of these systems are already deployed in hospitals and integrated with electronic health record platforms, assisting clinicians in daily practice.

However, the application of artificial intelligence in medicine raises ethical, legal, and technical concerns. Issues such as algorithmic transparency, explainability, data privacy, security, and liability for machine based decisions must be carefully considered. One major criticism of deep learning models is their black box nature, where the rationale behind final decisions is unclear and difficult to interpret. In medicine, this lack of interpretability can undermine the trust of both physicians and patients and may limit the acceptance of artificial intelligence tools in critical situations.

In summary, the foundational concepts of artificial intelligence in medical sciences are rapidly expanding. With the development of digital infrastructures, improvements in data quality, and closer interdisciplinary collaboration, artificial intelligence is expected to become an integral component of future diagnostic,

therapeutic, and disease management processes, particularly in complex conditions such as leukemia where large scale data integration and precise decision making are crucial.

Common Machine Learning Algorithms in Disease Diagnosis

Machine learning as a key subset of artificial intelligence refers to algorithms that learn from data to make decisions or predictions without requiring explicit programming of all rules. In medicine, machine learning algorithms are widely applied for analyzing large datasets, identifying hidden patterns, classifying patients, predicting disease progression, and optimizing treatment strategies. Their use in diagnosing conditions such as leukemia, solid cancers, diabetes, cardiovascular diseases, and infectious diseases is rapidly expanding across clinical and research environments. The choice of algorithm depends on the nature and structure of the data, the specific objective such as classification, regression, or clustering, and the complexity of the underlying patterns that must be captured.

One of the most common supervised learning algorithms is the decision tree. This algorithm implements a set of conditional rules in the form of a tree structure and is highly applicable for problems such as disease diagnosis based on clinical symptoms or laboratory results. Decision trees are popular in medical modeling because of

their conceptual simplicity, high interpretability, relatively low computational requirements, and fast execution, which are valuable in clinical workflows that demand transparency.

An advanced version of decision trees is the random forest algorithm, which builds an ensemble of decision trees and combines their outputs to improve accuracy and stability. Random forest has been successfully applied in diagnosing blood cancers, characterizing tumour histology, and predicting treatment responses in a variety of diseases. For example, in research focused on leukemia diagnosis using blood cell features, random forest has often outperformed several other algorithms in terms of classification accuracy and robustness, demonstrating its usefulness for hematologic applications.

Support vector machine is another widely used algorithm in medicine. It classifies data by identifying the optimal decision boundary in the feature space that maximizes separation between classes. Support vector machine is particularly effective for high dimensional and complex datasets, such as genomic profiles or medical imaging features, where conventional methods may struggle. In studies devoted to leukemia, support vector machine has shown remarkable performance in classifying acute leukemia subtypes using genetic and molecular data, demonstrating its power in precision diagnostics.

The k nearest neighbors algorithm is a simple yet

practical method that classifies new samples based on their similarity to training data. Although it may be less accurate than more sophisticated models, it is useful in projects with limited datasets or as a baseline in medical research. A key advantage of k nearest neighbors is that it makes no strong assumptions about data distribution, which can be beneficial when the underlying statistical properties of clinical data are not fully known.

Among regression algorithms, logistic regression is commonly used in clinical studies to predict disease occurrence or relapse. This model examines the relationship between input variables such as age, laboratory results, and genetic mutations and binary outcomes such as presence or absence of disease or survival status. Due to its interpretability, well understood statistical foundations, and extensive history in medicine, logistic regression remains in use alongside more advanced machine learning models and often serves as a benchmark for evaluating newer methods.

Artificial neural networks are also crucial machine learning algorithms with broad applications in medicine. Inspired by the brain's neural structure, they can model complex nonlinear relationships among variables. With the growth of medical data and computational resources, advanced neural networks known as deep learning architectures have been developed. Among them,

convolutional neural networks are highly effective for medical image processing and visual pattern recognition. In leukemia diagnosis, convolutional neural networks have achieved high accuracy in classifying blood cells from microscopic images and have begun to replace manual visual assessment in some automated pipelines, thereby reducing observer variability.

Gradient boosted algorithms such as XGBoost and LightGBM have shown excellent performance in medical projects involving structured data such as clinical tables and laboratory indices. These models sequentially build weak decision trees and optimize the errors of previous models to gradually form stronger predictors. Gradient boosting models have consistently ranked highly in disease detection challenges and clinical data competitions, offering strong accuracy when combined with appropriate feature selection, parameter tuning, and careful validation.

In unsupervised problems such as discovering new patterns in genetic data or clustering patients into subgroups, algorithms like k means clustering and principal component analysis are commonly applied. These methods reveal hidden structures without using labeled data and help in identifying novel disease subgroups, risk categories, or response clusters, which can be especially important in heterogeneous conditions such as leukemia and other hematologic malignancies.

When selecting an algorithm, several factors must be considered, including the type of data such as numeric, imaging, or text, the dataset size, class balance, interpretability needs, training time, and required accuracy. For example, in clinical environments where critical decisions are made, interpretable algorithms like decision trees or logistic regression may be preferred to ensure that clinicians can understand the reasoning behind predictions. In contrast, for research purposes, complex models like convolutional neural networks or XGBoost, although more black box in nature, may be appropriate because of their higher potential accuracy and ability to capture subtler patterns.

Moreover, combining algorithms in ensemble approaches can further improve performance. By leveraging the strengths of multiple models, ensemble methods reduce overall error and enhance prediction stability. Combinations such as random forest with support vector machine or ensembles that incorporate neural networks and gradient boosting have been successfully applied in various medical diagnostic projects, including hematologic disease classification.

Finally, deploying machine learning algorithms in real world clinical settings requires addressing technical and ethical issues such as data quality, elimination of bias, patient privacy, transparency, and model explainability. In leukemia projects and other hematologic domains, combining these

algorithms with physician expertise can lead to more accurate diagnoses, optimized treatment strategies, and improved prognostic assessments, ultimately supporting better patient outcomes.

Applications of Artificial Intelligence in Diagnosing Hematologic Diseases

In recent years, artificial intelligence has become a key tool in diagnosing hematologic diseases, particularly because of the massive volumes of laboratory, imaging, and genomic data whose analysis often exceeds human cognitive capacity. Hematologic conditions, including various leukemias, lymphomas, anemias, coagulopathies, and myelodysplastic syndromes, have traditionally been evaluated using tests such as complete blood count, peripheral blood smear, bone marrow biopsy, and molecular assays. However, accurate and simultaneous interpretation of these diverse data sources requires advanced analytical tools. Artificial intelligence algorithms, especially machine learning and deep learning methods, enable rapid and high accuracy detection of hidden patterns in clinical and laboratory data and thereby facilitate early diagnosis and better risk stratification.

One of the earliest applications of artificial intelligence in hematology is automated processing of microscopic peripheral blood smear images. Convolutional neural networks have

been used to automatically distinguish normal from abnormal cells and have achieved very high accuracy in classifying blasts, lymphocytes, monocytes, and neutrophils. In several studies, convolutional neural network based models have distinguished leukemic from normal cells with accuracy rates exceeding ninety percent. In these models, features such as nuclear shape, nucleus to cytoplasm ratio, texture, and staining characteristics are extracted from images, enabling high throughput analysis without the need for continuous human intervention.

Beyond microscopy, flow cytometry data also provide a rich substrate for machine learning applications. Algorithms such as support vector machines and random forests have been applied to phenotype classification of blood cells, identification of leukemia subgroups, and differentiation of blasts from reactive lymphocytes. Using such models to analyze flow cytometry data can produce results comparable to expert diagnoses while operating in significantly shorter time frames, which is particularly valuable in emergencies or in hospitals with limited staff.

Genomic and transcriptomic analysis is another rapidly expanding domain for artificial intelligence in hematology. Models such as gradient boosting algorithms and deep neural networks trained on RNA sequencing data can identify specific mutations, generate risk scores, and predict treatment response. By combining

clinical characteristics, cytogenetic information, and genomic data with deep learning approaches, researchers can produce personalized risk profiles for patients with acute leukemias, thereby aiding therapy selection and predicting relapse with greater precision.

Another notable application is the development of alerting and decision support systems that automatically notify clinicians when dangerous patterns are detected in laboratory results or vital signs. Often deployed in intensive care units or hematology wards, these systems continuously analyze data streams to prevent clinical crises. For example, deep learning networks have been used to analyze many laboratory parameters and vital indices in order to predict organ failure, severe infection, or the need to change therapy in hematologic patients, providing early warnings that can guide timely intervention.

In lymphoma diagnosis, deep learning has been employed to interpret digital histopathology images. Models such as ResNet and DenseNet analyze cellular architecture and tissue morphology on whole slide images. These convolutional neural network based systems have achieved high accuracy for classifying lymphoma subtypes, sometimes matching or surpassing the performance of human pathologists and providing decision support for complex cases.

Artificial intelligence usage is also expanding in anemias, thalassemia, hemophilia, and platelet

disorders. In thalassemia screening, decision trees and random forests using hematologic indices such as mean corpuscular volume, mean corpuscular hemoglobin, and red cell distribution width can provide noninvasive identification and reduce the need for expensive molecular testing. In hemophilia, machine learning methods are being explored to predict bleeding risk and individual response to factor replacement therapy, allowing more personalized dosing strategies.

A recent advance is the development of multimodal artificial intelligence models that jointly process heterogeneous inputs such as images, numeric data, and free text. By analyzing blood tests, clinical reports, and bone marrow images simultaneously, these models can make more precise decisions. For instance, systems that combine natural language processing for physician notes with convolutional neural networks for smear images have achieved high diagnostic accuracy for leukemia and related disorders, demonstrating the benefit of integrated approaches.

Overall, artificial intelligence in hematologic diseases now extends beyond diagnosis to prognosis estimation, therapy selection, disease subgrouping, and post treatment monitoring. By reducing human error, accelerating analysis, and uncovering hidden patterns, artificial intelligence opens new frontiers in hematology. Nevertheless, ongoing challenges including data quality,

model interpretability, fairness, and ethical considerations require standardized frameworks, large scale clinical validation, and careful oversight to ensure safe and effective clinical deployment.

Neural Network Based Models for Leukemia Prediction

Artificial neural networks, particularly deep learning architectures, have become powerful tools for medical data analysis. In hematology, and specifically in leukemia prediction and diagnosis, these models excel because of their ability to capture complex patterns, nonlinear relationships, and large scale multimodal inputs. Unlike classical statistical methods that require strict distributional assumptions, neural networks learn patterns directly from data and often achieve superior predictive performance when adequately trained and validated.

A key application is the classification of microscopic blood cell images. Convolutional neural networks have shown excellent performance in this domain by automatically extracting features such as edges, textures, shapes, and color distributions. In research on Acute Lymphoblastic Leukemia, convolutional neural network based systems have reported accuracy levels above ninety five percent in classifying leukemic cells without manual feature engineering. Early layers in the network learn

low level visual features, whereas deeper layers capture more abstract representations such as nuclear structure patterns and chromatin organization.

Neural networks are also applied to numeric laboratory data including white blood cell counts, platelet counts, blast percentages, mean corpuscular volume, red cell distribution width, and biochemical markers. These features can be fed into multilayer perceptron architectures to predict leukemia presence, subtype, or risk categories. In multiple studies, multilayer perceptrons trained on a limited set of laboratory variables have achieved high accuracy in distinguishing leukemia from other hematologic conditions, illustrating the usefulness of neural networks even with relatively small feature sets.

For longitudinal prediction tasks such as disease progression or relapse risk, recurrent neural networks, especially long short term memory networks, are used to model temporal dependencies in clinical trajectories, treatment histories, sequential responses, and biomarker trends. By analyzing time series data from leukemia cohorts, these models can achieve credible accuracy in predicting time to relapse or progression, thereby informing follow up schedules and treatment adjustments.

A major advantage of neural networks is their capacity for data fusion. Multi input or multimodal architectures can accept clinical

variables, laboratory measurements, images, and genomic data simultaneously, with intermediate layers integrating these signals to produce more accurate decisions. For example, architectures in which smear images are processed by a convolutional neural network while laboratory or genomic data are fed into a multilayer perceptron have achieved improved accuracy for early leukemia diagnosis compared with single modality models.

Neural networks also perform strongly in survival prediction and treatment response modeling. By integrating demographic factors, genetic markers such as FLT3, NPM1, and BCR ABL, treatment regimens, and early response indicators, models can estimate therapy success probabilities or overall survival. Analyses that combine registry data with gene expression profiles have shown that neural network models can predict outcomes in chronic leukemias and acute leukemias with high accuracy, supporting more informed clinical decision making.

However, challenges remain in deploying neural network models. High performance typically requires large, diverse, and well curated datasets; explainability is limited because of black box behavior; and training demands substantial computational resources and careful hyperparameter tuning. Overfitting is a major risk with small datasets, and mitigation techniques such as dropout, regularization,

data augmentation, and cross validation are essential. For interpretability, methods like feature attribution and visualization of salient image regions help explain which patterns contribute most to a given prediction.

In summary, neural network models, especially convolutional neural networks, multilayer perceptrons, and long short term memory networks, offer advanced, accurate, and flexible tools for leukemia prediction and diagnosis. They are increasingly moving from research laboratories into clinical decision support systems. With broader access to structured and unstructured data, interoperable health information technology, and scalable computing resources, these technologies are poised to become integral components of leukemia care and personalized hematologic oncology.

Deep Learning for Genetic and Imaging Data Analysis

Deep learning, which refers to multilayer neural methods with high representational capacity, has transformed the analysis of complex medical data over the last decade. In hematology, and particularly in leukemia, applying deep learning to genetic and imaging datasets has enabled more precise identification of disease, faster diagnosis, and improved prediction of disease course. Two primary implementation arenas are analysis of gene expression, sequencing, and mutation data

and analysis of cellular microscopy and digital histopathology images.

In genetics, analyzing RNA sequencing, DNA methylation, single nucleotide polymorphisms, and structural variants entails processing very large sets of context dependent measurements. Deep architectures, including deep neural networks, autoencoders, and sequence oriented models such as long short term memory networks, can learn nonlinear gene gene relationships and expression patterns that help classify patients, identify leukemia subgroups, and predict treatment response. For example, training deep networks on RNA sequencing data from Acute Lymphoblastic Leukemia patients has enabled the identification of high risk subgroups with accuracy that surpasses classical statistical models, demonstrating the added value of deep learning for risk stratification.

On the imaging side, convolutional neural networks are widely deployed. For leukemia, peripheral blood smear images and digital bone marrow slides are primary visual sources. Convolutional neural networks automatically extract nuclear morphology, texture, cell size, and staining cues to separate normal from blast or abnormal cells. Several studies have reported accuracy close to or above ninety six percent for leukemia cell classification, exceeding many traditional image processing methods and improving consistency among assessments.

A key advantage over traditional techniques is automated feature learning, which eliminates the need for manual feature engineering. This is particularly crucial in genomics, where thousands of variables interact in complex ways. Autoencoders and related architectures can effectively reduce dimensionality, generating compact gene embeddings that subsequently power survival, relapse, or drug response prediction models. This approach enables better modeling of relationships among genes and pathways involved in leukemogenesis.

Combining imaging and genetic data is an emerging and powerful approach. In such multimodal pipelines, smear images are analyzed with convolutional neural networks while genomic or laboratory data are modeled with deep neural networks or multilayer perceptrons; their outputs are then fused for final decisions. Studies that apply this strategy for classification and survival prediction in acute leukemia have reported significantly higher performance compared with single modality models, highlighting the value of integrating complementary information sources.

For advanced imaging, such as digital bone marrow and lymph node slides, deep architectures including ResNet, Inception, and EfficientNet have shown outstanding performance in detecting abnormal or tumoral tissue. Automated systems based on these architectures can identify and

quantify blasts in bone marrow images of acute leukemia, supporting more objective assessment and reducing interobserver variability.

Deep learning has also been leveraged to predict drug resistance. By integrating genotype, gene expression levels, treatment type, and clinical response, models estimate resistance to agents such as tyrosine kinase inhibitors or targeted small molecules in chronic and acute leukemias. Multiple studies report high accuracy in predicting which patients are likely to develop resistance, facilitating early modification of treatment strategies.

Challenges include the need for large, well labeled datasets; risks of overfitting on limited data; and the clinical imperative for interpretability and robustness. Mitigation approaches include data augmentation, dropout, early stopping, and regularization, alongside explainability tools such as gradient based visualization to highlight salient image regions and feature attribution tools for genomic variables. These tools help clinicians better understand model behavior and increase trust in deep learning predictions.

Overall, deep learning for genetic and imaging analysis in leukemia has opened new horizons in diagnosis, prognosis, and personalized therapy. Integrating these models with health information systems, electronic health records, and clinical algorithms can yield decision support platforms that are likely to become integral components of

diagnostic and prognostic services in hematology.

Comparative Performance of AI Models in Leukemia Diagnosis

In recent years, the use of diverse artificial intelligence models for diagnosing leukemia has become a central focus of medical and computational research. By leveraging machine learning and deep learning methods, these models aim to distinguish normal from leukemic cells with the highest possible accuracy, minimal error rates, and rapid processing times. Comparing their performance using metrics such as accuracy, sensitivity, specificity, area under the receiver operating characteristic curve, and computational efficiency is crucial for selecting the most appropriate algorithm in clinical and research settings.

One of the simplest algorithms employed in early studies was the decision tree. Its key advantages are simplicity, high interpretability, and fast execution. However, its accuracy declines when confronted with highly complex data such as high resolution images or large gene expression matrices. In comparative analyses, decision trees often achieve acceptable but moderate accuracy, whereas ensemble methods such as random forests, which aggregate multiple trees, improve accuracy and robustness considerably.

Support vector machines have also been widely used, particularly with gene expression datasets

and statistical feature sets derived from laboratory data. Support vector machines perform well in high dimensional spaces and can handle complex class boundaries. On RNA sequencing data from acute leukemia patients, support vector machines have identified malignant cases with high accuracy and sensitivity. A limitation, however, is the difficulty of selecting optimal kernels and hyperparameters for large, nonlinear datasets, which can complicate their practical application.

Deep learning models such as convolutional neural networks have excelled with imaging data. In studies of peripheral blood smear analysis, convolutional neural networks for detecting blasts have achieved accuracy values above ninety six percent, with both sensitivity and specificity outperforming manual assessment and many classical algorithms. In another line of work, hybrid models that integrate convolutional neural networks for image analysis with multilayer perceptrons for laboratory or clinical data have pushed overall accuracy even higher, often above ninety eight percent.

Boosting models like XGBoost and LightGBM have proved effective for structured inputs such as hematologic parameters, genetic markers, and treatment histories. By sequentially building trees that correct prior errors, these models raise final accuracy while remaining relatively efficient computationally. When applied to combinations of clinical and genetic features, gradient boosting

models have predicted leukemia presence or risk with accuracy greater than ninety four percent in several studies and often require less complex tuning than deep neural networks.

For sequence and temporal analyses, recurrent models, particularly long short term memory networks, have been successful in predicting disease course or relapse. By training on time series data from acute leukemia patients, long short term memory networks have achieved high accuracy for predicting relapse within specified time windows, capturing biomarker dynamics and treatment response patterns that may not be apparent in static models.

A key consideration in comparing models is the match between data modality and analytic goal. For rapid image based diagnosis, convolutional neural networks tend to perform best. For predicting treatment response or survival from numeric or tabular data, models built on structured inputs such as XGBoost or multilayer neural networks may be more suitable. When high interpretability is required, algorithms like decision trees or logistic regression are preferred, whereas deeper models, despite their higher accuracy, are less transparent and more difficult to explain to clinicians and patients.

Execution speed and hardware requirements also vary. Simple models such as decision trees and support vector machines run very quickly on modest datasets and standard hardware,

whereas training convolutional neural networks or long short term memory networks on large datasets typically requires graphics processing units and substantial computational resources. Consequently, for clinical environments or low resource settings, lightweight models or pretrained networks may be recommended to balance performance and practicality.

Finally, rather than choosing a single model, some studies use ensemble or stacked approaches that combine outputs from multiple algorithms to increase accuracy and stability. For example, ensembling predictions from a convolutional neural network, a random forest, and a gradient boosting model can yield final accuracy close to or above ninety eight percent for leukemia detection. Such hybrid strategies aim to exploit the strengths of different methods while compensating for their individual weaknesses.

In summary, no single algorithm is universally best for all leukemia diagnosis tasks. Model selection should be tailored to data type, analytic objective, computational resources, and interpretability needs. Hybrid intelligent systems, careful hyperparameter tuning, rigorous cross validation, and high quality datasets together pave the way to optimizing artificial intelligence performance in leukemia diagnosis and to translating these tools into reliable clinical decision support systems.

Challenges and Limitations of Using Artificial Intelligence in Medicine

Despite the remarkable progress of artificial intelligence technologies in healthcare, numerous challenges and limitations still hinder their widespread, safe, and sustainable adoption in clinical and research settings. These challenges span technical, clinical, legal, ethical, and social dimensions. If they are not properly addressed, each of these barriers can undermine the accuracy, reliability, trust, and public acceptance of intelligent medical systems.

The first major challenge is the quality and quantity of medical data available for model development and validation. Machine learning and deep learning algorithms require large, complete, clean, and well annotated datasets. In practice, however, many medical datasets are incomplete, inconsistent, contain missing values, suffer from various forms of bias, or lack reliable labels. This issue is especially pronounced in developing countries with weaker digital infrastructures and fragmented health information systems. Moreover, a significant portion of patient information exists as free text or handwritten reports that are not easily transformed into structured formats suitable for computational analysis.

The second important challenge is model generalizability. Many artificial intelligence

models that are trained in specific environments or using data from a single hospital lose accuracy when applied to real world conditions or diverse populations. For example, a model trained on European patient data may underperform when used for Asian, African, or Middle Eastern populations because of genetic, environmental, behavioral, socioeconomic, or data recording differences. Without careful external validation, such models may provide misleading or unsafe recommendations.

Another major concern is algorithm transparency and interpretability. Many deep learning models, especially neural networks with millions of parameters, function as black boxes, meaning that even developers cannot fully explain how outputs are generated from inputs. In medicine, where decisions must often be justified to patients, families, and care teams and sometimes in legal contexts, this opacity becomes a serious barrier. Although techniques such as feature attribution and saliency visualization have been developed to improve interpretability, they still offer only partial insight into model decision making and may not provide explanations that are fully intuitive for clinicians.

Bias represents another serious risk in artificial intelligence models. If training data are unevenly sampled from different demographic groups, model outputs may perform unevenly across gender, race, ethnicity, or age categories. For

example, a leukemia diagnosis model trained primarily on middle aged men may perform poorly in children, adolescents, or women. Such biases not only reduce accuracy for underrepresented groups but also raise ethical and legal concerns regarding fairness and equity in healthcare delivery.

Integration with health information systems is also a significant challenge. Many hospitals still use legacy systems that are incompatible with modern artificial intelligence platforms. Implementing artificial intelligence requires upgrading infrastructures, adopting standardized data formats, ensuring cybersecurity, and training users in new workflows. Embedding artificial intelligence tools into clinical practice without disrupting care delivery or overloading clinicians with extra tasks is a key concern, and poorly integrated systems may be ignored or misused.

Legal issues also represent substantial limitations. One central question is responsibility: if an algorithm makes an incorrect suggestion that leads to patient harm, who is accountable, the physician who relied on the tool, the algorithm developer, or the company that deployed the system. The lack of clear legal and regulatory frameworks has prevented many institutions from formally adopting artificial intelligence tools in routine care. Concerns about data privacy and confidentiality, especially when dealing with sensitive genomic or behavioral information,

add further complexity and necessitate strict governance and security.

Cultural and human factors matter as well. Some physicians resist substituting or even supplementing human judgment with algorithmic decision making, particularly when they feel that their professional autonomy is threatened. Conversely, some patients distrust diagnoses or recommendations delivered by non human systems, even when accuracy may surpass that of individual experts. Building mutual trust between humans and artificial intelligence requires education, transparent communication, large scale clinical trials, and credible regulatory approvals.

Cost is another major barrier. Developing and training advanced artificial intelligence models requires significant computational resources, specialized software, and high quality datasets, all of which entail considerable expense. Maintenance, updates, monitoring for model drift, and adapting systems to evolving disease patterns also incur ongoing costs. For many healthcare centers, particularly in low income countries or underfunded regions, such investments are not feasible and may widen the global digital divide in access to advanced diagnostic and therapeutic technologies.

In conclusion, despite these challenges, the outlook for artificial intelligence in medicine remains promising. Addressing

the limitations through ethical frameworks, transparent standards, improved data quality, robust evaluation protocols, interdisciplinary collaboration, and targeted investment can pave the way for effective and responsible integration of artificial intelligence into healthcare systems, including in complex fields such as hematologic malignancies.

Databases Used in Leukemia Diagnosis

One of the most important elements in developing and evaluating artificial intelligence algorithms in medicine, particularly for leukemia diagnosis, is access to comprehensive, high quality, and reliable databases. These databases typically include collections of microscopic blood cell images, laboratory test results, clinical patient information, genetic and gene expression data, and in some cases clinical reports and treatment outcomes. Without large, well annotated datasets, it is impossible to train machine learning and deep learning models with high accuracy and generalizability. In recent years, several national and international databases have been created for leukemia research and have played a vital role in the development of intelligent diagnostic systems. One of the most well known and widely used resources for microscopy images is the ALL IDB database, developed by the University of Padua in Italy. It contains color images of peripheral blood

smears from patients with Acute Lymphoblastic Leukemia as well as from healthy individuals. The database consists of two subsets, one for single cell classification and another for full smear analysis. Carefully annotated by experts, it has been extensively used in convolutional neural network based studies and is considered one of the earliest free and standardized image repositories for leukemia research.

Another widely used dataset in blood cell image processing is the C NMC leukemia dataset, which contains thousands of red, green, blue images of blood cells from leukemic patients and healthy individuals. Designed for international competitions on leukemia detection algorithms, its high resolution images and cellular diversity have made it a popular resource for deep learning model training and benchmarking.

For genomic data, The Cancer Genome Atlas is one of the most comprehensive databases. It includes genetic, gene expression, DNA sequencing, RNA sequencing, and methylation data from cancer patients, including those with Acute Myeloid Leukemia. Developed under the leadership of major research institutes, this resource offers open access to investigators worldwide. Using these data, researchers have built machine learning models to identify mutations that drive leukemia onset or progression and to define molecular subgroups.

Alongside this, the Gene Expression Omnibus

serves as another key repository for gene expression data in hematologic diseases. It hosts thousands of datasets, including time series experiments, therapeutic response projects, and patient cohorts across Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and other subgroups. Researchers can mine these datasets to discover shared gene expression signatures and to propose novel leukemia subtypes and prognostic markers.

For clinical and patient record data, large epidemiological databases provide information on incidence, treatment types, and survival outcomes for cancers including leukemia. Researchers have applied regression models, neural networks, and gradient boosting methods to such data for survival modeling and risk stratification. Combining clinical registries with genomic repositories enables the construction of powerful multimodal models that leverage both biological and epidemiologic factors.

In recent years, projects have also aimed at creating multimodal databases that integrate images, genomic data, pathology reports, and even audio recordings of clinical examinations. Some datasets include digital bone marrow images, textual pathology reports, and gene expression profiles from patients with acute leukemias and have been used in studies involving multi input architectures and transfer learning. These resources support research on models that jointly

analyze heterogeneous data types.

In real world clinical settings, data are often fragmented across hospital information systems such as hospital information systems and electronic medical records. Some hospitals, with patient consent and appropriate ethical oversight, compile anonymized data into clinical data warehouses that include medication histories, treatment responses, longitudinal laboratory tests, and evolving blood cell counts. Recurrent neural networks such as long short term memory and gated recurrent units have been applied to analyze such temporal data to predict relapse, response, or complications.

Commercial platforms have also developed proprietary databases for training specialized blood cancer models, although these datasets are generally not publicly available. Establishing local databases tailored to the genetic, environmental, and epidemiological characteristics of specific populations is essential to ensure equitable and effective use of artificial intelligence in leukemia diagnosis and prognosis across different regions.

In summary, the development of standardized databases with diverse biological and demographic representation, structured data, and precise annotations is a foundational requirement for artificial intelligence success in leukemia diagnosis. Open access where possible, strong privacy protection, complete metadata, and adherence to global standards are key elements

in designing effective repositories that support reproducible and generalizable research.

Performance Metrics for Evaluating AI Models

Evaluating the performance of artificial intelligence models in medicine, especially in critical applications such as leukemia diagnosis, requires precise, reliable, and context appropriate metrics. These metrics are not only used to compare algorithms but are also essential for ensuring clinical safety, regulatory compliance, and trustworthiness. Models that perform well in controlled laboratory settings may not succeed in real world clinical environments unless they are assessed against rigorous and meaningful indicators.

One of the most common metrics is accuracy, defined as the ratio of correct predictions to the total number of predictions. While accuracy is useful when datasets are balanced, meaning similar numbers of positive and negative cases, medical data are often imbalanced. For leukemia diagnosis, only a small fraction of samples may be positive. In such cases, a model that predicts no disease for all samples might achieve high accuracy yet be clinically useless because it fails to detect any true patients.

Therefore, sensitivity and specificity become more critical in medical evaluation. Sensitivity, also called recall or true positive rate, refers to the

ability to correctly identify positive cases, which is vital in medicine because missing a true patient can have serious or even fatal consequences. Specificity, the true negative rate, measures the ability to correctly identify negative cases such as healthy individuals. A clinically useful model in leukemia must maintain high sensitivity to avoid missed diagnoses while preserving sufficient specificity to limit unnecessary anxiety and interventions in healthy or low risk individuals.

Another important metric is precision, which indicates how many of the predicted positive cases are truly positive. Precision, combined with recall, is crucial in conditions where false positives carry high costs, such as initiating expensive, toxic, or invasive treatments. The F1 score, which is the harmonic mean of precision and recall, is often used to balance these metrics and to provide a single summary value that reflects performance on positive cases.

The receiver operating characteristic curve and its area under the curve are widely applied for classification performance evaluation. The receiver operating characteristic curve illustrates the trade off between false positive rates and true positive rates across different decision thresholds. The area under the curve ranges from zero to one, with values closer to one indicating better overall performance across thresholds. Values above 0.90 generally represent a strong model in many medical contexts and provide an intuitive

summary of discriminative ability.
For multi class problems, such as distinguishing between Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia, a confusion matrix becomes crucial. It provides class specific counts of correct and incorrect predictions and highlights strengths and weaknesses in identifying particular subtypes. This information can guide model refinement and inform clinicians about which categories may require additional human review.
When models are designed for regression tasks such as survival prediction, gene expression level estimation, or treatment duration, metrics such as mean squared error, root mean squared error, and the coefficient of determination are used. The coefficient of determination measures the proportion of variance in the dependent variable that is explained by the model; values closer to one indicate stronger explanatory and predictive power.
In clinical settings, prediction time and computational efficiency also matter. Even a highly accurate model is impractical if its predictions take many minutes or hours to compute, especially in emergencies or high throughput laboratories. Thus, algorithms that balance speed and accuracy, such as optimized gradient boosting or compact neural networks, are often preferred unless the absolute highest

accuracy is essential and time constraints are less critical.
Interpretability is another informal yet critical metric. Models such as decision trees and logistic regression are easily interpretable by physicians, who can review their rules and coefficients, whereas deep networks may deliver higher accuracy but lack transparency. In medicine, decision explainability is vital for gaining clinician and patient trust, and in some jurisdictions regulatory systems restrict or scrutinize the use of black box models for direct clinical decision making.
Given the multidimensional nature of model performance, relying on a single metric is insufficient. Most successful studies report multiple measures, including accuracy, precision, recall, F1 score, area under the curve, and processing time, so that decision makers can select the most balanced option for their operational needs and risk tolerance.

Domestic Studies on Leukemia Modeling

In recent years, with increased access to medical data and computational capacity, researchers in Iran have also applied artificial intelligence methods for leukemia diagnosis, prediction, and classification. Although challenges such as limited datasets, labeling accuracy, and hardware and software infrastructure remain, domestic studies

have taken significant steps toward developing intelligent medical systems and present a promising outlook for national advancement in this field.

Some early work used support vector machine algorithms to classify blood test data from leukemia patients. Features such as white blood cell count, platelet level, blast percentage, and other hematologic indices served as inputs and achieved high accuracy levels in distinguishing affected individuals from controls. These studies emphasized the role of machine learning algorithms in early stage leukemia screening and highlighted their potential as decision support tools for clinicians.

Other research has applied decision trees and random forests to laboratory and clinical data from Acute Myeloid Leukemia patients. In many of these studies, random forest outperformed individual decision trees, achieving high accuracy in detecting positive cases and demonstrating the importance of ensemble methods. Feature selection techniques, including dimensionality reduction with principal component analysis, were also used to identify the most informative variables and to improve model performance.

Artificial neural networks have been explored for identifying abnormal cells in blood smear images. After preprocessing and extracting geometric, textural, and color features, neural networks classified leukemic cells with high accuracy and

demonstrated the feasibility of computer assisted image analysis for microscopy in local settings. These efforts represent some of the earliest attempts to apply deep learning related methods to hematologic image analysis using domestic data.

Ensemble approaches have also been proposed, combining algorithms such as gradient boosting, support vector machines, and neural networks for survival prediction in leukemia patients. Data from specialty hospitals, including age, leukemia type, gene expression levels, and treatment histories, have been used to build models with high area under the curve values, outperforming individual algorithms and illustrating the benefit of model combination in complex prognostic tasks.

Some groups have analyzed RNA sequencing data from Iranian Acute Lymphoblastic Leukemia patients using deep neural networks to differentiate high and low risk subgroups. Autoencoder layers have been used for dimensionality reduction and extraction of key genetic patterns, demonstrating the feasibility of genomic analysis with relatively limited patient numbers when leveraging deep learning to capture essential features.

Recurrent neural networks, including long short term memory architectures, have been employed to predict treatment response to targeted therapies in Chronic Myeloid Leukemia patients.

Using sequential laboratory data, these models have accurately forecasted response trajectories and provided some of the first examples of applying deep learning to medical time series data in the local context.

Clinical decision support systems have also been tested. Some designs analyze daily hospital data to predict disease exacerbation or therapy adjustment needs, using machine learning backends and clinician facing dashboards. These systems illustrate how artificial intelligence can be embedded into hospital information environments to provide practical guidance.

Overall, domestic leukemia modeling studies show growing progress and diversification. Despite limitations such as small datasets, limited computational infrastructure, and lack of standardization across centers, there is a clear trend toward modern algorithms, genomic analysis, and real world system development. Future research that emphasizes multimodal data integration, advanced deep learning methods, and collaboration between universities, hospitals, and research institutes may drive major advances in artificial intelligence powered leukemia diagnosis and prognosis within the country.

Summary of Theoretical Foundations and Conceptual Framework

Reviewing the theoretical foundations of

leukemia and the applications of artificial intelligence in medical diagnosis, particularly in genomic and imaging contexts, indicates that advanced machine learning and deep learning algorithms can significantly improve the quality, accuracy, and speed of leukemia detection and classification. Earlier sections discussed leukemia types, risk factors, diagnostic and therapeutic methods, together with information technology based tools, especially machine learning, and their potential for clinical data modeling.

Findings from prior studies suggest that deep neural networks, especially convolutional neural networks, are highly effective for blood smear image analysis and for distinguishing normal from blast cells. Meanwhile, models such as random forest, gradient boosting, and support vector machine perform strongly with structured laboratory data, particularly when datasets are of modest size. Long short term memory based models and other recurrent architectures have been applied for time series predictions, such as disease progression and treatment response, by modeling temporal patterns in clinical data.

Given the diagnostic sensitivity and complexity of leukemia, relying on a single algorithm is often insufficient. Hence, recent trends emphasize hybrid and multimodal models that integrate laboratory features, imaging data, genomic information, and treatment histories. By combining these inputs in joint learning

layers, final decisions become more accurate and robust. Hybrid approaches such as convolutional neural network plus multilayer perceptron, or gradient boosting plus recurrent neural networks, have consistently shown superior performance in complex medical contexts compared with single model strategies.

A review of domestic studies shows that, while Iran is in relatively early stages of developing intelligent leukemia diagnostic systems, notable efforts have already applied classification algorithms and neural networks to local patient data. These studies indicate that even with small datasets, careful model tuning, feature selection, and dimensionality reduction can achieve acceptable predictive accuracy and provide valuable decision support.

Data infrastructure has also been highlighted as critical. Resources such as publicly available image and genomic repositories are foundational for model training and validation. Because centralized datasets are limited domestically, collaboration between medical institutions and universities to establish local repositories of images, genomic profiles, and treatment records is strongly recommended.

Evaluation metrics were also discussed, and it was emphasized that relying solely on accuracy is insufficient. Metrics such as sensitivity, specificity, F1 score, and area under the curve must be considered together. In leukemia, where false

negatives carry especially high costs because of missed diagnoses and delayed treatment, sensitivity is of paramount importance, although specificity and precision also remain relevant to avoid unnecessary interventions.

This conceptual framework underpins the subsequent chapters, which will cover model design, data collection, algorithm implementation, and results analysis. The main hypothesis is that combining deep learning with multimodal datasets can significantly enhance leukemia diagnosis performance compared with conventional methods and single source models, thereby supporting more precise and timely clinical decision making.

2. AI FOR HARD-TO-TREAT NEUROLOGICAL CANCERS

Background

Neurological cancers form a dangerous category of cancers that cause severe harm to patients because they lead to poor survival rates and high incidence rates. The three brain tumours glioblastoma and diffuse intrinsic pontine glioma and specific types of medulloblastoma are classified as hard to treat because of their aggressive nature and unfavourable treatment outcomes and restricted available treatment choices. Glioblastoma functions as the most common aggressive brain tumour that affects adults because it makes up 50% of gliomas and patients survive only 15 to 18 months with current medical interventions. The treatment of diffuse intrinsic pontine glioma and other pediatric tumours remains challenging because these tumours exist in locations that prevent surgical removal and conventional radiotherapy offers only short term benefits. The worldwide healthcare system faces a significant problem because these cancers present ongoing treatment obstacles to both patients and medical staff.

The distinct biological characteristics of these tumours make them resistant to treatment.

The protective blood brain barrier and intra tumoral heterogeneity and adaptive signalling networks function as multiple obstacles that prevent drugs from effectively targeting their intended sites. The process of traditional clinical decision making becomes more challenging because it requires the combination of multiple data sources which include imaging results and histopathology findings and genomic sequencing data and ongoing clinical patient records for proper diagnosis and treatment planning. The data contains complex nonlinear patterns that humans cannot effectively understand. People now understand that artificial intelligence and machine learning methods can effectively address these issues.

The application of artificial intelligence technologies in radiology and pathology and molecular profiling has revolutionized oncology practice. Artificial intelligence systems achieve better performance through large scale datasets that enable them to identify complex patterns that traditional statistical models cannot match for improved image segmentation and tumour classification and biomarker discovery. Artificial intelligence based models in neuro oncology show successful results for MRI based tumour boundary definition and glioma grading and molecular subtype prediction. Radiomic and radiogenomic methods allow doctors to create individualized

treatment plans through their ability to link imaging characteristics with genetic changes.

Artificial intelligence technology shows promise for neurological cancer treatment but its application exists in the initial stages of development. The lack of sufficient high quality brain tumour datasets hinders the development of dependable algorithms because it makes it difficult to train and validate them. The use of different imaging protocols across institutions leads to inconsistent results when trying to obtain accurate outcomes. Artificial intelligence models need to be implemented in clinical environments as soon as possible because they need to solve essential privacy protection problems and create transparent prediction systems and unbiased data platforms. The drive toward artificial intelligence based healthcare continues to accelerate and neuro oncology will gain significant advantages because it requires immediate development of innovative diagnostic and therapeutic methods.

This chapter presents an in depth evaluation of artificial intelligence based treatments for neurological cancers that show resistance to conventional therapies. The first section provides information about tumour biology and clinical aspects before discussing artificial intelligence applications for tumour diagnosis and treatment planning and drug discovery and prognosis. The research paper identifies existing barriers to

practical deployment of proposed methods while proposing three promising research directions that include federated learning and multi modal data integration and large scale foundation models. This chapter shows how artificial intelligence technology provides benefits and drawbacks to neuro oncology that will enhance precision medicine for treating dangerous brain tumours.

Artificial intelligence has significantly transformed the diagnosis, treatment, and overall management of hard to treat neurological cancers, particularly glioblastoma and diffuse midline gliomas. Recent progress has demonstrated clinical grade performance in multiple areas, ranging from diagnostic accuracy comparable to or surpassing human specialists to real time guidance systems used during neurosurgical procedures. The integration of machine learning algorithms with advanced neuroimaging has created new opportunities for highly personalized cancer care, and several AI systems are now nearing regulatory approval for implementation in clinical environments.

The most notable breakthrough is found in diagnostic applications, where deep learning models reach exceptional accuracy in brain tumor classification and subtype identification. Current findings show that AI systems can match or exceed the diagnostic capabilities of experienced

neuroradiologists, signaling a major shift in clinical workflows and diagnostic standards.

Modern deep learning architectures have reshaped diagnostic practices for highly aggressive brain tumors. An extensive clinical study developed an automated diagnostic system trained on tens of thousands of patient cases that achieved strong multiclass accuracy across numerous brain tumor categories. When neuroradiologists incorporated AI support into their assessments, their diagnostic accuracy showed significant improvement compared to unaided evaluation. This result highlights the clinical advantage of a collaborative model where human reasoning and artificial intelligence operate together to achieve superior performance.

The use of transfer learning techniques has gained attention due to impressive performance in brain tumor detection tasks. Models based on optimized convolutional networks have demonstrated extremely high accuracy in identifying tumor presence, setting new standards for automated diagnostic capability. These systems have shown particular strength in distinguishing glioblastoma from other brain tumor types, and this is essential for rapid intervention and treatment planning in urgent clinical situations.

Research efforts are increasingly focused on rare and highly malignant tumor types. Innovative hybrid methods combining whole slide digital

pathology with multiparametric MRI have been developed to classify glioma molecular subtypes, achieving competitive results in global evaluations. For diffuse midline gliomas, survival prediction models based on deep learning have outperformed traditional techniques, demonstrating strong predictive power even in external patient cohorts.

Radiomics combined with machine learning has significantly improved prognostic strategies in neuro oncology. By extracting and analyzing detailed quantitative imaging features, these methods have produced robust survival prediction models for glioblastoma. Such approaches combine radiomic features with characteristics derived from deep learning applied to preoperative imaging, helping clinicians estimate outcomes more accurately and adjust treatment plans accordingly.

Multi parametric imaging work has shown that combined diffusion weighted and perfusion weighted MRI features enhance prognostic performance when compared to the use of clinical information alone. Through careful feature selection procedures, strong predictive models have been developed that surpass traditional risk classification strategies, offering more precise patient stratification.

Recent studies highlight the essential integration of clinical data, molecular biomarkers, and

imaging features for predicting therapeutic response. Machine learning approaches that include MGMT methylation status together with radiomic markers successfully differentiate true tumor progression from pseudoprogression, which remains one of the most challenging diagnostic dilemmas in glioblastoma management. These multimodal strategies indicate the direction of future precision neuro oncology approaches.

Deep learning contributions to brain tumor imaging have also reached advanced performance in automated segmentation. Volumetric convolutional neural networks combined with 3D modeling techniques provide high quality segmentation of tumor regions and assist in monitoring treatment response through objective and repeatable measurements. These networks have demonstrated competitive performance on benchmark datasets widely adopted in neuroimaging research.

Comprehensive evaluations show that ongoing advancements in deep learning have significantly impacted the field of medical image analysis. The progression from early convolutional architectures to optimized systems capable of self adapting network configurations has supported state of the art segmentation across diverse imaging modalities. Convolutional auto encoder models have also shown high accuracy in

brain tumor classification tasks, successfully identifying common tumor categories and exhibiting excellent performance across internal validation metrics.

AI supported systems for neurosurgical procedures represent another rapidly advancing development. Systematic reviews of extensive research demonstrate a wide variety of applications, including recognition of surgical workflows, real time tool tracking during microsurgery, and intelligent navigation systems designed to compensate for brain shift and increase tumor resection precision. These innovations further contribute to enhanced patient safety and surgical training.

Clinical validation has confirmed the practical effectiveness of artificial intelligence in neurosurgical environments. A large multicenter trial demonstrated that an AI based intraoperative imaging system using stimulated Raman histology produced diagnostic accuracy comparable to traditional pathology, while delivering results within seconds instead of the longer time required for standard processing. The speed and reliability of this approach support its potential for widespread adoption in operating rooms.

Major advancements have also been reported in intraoperative detection of tumor infiltration. Deep learning systems have been tested across

international medical centers and demonstrated strong performance in identifying infiltrative boundaries that are often missed using standard inspection techniques. These systems have shown the ability to reduce the likelihood of leaving behind high risk residual tumor tissue, which contributes to earlier recurrence.

Emerging temporal deep learning methods have improved monitoring of tumor recurrence, especially in pediatric neuro oncology. By analyzing sequential brain imaging, these models can forecast relapse risk with high accuracy and help guide personalized surveillance strategies. The development of standardized clinical guidelines for artificial intelligence evaluation ensures that new applications meet strict safety, quality, and reproducibility requirements.

The integration of artificial intelligence with neuro oncology has fundamentally changed clinical capabilities across all stages of cancer care. Diagnostic systems that outperform human expertise in specific tasks and real time surgical technologies validated in clinical practice illustrate the maturity of current AI innovations. With regulatory pathways becoming more defined and validation standards established, these systems are poised to broaden access to expert level brain tumor care and support highly individualized treatment strategies for patients facing the most severe neurological cancers.

Background on AI in Oncology

The medical field benefits most from artificial intelligence through its various computational systems that use machine learning and deep learning to achieve human like intelligence. The methods in oncology identify intricate nonlinear relationships between different data types which include imaging results and histopathology samples and genomic information and medical records that standard statistical models fail to detect. The healthcare industry has experienced rapid growth of artificial intelligence systems because of quick computing advancements and expanded biological data availability and large digital image databases.

Machine learning operates through algorithms that learn from data while remaining free from specific programming instructions for rule based operations. The field of cancer research has traditionally used support vector machines and random forests and logistic regression as its main machine learning models for classification and risk stratification tasks. These methods depend on engineered features which include radiomic descriptors extracted from imaging data and gene expression signatures from omics datasets yet their performance requires both high quality features and sufficient dataset size. The algorithms provide efficient operation and interpretability but struggle to process neuro

oncology data because of its complex high dimensional structure and diverse nature.

Deep learning operates as a subfield of machine learning that uses neural networks with multiple layers to learn hierarchical representations from unprocessed data. Convolutional neural networks achieve outstanding performance in medical imaging because they learn to recognize specific features which enable tumour detection and segmentation and classification tasks. Deep learning architectures that include recurrent neural networks and transformer based models enable the analysis of sequential clinical data and molecular profiles to produce enhanced survival analysis and treatment response predictions. The new imaging technologies provide outstanding value for brain tumour diagnosis through their ability to analyse intricate biological patterns and imaging data using sophisticated data driven pattern recognition systems.

Radiomics and radiogenomics serve as fundamental artificial intelligence based methods that support oncology practice. Radiomics uses medical imaging data to extract numerous quantitative features that researchers link to tumour characteristics and patient results. Radiogenomics establishes a connection between imaging features and genetic alterations to develop a non invasive imaging to molecular analysis pathway. These methods need special

attention for glioblastoma and central nervous system tumours because non invasive biomarkers are necessary due to limited tissue access.

Artificial intelligence applications in oncology have achieved stability that allows their deployment for neurological cancer treatment. Artificial intelligence has proven useful in breast and lung cancer diagnosis through its applications in mammography screening and risk assessment and biomarker identification. Machine learning models help doctors identify molecular subgroups in hematologic malignancies which leads to better treatment response predictions for patients. These examples illustrate how artificial intelligence can complement traditional oncology workflows, reduce diagnostic errors, and accelerate drug discovery pipelines.

The neuro oncology field requires special treatment approaches because of its unique characteristics. Brain tumours show significant diversity between patients and within individual patients while treatment success remains limited by both physical barriers and drug resistance mechanisms. Artificial intelligence provides a solution to these complex problems through its ability to combine various data types including MRI and CT scans with histopathology images and genomic data and electronic health records into single predictive models. The integration of multiple diagnostic methods enables better

medical accuracy and customized treatment strategies and enhanced patient survival forecasts.

The background of artificial intelligence in oncology shows how methodological progress and translational capabilities have made artificial intelligence more prevalent in medical practice. The learning ability of artificial intelligence will transform brain cancer diagnosis and treatment methods by studying various cancer types to develop individualized treatment plans for neurological tumours.

Applications of AI in Hard to Treat Neurological Cancers

Diagnosis and Early Detection

Neurological cancer management depends on precise and prompt diagnosis, but this process remains challenging because tumours display diverse characteristics and show faint imaging signs and present difficulties in distinguishing cancerous growths from non cancerous ones. Deep learning as part of artificial intelligence technology shows promising results for enhancing neuro oncological diagnostic precision.

Medical imaging remains the main diagnostic method for brain tumours, especially MRI, yet its interpretation heavily relies on radiologist expertise and remains based on subjective assessment. The accuracy of tumour boundary

detection has improved through the use of convolutional neural networks including U Net and V Net which learn from annotated datasets. The automated systems generate standardized tumour volume measurements which serve as critical elements for treatment planning and response assessment while reducing observer variability. Radiomics enables the analysis of imaging features including texture and shape and intensity which researchers can link to molecular markers and treatment results.

Histopathology and molecular profiling benefit significantly from the integration of digital pathology systems with deep learning algorithms which provide fast analysis of multiple tissue slides because of their joint operational features. The system applies artificial intelligence models to analyse standard H and E images for glioma subtype identification and tumour grade assessment as well as IDH1 or IDH2 mutation detection and MGMT promoter methylation status evaluation. This capability enables pathologists to obtain rapid information about tumour biology which decreases their reliance on traditional invasive molecular testing.

Non invasive biomarkers are gaining importance through radiogenomic methods which link imaging results to the genetic transformations that occur within the human body. MRI imaging signatures have been associated with

EGFR amplification and 1p or 19q co deletion in gliomas which enables molecular subtype prediction without the need for biopsy. This non invasive approach holds significant value for treating diffuse intrinsic pontine glioma because biopsies become challenging to perform when the tumour develops in that location. Artificial intelligence integration with diagnostic methods will improve tumour detection accuracy by using automated grading systems to analyse standard clinical information for molecular data extraction which speeds up treatment choices and enables personalized medical care.

Treatment Planning

The treatment of hard to treat neurological cancers requires surgery and radiotherapy and chemotherapy, yet patients still face poor treatment results. Artificial intelligence technology continues to find new applications in optimizing treatment methods.

Surgical guidance remains difficult because doctors must extract maximum tumour tissue while protecting essential brain functions. The combination of intraoperative MRI and neuronavigation systems with artificial intelligence algorithms enables surgeons to achieve better surgical planning accuracy. Artificial intelligence based segmentation tools allow real time tumour margin and critical

structure identification which helps surgeons achieve better resection outcomes with reduced postoperative complications.

Radiotherapy optimization benefits from artificial intelligence models that are being developed to predict tumour radiosensitivity and execute automated dose planning. Deep learning algorithms produce customized dose distributions which adapt to tumour shapes while maximizing normal tissue protection through rapid processing. Radiotherapy benefits from predictive models that combine imaging data with genomic biomarkers to select patients who need treatment most while reducing harmful side effects.

Chemotherapy and targeted therapy show improved personalization because machine learning algorithms can predict temozolomide treatment results for glioblastoma patients by analysing imaging data and molecular markers and clinical information. Research studies that combine radiomics with genomics have proven their effectiveness in identifying patients who will not respond to treatment so doctors can initiate alternative treatments promptly. Artificial intelligence technology helps physicians choose specific treatments by finding new biomarkers that show how well new drugs work which speeds up the development of personalized cancer therapies.

Prognosis and Survival Prediction

Artificial intelligence technology in treatment planning enables personalized care through optimized therapeutic outcomes and decreased reliance on dangerous aggressive medical procedures. The development of prognostic models in neuro oncology faces major obstacles because patients show wide differences in their responses and neuro oncology patients generally have low survival rates. Artificial intelligence systems generate personalized predictive information through their capabilities which lead to better accuracy in predictions.

Survival prediction models have improved because the Cox proportional hazards regression model has received enhancements through machine learning techniques which include random survival forests and deep learning based survival models. These models generate personalized survival predictions by combining clinical data with radiomic features and genomic alterations.

Histology and genomics integration continues to show strong progress because deep learning frameworks analyse histology slides and genomic profiles to create immediate survival outcome predictions. A convolutional neural network has been developed that integrates histopathological and genomic data to predict glioma patient survival with significantly higher accuracy than

conventional methods.

Risk stratification benefits from artificial intelligence tools that analyse various patient information to create risk categories which help doctors select suitable clinical trial participants and develop individualized treatment plans. The models improve predictive accuracy and enable doctors to identify patients who require advanced medical care or experimental therapies.

Drug Discovery and Repurposing

Artificial intelligence provides more accurate predictions by using data that extends beyond population averages which enables patients and doctors to make better decisions. The development of fresh medications together with reassessments of current treatments serves as a vital approach to enhance treatment choices for hard to treat neurological cancers because current therapeutic strategies fail to deliver satisfactory results. The field of compound discovery has seen fast paced development because artificial intelligence systems now allow scientists to use novel approaches for compound identification and testing.

Virtual screening and drug design rely on deep learning models that use large chemical databases to predict compound binding properties for glioblastoma and multiple molecular targets in brain tumours. A research team uses generative

adversarial networks and reinforcement learning systems to develop new molecules that match specific drug properties.

Drug repurposing advances through artificial intelligence systems that use existing drugs to identify their possible uses in cancer therapy. Network based models analyse gene expression data and signalling pathways and drug target interactions to identify potential glioblastoma treatment options. Machine learning techniques discovered new medical applications for drugs originally designed for epilepsy and viral infection which now demonstrate potential for glioma therapy.

Multi omics integration supports the detection of therapeutic vulnerabilities through the combination of genomic information with transcriptomic and proteomic data. The combination of these methods reveals new potential drug targets which could help treat cancer cells that do not respond to standard treatments. Artificial intelligence technology accelerates drug development and improves drug repositioning capabilities which represent vital progress for aggressive brain tumour treatment because these cancers need rapid medical solutions to improve patient survival outcomes.

Challenges and Limitations

The clinical use of artificial intelligence in neuro

oncology encounters various critical barriers that block its complete implementation. The technical and clinical and ethical boundaries of these limitations result from the intricate characteristics of brain cancers and the current state of artificial intelligence technology advancement.

Data availability and quality remain the main obstacles because researchers do not have enough high quality datasets that include precise annotations for brain tumour analysis. Unlike breast or lung cancers, glioblastoma and other neurological cancers are relatively rare which limits the number of available cases for training robust algorithms. The application of models faces difficulties because institutions employ various imaging protocols and scanner types and acquisition parameters. The limited size of numerous datasets increases the likelihood that models will overfit training data which results in poor performance when tested with external validation data. The Cancer Imaging Archive and multi institutional collaborations continue working to solve this problem, but the requirement for standardized large scale data collection continues to exist.

Model interpretability and trust remain major concerns because deep learning models that achieve high performance still function as black boxes with predictions that cannot be fully explained. Physicians need to understand

clinical results to maintain trust in decisions that affect patient safety and care. The current state of saliency maps and feature attribution methods demonstrates significant shortcomings in their ability to provide clinically acceptable explainability. Medical professionals remain cautious about relying on artificial intelligence systems for critical healthcare decisions because they lack clear insight into how these systems operate.

Integration into clinical workflows also proves challenging because the excellent performance of artificial intelligence models in controlled environments does not easily translate into clinical settings. Artificial intelligence tools must operate within existing hospital systems by integrating with electronic health records and picture archiving and communication systems and other essential infrastructure. These systems must generate immediate results through interfaces that healthcare providers can understand easily. The effective evaluation of artificial intelligence guidance depends on clinicians receiving proper training to interpret and assess these recommendations. Healthcare providers will experience increased workloads when artificial intelligence systems lack interoperability or cannot communicate effectively with each other.

Ethical and legal and privacy concerns also remain significant issues because the use

of artificial intelligence in neuro oncology requires access to sensitive personal health information. Protecting privacy, obtaining informed consent, and meeting regulatory compliance remain ongoing challenges. Training data frequently contains embedded biases based on demographic information and tumour subtypes and institutional practices which can lead to inequitable outcomes in care. Safe implementation of artificial intelligence requires strong regulatory frameworks and equal access to artificial intelligence technologies so that benefits serve all patients.

Biological and clinical complexity further limits artificial intelligence progress because brain tumours display significant biological diversity within individual tumours and between different patients. The complex biological mechanisms of cancer challenge even advanced algorithms because these models may oversimplify disease behaviour or fail to detect rare subtypes. Neuro oncology treatment outcomes depend on tumour biology and individual patient factors including age and comorbidities and functional status which artificial intelligence must consider. Artificial intelligence models require continued development to process multiple types of clinical and biological information to produce accurate and reliable predictions.

Artificial intelligence demonstrates great potential to revolutionize neuro oncology yet

multiple significant obstacles continue to exist. The solution to these problems requires collaboration across institutions to create high quality datasets and develop transparent models and ensure seamless clinical workflow integration along with strong ethical governance systems. Delivering the benefits of artificial intelligence to patients with hard to treat neurological cancers requires addressing the current limitations that restrict progress.

Future Directions

The field of neuro oncology is expected to undergo significant transformation through artificial intelligence implementation during the upcoming decade even though its development remains in an early stage. The creation of new technological strategies shows great potential to solve present challenges while advancing precision medicine for hard to treat neurological cancers.

Multi modal data integration will become increasingly important because artificial intelligence models of the future will unite imaging information with histopathology results and genomic profiles and proteomic measurements and clinical records to develop fully integrated predictive systems. The combination of diverse diagnostic methods enables researchers to analyse brain tumours within their complete biological and clinical context which improves accuracy in diagnosis

and treatment planning. Transformer based deep learning architectures support the integration of multiple large datasets, while the combination of advanced imaging techniques will establish new connections between imaging outcomes and molecular alterations which will accelerate biomarker development and treatment strategy innovation.

Federated and collaborative learning represents a strong solution to the problem of restricted neuro oncology data availability and fragmented distribution. Federated frameworks allow institutions to train models independently without sharing raw data which protects privacy while benefiting from diverse and extensive patient cohorts. Large scale deployment of these techniques would improve current data limitations and reduce institutional biases which would allow artificial intelligence models to function more effectively across different clinical environments. Achieving success requires support from international consortia and multi centre collaborations.

Explainability and clinical trust must improve for artificial intelligence tools to gain widespread clinical adoption. Future research will focus on creating explainable artificial intelligence methods that provide clear results through visual heatmaps and feature importance scoring and natural language descriptions. These developments will increase physician confidence

in artificial intelligence systems which will act as supportive decision tools instead of replacing healthcare expertise. The combination of artificial intelligence predictions with current clinical guidelines will further enhance their practical value.

Foundation models and large language models show rising potential for medical applications because success in natural language processing and computer vision continues to expand into healthcare. Neuro oncology will benefit from foundation models which serve as general purpose systems that combine diverse data sources with existing medical knowledge to produce predictions and generate personalized treatment strategies. The ability of these models to scale and adapt will drive progress faster than traditional task specific approaches can support.

The overall goal of artificial intelligence in neuro oncology focuses on developing precision medicine systems that provide specific treatments to individual patients at optimal stages of care. Artificial intelligence systems may eventually operate as digital twins that create virtual patient models capable of predicting disease progression and treatment responses. These virtual simulations allow clinicians to test therapies while reducing risks and generating valuable clinical insights. The new technologies show strong potential to improve outcomes for aggressive brain tumours because they can guide

timely intervention when treatment delays can lead to severe consequences.

The future of artificial intelligence in neuro oncology depends on integrating improved data access with privacy preserving collaboration methods and explainable systems and strong foundation model architectures. The partnership between technological progress and clinical requirements and ethical principles enables artificial intelligence to transform the treatment of hard to treat neurological cancers into a more effective data driven system of personalized care.

Conclusion

The medical field recognizes glioblastoma and diffuse intrinsic pontine glioma and aggressive medulloblastoma as among the most dangerous cancer types. Many decades of research have not produced meaningful improvements in patient outcomes which demonstrates that healthcare must adopt new approaches to solve its pressing problems. Artificial intelligence technology has emerged as a powerful tool that supports diagnosis and treatment planning and drug development and patient outcome prediction. This chapter has outlined how artificial intelligence is reshaping neuro oncology by improving MRI tumour segmentation with convolutional neural networks and enhancing workflow speed and clinical accuracy with predictive models that combine radiomics

data with genomics information and clinical records. Machine learning technology has become essential for drug discovery and drug repurposing because it accelerates the creation of new treatment possibilities for patients who currently have limited options. The application of these models in clinical settings continues to face multiple barriers that arise from limited data access and unclear algorithmic behaviour and difficulties in system implementation and ongoing medical ethics concerns. Healthcare systems can overcome these obstacles through extensive collaboration and standardized data collection practices and transparent trustworthy modelling approaches that satisfy clinical requirements. Meaningful progress in the field will occur through the combination of multiple data sources with federated learning and explainable artificial intelligence and foundation models. The integration of artificial intelligence with clinical expertise will support the development of customized treatment strategies for challenging brain cancers which outperform traditional medical approaches and offer renewed hope for improved patient outcomes.

3. AI FOR HARD-TO-TREAT GASTROINTESTINAL CANCERS

Background

Hard to treat gastrointestinal cancers include several malignancies that remain among the deadliest in oncology. These diseases often present late, progress rapidly, and demonstrate resilience against conventional therapies. Pancreatic cancer, cholangiocarcinoma, metastatic colorectal cancer that is microsatellite stable, select forms of hepatocellular carcinoma, refractory gastric cancer, and some gastrointestinal stromal tumors are key examples where the standard of care improves survival only marginally. Their biological heterogeneity, frequent genomic instability, and involvement of dense stromal or immune suppressive tumor environments contribute to the difficulty of effective detection and intervention. For many patients, the first diagnosis coincides with an advanced stage when curative treatments are no longer feasible. This trend reflects limitations in early screening, slow symptom development, and insufficient biomarkers that can reliably detect disease onset or therapeutic response.

The global burden of gastrointestinal cancers continues to rise, driven by population aging,

lifestyle changes such as increasing obesity and sedentary behavior, and dietary patterns rich in processed foods. In low resource settings, limited access to medical imaging, specialty care, and timely surgical intervention further deepens disparity. Mortality rates remain high not only because these tumors are aggressive but also because healthcare systems struggle to keep pace with emerging treatments, molecular diagnostics, and personalized care pathways. There is an urgent need for technologies that can accelerate diagnosis, improve decision making, optimize therapy selection, and provide ongoing monitoring using minimally invasive tools.

Artificial intelligence has emerged as a promising catalyst for transformation in this field. The ability of algorithms to integrate high dimensional clinical, genomic, imaging, and pathology data aligns well with the complexity inherent to hard to treat gastrointestinal malignancies. AI can uncover subtle patterns invisible to human interpretation, predict risk and treatment responses, and guide therapy personalization. In doing so, it may reduce the historical disadvantage these cancers have faced, particularly where conventional screening and treatment strategies fall short.

AI in Early Detection and Screening

Delayed diagnosis is a major determinant of

poor outcomes in cancers such as pancreatic or cholangiocarcinoma. Symptoms are often vague, imaging may overlook small lesions, and current blood biomarkers like CA19 9 lack sufficient sensitivity and specificity. AI fueled screening tools are being developed to bridge these gaps. Machine learning models can analyze electronic health records to detect early risk signatures long before clinical suspicion arises. For example, patterns in laboratory values, weight change trajectories, diabetes onset, and abdominal imaging reports can signal elevated risk for pancreatic cancer. Rather than waiting for a tumor to reach a detectable size, risk stratification enables targeted monitoring and timely referral for imaging or molecular testing.

Deep learning techniques applied to radiography, CT scans, and MRI can significantly enhance sensitivity in identifying small tumors or precancerous lesions. Algorithms trained on large image datasets can highlight subtle textural differences that precede visible changes. In bile duct cancers, AI analysis of imaging may reduce misclassification of benign strictures and shorten the diagnostic interval. Endoscopic technologies benefit in similar ways. Computer vision can assist gastroenterologists by identifying early lesions in the stomach or colon with greater precision, reducing miss rates associated with human fatigue or lack of visual contrast.

Integration of liquid biopsy data is another promising avenue. Complex biomarker panels, including circulating tumor DNA and extracellular vesicle signatures, require interpretation of multidimensional molecular landscapes. AI models can improve diagnostic accuracy and potentially distinguish between malignant and benign conditions. When systems combine multiple data sources, they achieve performance exceeding any single modality. This multimodal approach is particularly appropriate for cancers that evade detection through a single standard test.

AI for Personalized Treatment Planning

Treatment of hard to treat gastrointestinal cancers often involves combinations of surgery, radiation, chemotherapy, immunotherapy, and targeted agents. However, many patients fail to respond or experience severe toxicity due to biological variability. Precision oncology calls for better prediction of who will benefit from which treatment strategy. Machine learning models can analyze tumor genomic profiles, transcriptomic signatures, radiomic traits, and patient clinical characteristics to estimate likely drug responses. These tools may advise clinicians when a patient is unlikely to benefit from a conventional regimen and should instead pursue experimental therapies or clinical trials.

For example, microsatellite stable colorectal cancer tends to show limited response to immune checkpoint inhibition. AI can help stratify subsets within this group that have immune active tumor microenvironments and might still respond to immunotherapy combinations. In pancreatic cancer, where surgical resection offers the only realistic chance of cure, predicting which patients are likely to tolerate major surgery and derive long term benefit is essential. AI models incorporating performance status, nutritional state, tumor anatomy, and biological markers can inform multidisciplinary discussions and avoid futile interventions.

Radiomics, the extraction of quantitative features from imaging, has grown in importance. Subtle spatial patterns in tumor tissue captured in CT or MRI can correlate with molecular phenotypes and therapy sensitivity. AI systems translate thousands of radiomic variables into clinically actionable insights. Such approaches offer a noninvasive option for patients whose tumors are difficult to biopsy or exhibit strong intratumoral heterogeneity. Personalization also includes adaptive treatment adjustments. Throughout therapy, AI driven monitoring can detect early resistance, prompting rapid transitions to alternative strategies rather than allowing disease progression.

AI in Surgical and Interventional Decision Support

For many gastrointestinal cancers, surgery or locoregional interventions such as ablation or embolization remain crucial in improving survival. The complexity of these procedures demands meticulous preoperative planning. AI can enhance operative precision by mapping tumor boundaries, vascular anatomy, and potential lymph node involvement with high accuracy. Augmented intelligence platforms allow surgeons to visualize decision critical structures intraoperatively using real time image analysis, reducing the likelihood of incomplete resections.

Robotic surgery and advanced endoscopic procedures benefit from AI based guidance that stabilizes instrument motion, warns of proximity to vital tissues, and automates repetitive actions. In liver cancer care, patient selection for resection, transarterial therapies, or transplantation is a nuanced process. Predictive modeling supports hepatologists in determining which patients stand to gain meaningful survival benefit while minimizing risk of postoperative liver failure. By integrating sequential clinical data, AI can also update risk models continuously rather than relying on static scoring systems.

AI for Drug Discovery and Repurposing

The pipeline for developing new therapeutics for aggressive gastrointestinal tumors is expensive and slow. AI offers pathways to shorten discovery timelines and reduce failure rates. Computational models can simulate drug target interactions, identify vulnerabilities in tumor signaling networks, and propose novel compound structures with optimized pharmacodynamic properties. In cancers with limited actionable mutations, such as many pancreatic tumors, AI aided screens may uncover alternative dependencies or synthetic lethal relationships that could be drugged effectively.

Drug repurposing strategies, powered by AI scanning of pharmacologic and clinical trial databases, reveal unexpected applications of existing medications. Given that many gastrointestinal cancer patients cannot wait years for new therapies, repurposed agents that have already passed toxicity evaluation represent an attractive opportunity. AI can match biological signatures of resistant cancers with suitable compounds originally developed for other diseases, opening new therapeutic routes.

Another compelling area is the design of combination regimens. Synergistic effects among targeted agents, immunomodulators, and cytotoxic drugs are difficult to predict due to complex tumor microenvironment interactions. Machine learning models can forecast synergistic

or antagonistic drug interactions before clinical testing, reducing the trial and error burden. These methods help rationally construct regimens tailored to tumor biology while minimizing unnecessary toxicity.

AI Based Monitoring and Survivorship Support

After initial treatment, patients with hard to treat gastrointestinal cancers face a high risk of recurrence. Traditional follow up models often rely on periodic imaging and symptom reporting, which may delay recognition of relapse. AI enriched monitoring platforms employ continuous data streams from wearable sensors, laboratory tests, and digital health records to identify subtle shifts indicating disease progression or treatment toxicity. Earlier detection of relapse enables intervention during windows when disease remains manageable.

Patient reported outcomes are increasingly recognized as essential in guiding supportive care. Natural language processing can extract clinically relevant insights from patient communication, such as messages sent through electronic portals or conversational inputs captured by virtual assistants. These analyses alert care teams to concerning patterns like worsening pain, nutrition decline, or psychological distress. Personalized care recommendations based on

predictive analytics can improve quality of life even for patients with limited survival prospects.

Survivorship extends to caregivers and families who face significant emotional and logistical challenges. AI powered tools can provide education, coordinate appointments, and streamline access to resources. They reduce the cognitive load on patients during a vulnerable period marked by anxiety and complex treatment pathways.

Challenges and Ethical Considerations

Despite progress, there are persistent barriers to integrating AI into routine care for gastrointestinal oncology. One major challenge is data availability and quality. Rare cancer subtypes often lack large curated datasets required to train robust models. Biological diversity within tumors further complicates the situation. Without representative data, models may perform poorly across populations or exhibit bias. Ensuring equitable model performance across demographic groups is critical, especially considering known disparities in cancer outcomes.

Interpretability is another pressing issue. Clinicians are understandably hesitant to rely on systems whose reasoning is opaque. There is a growing movement toward explainable AI that can articulate which factors are driving a

given prediction. Interpretability is even more important in high risk decisions like treatment escalation or withdrawal. AI should supplement not replace clinical judgment, providing confidence rather than confusion in complex decision making.

Regulatory frameworks must evolve to match the pace of innovation. Many AI systems continuously update as new data arrives, challenging traditional approval processes that assume static medical devices. Accountability in the event of incorrect predictions must be clearly defined. To build trust, transparency in model development, validation, and monitoring is required.

Additionally, patient privacy and informed consent remain paramount. AI systems thrive on large scale data collection, yet sensitive health information must be protected. Ethical usage demands that patients understand how their data will be used and can opt out without compromising their care. Collaboration between industry, government regulation, and healthcare systems is essential to ensure responsible deployment.

Future Directions and Opportunities

The future of AI in managing hard to treat gastrointestinal cancers is promising. As multimodal datasets grow, models will become increasingly comprehensive and accurate.

Integration of real world clinical data from across diverse populations will help refine risk stratification tools and expand personalized therapy approaches. Cross collaboration between oncologists, surgeons, radiologists, data scientists, and patient advocates will shape development priorities toward meaningful impact.

Emerging technologies like federated learning allow AI models to train across distributed databases without transferring patient data, addressing privacy concerns while expanding access to large cohorts. Advanced generative models can simulate virtual cancer patient populations to test therapeutic strategies before implementation. Digital twins of tumors may help oncologists experiment with therapies in silico, predicting response and resistance developments dynamically.

In endoscopy and pathology, real time AI will become a standard feature, increasing diagnostic accuracy and reducing workload. Predictive care pathways will automate parts of the clinical workflow, directing high risk patients to expedited evaluation while reducing unnecessary procedures for low risk cases. Seamless connection between AI insights and clinical action is key, supported by interoperable digital infrastructure.

Patient empowerment will continue to grow as AI enabled tools bring clarity to complex treatment decisions. Personalized education,

emotional support, and treatment navigation will be integrated into holistic care models. As outcomes improve even modestly in the short term, increased survival will lead to further advancements by expanding opportunities for clinical research and treatment refinement.

Importantly, continuous evaluation of ethical, legal, and psychological impacts must accompany technological progress. The ultimate goal is not to replace human expertise but to augment the capabilities of clinicians and expand hope for patients who have historically faced limited options. Early commitments to equity, trust, and patient centered design will determine whether AI fulfills its transformative promise.

Conclusion

Hard to treat gastrointestinal cancers represent one of the most formidable challenges in current oncology due to biological aggressiveness, late detection, and limited treatment responses. Artificial intelligence has become a crucial tool in the mission to change this landscape. With capabilities spanning early detection, personalized therapy guidance, advanced surgical planning, accelerated drug discovery, and improved patient monitoring, AI stands to enhance every stage of the cancer care continuum. The technology is not without its hurdles, particularly in data quality, interpretability, regulatory oversight, and ethical

responsibility. Yet through careful collaboration and continued innovation, AI can shift outcomes in diseases where progress has long been constrained.

The journey is still in its early stages. Success will depend on responsible deployment and a patient centered approach that respects clinician expertise and societal values. By harnessing the full potential of artificial intelligence, the field may finally gain momentum against cancers that have remained unrelenting for decades. The future holds real possibility that early diagnosis becomes more common, treatments more effective, and quality of life more protected, bringing long awaited advances to those confronting some of the most challenging gastrointestinal malignancies.

4. AI FOR HARD-TO-TREAT BREAST AND LUNG CANCERS

AI for Hard to Treat Breast Cancer

Background

Breast cancer represents the most prevalent malignancy in women and a leading cause of cancer related mortality worldwide, especially with a remarkably high burden in low and middle income countries. Although advances in screening and treatment have improved survival in many patients, certain subgroups such as aggressive HER2 positive tumours, triple negative breast cancer, and therapy resistant cases remain a major therapeutic challenge. These hard to treat breast cancers frequently exhibit high recurrence rates, poor prognosis, and limited therapeutic options which emphasizes the critical need for early and precise intervention.

Conventional imaging techniques including ultrasound and mammography play an essential role in diagnosis, yet they continue to demonstrate limitations such as low sensitivity in dense breast tissue and significant interobserver variability. Hard to treat breast cancers including aggressive HER2 positive tumours, triple negative breast cancer, and therapy resistant cases present

major clinical difficulties among patients. These subtypes are typically defined by aggressive behaviour, reduced therapeutic effectiveness, and high recurrence risk which underscores the importance of early accurate diagnosis and treatment planning.

Early diagnosis is widely recognized as a key factor that significantly improves clinical outcomes and long term survival. Mammography has traditionally served as the cornerstone of breast cancer screening and remains fundamental in routine detection. However, the diagnostic sensitivity of mammography declines markedly in women with dense breast tissue, a group known to possess about a fourfold higher risk of breast cancer development. To address this limitation, ultrasound has increasingly been used as a complementary imaging technique. Advanced ultrasound modalities including elastography and Doppler imaging contribute to improved diagnostic precision and reductions in false positive outcomes.

Consequently, the combined use of ultrasound and mammography has become standard practice in many clinical settings and is supported by structured reporting systems such as the Breast Imaging Reporting and Data System (BI-RADS) Atlas. Although BI-RADS and standardized reporting lexicons have improved diagnostic consistency, a shortage of

experienced radiologists as well as the subjective nature of image interpretation and considerable intraobserver and interobserver variability continue to challenge the achievement of timely and accurate diagnosis. Missed diagnoses delay treatment and surgical intervention, while false positives expose patients to unnecessary invasive procedures and significant anxiety. Therefore, a strong need remains for improved diagnostic strategies that enhance radiologist performance and ensure patients receive optimal clinical care through early and accurate detection.

Artificial intelligence has recently played an important role in breast cancer management. The interpretation of ultrasound, magnetic resonance imaging, and mammography has improved with computer aided systems that reduce false positive rates and highlight suspicious regions. As a result, unnecessary biopsies are reduced and clinical workflow efficiency is increased. Deep learning models can reach or even surpass the diagnostic performance of experienced radiologists in recognizing malignant features. Beyond imaging, artificial intelligence combines multi omics information, including genomics and proteomics, to classify tumor subtypes and anticipate therapeutic responses. For example, computational assessment of homologous recombination deficiency provides valuable insights into triple negative breast

cancer, a subtype that commonly resists standard treatments.

Similar progress has been observed in lung cancer. Deep learning algorithms applied to positron emission tomography and computed tomography scans are capable of classifying pulmonary nodules, evaluating disease progression, and predicting programmed death ligand expression, which plays a critical role in determining eligibility for immunotherapy. When combined with genetic and clinical information, radiomics enables more accurate stratification of patients for immune checkpoint treatments. Multimodal deep learning and automated machine learning models have shown improved performance in predicting treatment outcomes for individuals with non small cell lung cancer compared to conventional analytical approaches. These innovations are particularly valuable for resistant cases where urgent alternatives to standard therapies are required.

An additional crucial aspect involves the relationship between immunology, infection, and oncology. Individuals with cancer often experience compromised immune function, which increases vulnerability to opportunistic pathogens such as Pseudomonas aeruginosa. This bacterium is recognized for its multidrug resistance and biofilm forming ability and is frequently associated with hospital acquired

infections that can worsen clinical outcomes. Furthermore, recent research suggests that the tumor microenvironment may host bacteria, including Pseudomonas species, which can influence immune function and possibly contribute to cancer progression.

Artificial intelligence offers promising solutions in this area as well. When microbiome sequencing data are integrated with immunological and clinical information, artificial intelligence can predict infection risk in oncology patients. Machine learning approaches are also applied to characterize host pathogen interactions and identify microbial biomarkers. These findings can guide antimicrobial therapy, support vaccine development, and even reveal bacterial antigens that may serve as potential targets for immunotherapy. This indicates that artificial intelligence, in addition to improving cancer diagnostics and treatment, can strengthen supportive care by addressing infection related complications in immunocompromised patients.

Altogether, artificial intelligence provides a transformative approach to the management of hard to treat lung and breast cancers. By synthesizing complex imaging, molecular, and immunological data, artificial intelligence enables clinicians to refine therapeutic strategies, anticipate treatment resistance, and protect vulnerable patients from infectious threats. The

integration of immunology, microbiology, and oncology within artificial intelligence driven systems represents a major shift toward precision medicine, offering the potential for improved quality of life and increased survival in affected individuals.

Multimodal AI Integration: Beyond Single Modality Limitations

Traditional diagnostic approaches continue to face major limitations. Mammography, although considered the primary modality for breast cancer screening, has reduced sensitivity in dense breast tissue which affects a significant portion of women at greater risk of breast cancer. Ultrasound has increasingly been integrated as a complementary technique, particularly through modalities such as elastography and Doppler imaging which contribute to decreased false positive rates and improvements in diagnostic precision.

The BMU Net model reflects the strength of multimodal integration by analysing more than nineteen thousand medical images collected from thousands of patients across multiple centres. This artificial intelligence system combines mammography interpretation using cranial caudal and mediolateral oblique views, trimodal ultrasound assessment including B mode and colour Doppler and elastography imaging,

clinical metadata incorporating demographic information, body mass index, and clinical history, and molecular profiling using circulating tumour DNA evaluation. Through this comprehensive design, the model achieved over ninety percent overall accuracy when compared with preliminary pathology analysis and demonstrated performance at a level similar to experienced radiologists for tumour classification and superior capability in differential diagnosis at the pathology standard.

Beyond specific systems such as BMU Net, the continuous development of artificial intelligence and machine learning approaches is expected to play an important role in overcoming diagnostic challenges. Early machine learning models utilized handcrafted features that frequently failed to generalize across different scanner types and imaging protocols which limited their clinical usability. In contrast, deep learning methods are now capable of automatically extracting predictive features from medical data, showing sensitivity and specificity results comparable to board certified radiologists.

Multimodal artificial intelligence models enhance this ability further by integrating diverse data types including clinical information, radiological data, histopathological details, molecular characteristics, and text based electronic health record information. This integration results in

more comprehensive diagnostic support than unimodal artificial intelligence implementations. However, critical barriers still remain. Existing standards require cranial caudal and mediolateral oblique mammographic views, while full ultrasound evaluation requires B mode, colour Doppler, and elastography imaging. In clinical practice, physicians must also assess contextual patient characteristics including age, body mass index, and clinical history which are often overlooked in artificial intelligence systems. Additionally, many existing studies have not been prospectively validated in diverse populations and real world clinical environments where missing or incomplete data frequently occur. These challenges highlight the importance of continued evaluation to determine the advantages of multimodal artificial intelligence over unimodal systems in improving diagnostic accuracy for hard to treat breast cancer.

Unimodal artificial intelligence systems, which operate based on a single imaging modality such as mammography, ultrasound, magnetic resonance imaging, digital breast tomosynthesis, or nuclear medicine techniques, have demonstrated promising results in breast cancer detection. Nevertheless, their application remains limited because they cannot fully capture the biological and clinical heterogeneity associated with aggressive and therapy resistant breast

cancer subtypes. Multimodal artificial intelligence approaches, by contrast, combine heterogeneous sources of medical information and therefore provide improved performance and enhanced biological interpretability. This combination creates a more complete framework for clinical decision making and supports efforts to advance personalized medicine in oncology.

Conclusion and Future Direction

Artificial intelligence models have not yet undergone sufficient prospective validation across diverse patient populations, and challenges regarding incomplete real world clinical data persist which continues to hinder consistent implementation. Despite these difficulties, emerging evidence demonstrates that multimodal artificial intelligence can support clinical translation by improving risk stratification, therapy selection, and personalized disease management for hard to treat breast cancer.

Although multimodal artificial intelligence typically achieves improved sensitivity and specificity when compared with unimodal systems, significant challenges remain concerning the seamless integration of complex imaging and molecular and histopathological and clinical data into healthcare practice. Future research should focus on prospective multi centre validation, continued refinement of hybrid architectures,

and incorporation of contextual clinical variables to enhance performance reliability and general applicability.

Continued advancement of multimodal artificial intelligence promises earlier detection, more precise treatment planning, and improved management strategies for patients with hard to treat breast cancer, ultimately supporting enhanced clinical decision making and improved patient outcomes.

AI for Hard to Treat Lung Cancer

Background

According to recent cancer statistics, approximately 226,650 new cases of lung cancer including both small cell and non-small cell types were diagnosed in the United States, along with 124,730 deaths which confirms lung cancer as the deadliest malignancy. A substantial majority of cases and related deaths occur in adults aged 65 years and older, with many individuals diagnosed at approximately 70 years of age. More than half of patients receive a diagnosis at an advanced stage, which prevents curative treatment and decreases survival. Diagnostic delays and extended treatment intervals often exceed recommended guidelines, influenced by multiple risk factors including disease related variables such as TNM staging and tumour histology, patient related variables such as comorbidities and

demographics, provider related factors including clinical decision making variations, and system level barriers such as limited access to specialized palliative care. Early detection strategies, rapid access programs, and multidisciplinary coordination show potential to improve outcomes in this hard to treat malignancy.

Artificial intelligence algorithms including deep learning have been applied to multiple domains such as microbiomics, pathomics, radiomics, genomics, transcriptomics, proteomics, and metabolomics in lung cancer research. These applications foster personalized treatment strategies within precision medicine, enhance early detection capabilities, and support accelerated therapeutic development. Through multimodal data integration, artificial intelligence advances clinical decision making across drug discovery, treatment planning, diagnostic evaluation, and disease monitoring. In imaging based screening, artificial intelligence can identify pulmonary nodules with high sensitivity and strong specificity, outperforming traditional radiologist sensitivity levels in specific settings and supporting earlier intervention and improved patient outcomes.

Despite the progress of artificial intelligence assisted imaging for pulmonary nodule detection, traditional screening modalities including chest X rays and low dose computed tomography

still experience limitations such as high false positive results, reader dependent variability, and reduced sensitivity for early stage lesions. Clinical screening trials have shown that low dose computed tomography reduces lung cancer mortality in high risk populations, yet widespread implementation is hindered by limited accessibility, eligibility restrictions, insurance reimbursement challenges, and operational costs.

Research has increasingly focused on blood based biomarkers including circulating tumour DNA as complementary strategies for early lung cancer detection. Liquid biopsy technology enables the identification of molecular and genetic alterations that may appear before radiological detection, increasing opportunities for timely therapeutic intervention. Combining artificial intelligence assisted imaging with biomarker based approaches allows a more precise and efficient screening strategy that improves diagnostic accuracy, supports individualized patient pathways, and reduces unnecessary follow up procedures. These advances hold strong potential to transform detection and treatment, ultimately improving survival and patient quality of life.

Artificial intelligence strategies are also expanding into prognosis prediction and treatment response evaluation. Machine learning models can analyse extensive clinical, molecular,

and imaging datasets to forecast patient outcomes, enable therapeutic regimen selection, and identify individuals most likely to benefit from immunotherapy or targeted therapy. These capabilities help optimize resource allocation, reduce ineffective treatment exposure, and enhance personalized management in both early and advanced stage lung cancer.

Large language models continue to emerge as promising tools within lung cancer care due to their ability to respond to clinical queries in free text format without requiring specific task training. They enable rapid interpretation of large amounts of medical knowledge and offer support in clinical decision assistance, patient counselling, and clinical trial selection. Medical chatbots based on large language models can generate responses comparable to clinician replies in both factual accuracy and communication quality. Artificial intelligence systems also facilitate efficient extraction of patient data for matching individuals with appropriate clinical trial eligibility criteria. However, challenges remain because large language models may generate incorrect or fabricated information as a result of relying on patterns in text rather than true comprehension. For these reasons, human supervision is essential to ensure safe and reliable integration into clinical workflows.

Approved AI Devices in Lung Cancer

The implementation of artificial intelligence algorithms into clinical care for hard to treat lung cancer requires formal regulatory authorization to ensure safety and effectiveness. Rapid development in artificial intelligence technologies challenges existing regulatory frameworks and requires sufficient review mechanisms. Regulatory bodies classify artificial intelligence based medical tools according to patient risk levels. Many oncology artificial intelligence applications are categorized as moderate risk devices where randomized controlled trial evidence may not always be mandatory.

Although approved artificial intelligence technologies demonstrate strong performance in use cases such as lung nodule detection, diagnostic classification, and radiotherapy planning, validation across diverse populations remains essential to ensure reliable real world performance. Regulatory approvals primarily focus on imaging based applications, and successful adoption requires ongoing collaboration among technology developers, manufacturers, healthcare institutions, and policymakers. Refining regulatory standards, creating standardized development protocols, and maintaining post market surveillance are necessary to support safe translation into clinical practice. Such coordinated efforts will strengthen

precision oncology delivery for patients with hard to treat lung cancer.

Challenges and Opportunities in AI for Lung Cancer

Artificial intelligence offers significant promise for lung cancer detection and management, yet clinical implementation continues to encounter major barriers. Access to large and high quality datasets from different clinical institutions is necessary to train and validate robust artificial intelligence models. However, limitations in data sharing because of privacy concerns, regulatory requirements, and ownership issues remain a major obstacle. Methods such as centralized learning initiatives, anonymized public databases, and federated learning approaches offer partial solutions with different benefits and constraints.

Bias and fairness considerations are crucial because artificial intelligence models may inadvertently favor specific demographic or socioeconomic groups, creating or worsening disparities in healthcare delivery. Interpretability presents another key challenge because many deep learning models operate as complex black box systems that provide limited insight into how decisions are produced. Lack of transparency can hinder clinician acceptance and reduce practical usability in critical decision processes.

Reproducibility and generalizability represent

vital requirements because differences in imaging protocols, motion artifacts, scanner variations, noise levels, and inconsistencies in radiologist annotation can diminish model reliability. The adoption of standardized preprocessing workflows, structured reporting guidelines, and standardized feature extraction initiatives contribute to improved consistency in artificial intelligence outcomes. Continued attention to these concerns supports safe and effective deployment in clinical environments and improves precision medicine in lung cancer.

Pathology

Once a suspicious lesion is detected, tissue biopsy remains essential for definitive diagnosis. Traditionally, pathologists review slides manually to identify cancer cells and evaluate features such as tumor grade and biomarker expression. With recent advances, pathology slides can now be digitized into high resolution images, enabling artificial intelligence to support this process. Deep learning algorithms are able to scan entire slides and highlight regions of interest, improving speed and reducing the risk of oversight. These systems serve as valuable diagnostic partners to pathologists by identifying very small tumor deposits, such as early nodal metastases in breast cancer. Artificial intelligence is also increasingly used for quantitative biomarker assessment, including proliferation and receptor expression

markers, providing consistent measurements that contribute to treatment planning. Similar progress is observed in lung cancer pathology, where algorithms have demonstrated the ability to classify subtypes on standard stained slides and predict genetic mutations based on microscopic tissue architecture. These computational pathology technologies hold promise for more automated and quantitative interpretation of tissue specimens.

In summary, artificial intelligence has become integrated into multiple aspects of cancer diagnosis, including interpretation of computed tomography scans and mammograms, digital slide analysis, and detection of subtle features that may otherwise be missed. These systems have already entered routine practice in some settings, with several receiving regulatory clearance for identifying lung nodules or breast abnormalities. Early adopters report that artificial intelligence acts as a dependable assistant, improving diagnostic speed and enhancing accuracy. As clinical experts note, the purpose of artificial intelligence is to support rather than replace clinical judgment, helping healthcare providers make better decisions, reduce diagnostic errors, and improve survival outcomes.

Personalizing Treatment with AI

Every cancer develops uniquely, which requires

treatment strategies tailored to each individual. Artificial intelligence supports precision oncology by integrating genomic markers, clinical characteristics, and imaging features to recommend therapies that are more likely to be effective. In breast cancer, machine learning can predict responses to targeted therapy and immunotherapy by analyzing tumor microenvironment properties and biological traits, making treatment choices more accurate. In lung cancer, artificial intelligence can identify actionable mutations and recognize early indicators of therapeutic resistance, such as resistance to epidermal growth factor receptor inhibitors in non small cell lung cancer. These predictive capabilities allow clinicians to modify treatments at an optimal time, improving patient outcomes and reducing exposure to ineffective medications.

Predicting Outcomes with Precision

Artificial intelligence is reshaping prognostic evaluation in breast and lung cancers. By combining radiomics, pathology, and clinical information, predictive models estimate recurrence risk and survival with notable accuracy. For patients with lung cancer, deep learning applied to computed tomography features contributes to forecasting long term outcomes, supporting personalized follow up planning and risk counseling. In breast cancer,

predictive analytics help identify patients who are unlikely to benefit from aggressive therapy, which reduces unnecessary chemotherapy while maintaining favorable prognoses. These advancements enable patients and clinicians to make more informed decisions, preparing for the future with clearer expectations.

Conclusion and Future Direction

Advancements in artificial intelligence have significantly influenced the field of lung cancer research and clinical management. Artificial intelligence supports early detection, screening accuracy, prognosis prediction, and treatment optimization while enabling personalized care through integrated analysis of complex data streams. Large language models and deep learning architectures show potential to enhance decision support and improve communication between clinicians and patients facing difficult therapeutic choices.

However, regulatory approval processes, challenges in data access and privacy, bias risk, interpretability limitations, reproducibility issues, and generalizability concerns remain barriers to widespread clinical adoption. Continuous development of explainable artificial intelligence approaches, standardized data methodologies, and multi institution collaborations will be essential to facilitate safe integration of these systems

within healthcare.

Looking ahead, artificial intelligence is poised to offer transformative contributions to precision oncology in lung cancer. Integration of artificial intelligence within multidisciplinary care pathways combined with rigorous validation and ethical oversight will support improved early detection, optimized treatment decisions, and enhanced survival and quality of life for patients experiencing this highly lethal disease. Continued collaboration between clinicians, researchers, regulatory agencies, and technology innovators remains crucial to achieving these advancements.

5. AI FOR HARD-TO-TREAT UROGENITAL CANCERS

Background

Hard to treat urogenital cancers represent a major challenge in modern oncology because they often show aggressive biological characteristics, poor clinical responses to available therapies, and substantial diversity in tumor genetics and microenvironment features. These cancers arise in the urinary and genital systems, including prostate cancer in its metastatic or castration resistant forms, muscle invasive bladder cancer, advanced renal cell carcinoma, testicular cancers that relapse after first line therapy, and rare malignancies such as penile carcinoma or upper tract urothelial carcinoma. Patients diagnosed with these diseases may experience late stage detection, limited access to precision therapies, rapid development of resistance, and physical or psychological burdens that negatively affect survival and quality of life.

Epidemiologically, prostate cancer remains one of the most commonly diagnosed malignancies in men around the world, but while early stage disease is often curable, metastatic castration resistant prostate cancer continues to carry a poor prognosis. Bladder cancer frequently recurs

and can progress to muscle invasive disease that requires complex multimodal treatment. Renal cell carcinoma shows unpredictable behavior and immunologic complexity, while late relapses in testicular cancer can require salvage regimens that lack optimal patient selection strategies. Health disparities and resource limitations further exacerbate outcomes, particularly where delayed diagnosis and limited access to expert oncology teams persist.

Biomedical research over the last decade has made meaningful progress toward precision oncology, yet the clinical management of these complex cancers remains constrained by insufficient predictive tools and fragmented data availability. Imaging modalities, genomic sequencing, pathology interpretation, and clinical data all play a role in characterization and treatment selection, but integrating these diverse information sources remains an ongoing challenge. The urgent need for earlier diagnosis, improved risk assessment, optimized treatment allocation, and better monitoring of recurrence and toxicity motivates breakthroughs in computational and analytic techniques.

Artificial intelligence is rapidly emerging as a powerful set of tools capable of changing the way clinicians detect, classify, and treat urogenital cancers. Through machine learning, deep learning, and decision support applications,

AI offers abilities to analyze high dimensional data at a scale no human can match. The goal is not simply faster computation but deeper understanding of tumor biology, more accurate interpretation of medical information, and actionable predictions that improve outcomes. The integration of AI into urogenital oncology promises new opportunities in screening, image analysis, molecular discovery, treatment optimization, and personalized survivorship.

This chapter examines how AI technologies are being applied across the care continuum for hard to treat urogenital cancers, the current limitations that must be addressed, and the future directions likely to define the next era of oncology innovation.

AI in Early Detection and Risk Stratification

Early detection remains one of the most powerful predictors of survival in urogenital cancers. Prostate cancer screening through prostate specific antigen testing has reduced mortality but also resulted in overdiagnosis and overtreatment. AI models have the potential to refine screening decisions by combining longitudinal PSA values with clinical history, imaging reports, and genetic risk markers. Risk prediction tools powered by machine learning can identify individuals who are more likely to harbor clinically significant tumors

and reduce unnecessary biopsies.

Multiparametric MRI has become central to detecting prostate cancer, yet radiologic interpretation varies across clinicians. AI driven radiology solutions can detect suspicious regions, characterize tumor aggressiveness, and assist biopsy planning with improved consistency. These systems can improve cancer detection rates while lowering false positives. Algorithms that evaluate temporal changes in imaging can also support better surveillance strategies for patients on active monitoring programs.

Bladder cancer screening remains difficult because common tests such as urine cytology have limited sensitivity. AI enhanced interpretation of urinary biomarkers, cellular morphology, and genomic signatures can increase diagnostic accuracy and may identify disease earlier than current methods. In renal cell carcinoma, incidental detection is common but prognosis depends heavily on stage at diagnosis. Machine learning applied to electronic health records can help recognize individuals at high risk due to genetic disorders, occupational exposures, or metabolic conditions, potentially enabling earlier imaging referrals.

Testicular cancer often manifests with palpable symptoms, yet delayed medical attention among young men remains an issue. AI enabled educational outreach programs and digital symptom checkers can encourage earlier

evaluation, especially in underserved populations. Once a tumor is identified, algorithms that analyze serum markers and ultrasound images may support more accurate staging and help determine who can safely avoid overtreatment.

Overall, intelligent risk stratification and early detection tools enhance precision at the front end of care, allowing clinicians to intervene during the window when cure is achievable.

AI for Imaging Interpretation and Tumor Characterization

Medical imaging plays a critical role in diagnosing and staging urogenital cancers, but conventional reading relies heavily on expert interpretation. AI methodologies transform imaging into quantitative data rich in biological information. In prostate cancer, deep learning networks trained on thousands of MRI scans can differentiate low grade from clinically significant disease more accurately than standard assessment alone. Algorithms can measure tumor volume, shape irregularities, and tissue texture that correlate with histopathology.

For bladder cancer, cystoscopic visualization is the primary diagnostic technique. Automated image recognition can assist urologists by highlighting suspicious lesions in real time, reducing the number of tumors that escape detection. Fluorescent imaging techniques paired with AI can identify cancerous regions invisible

under white light endoscopy, improving resection completeness.

In renal cell carcinoma, radiomics provides insights into tumor vascularity, necrosis, immune cell infiltration, and potential drug sensitivity. AI models that integrate CT imaging data with clinical and molecular indicators offer a platform for noninvasive tumor subtyping, helping clinicians distinguish indolent tumors from those that may require early systemic intervention. These imaging supported predictions can reduce unnecessary surgeries and guide the use of active surveillance.

Metastatic disease evaluation also benefits from computational interpretation. In castration resistant prostate cancer, bone metastasis detection with whole body imaging can be challenging. AI systems outperform humans in identifying skeletal lesions and quantifying disease burden, improving treatment planning and prognosis assessment. Automated tracking of metastasis response to therapy supports adaptive treatment modifications that protect quality of life.

The evolution of imaging into a data rich diagnostic platform depends significantly on AI, facilitating more comprehensive tumor characterization and more precise treatment strategies.

AI for Molecular Profiling and Precision Therapy

Advances in genomic sequencing have expanded knowledge of actionable mutations in urogenital cancers, yet connecting molecular data to effective therapies remains complex due to heterogeneity and limited biomarkers. Machine learning models can interpret genomic alterations, epigenetic changes, transcriptomic activity, and proteomic patterns to predict treatment response or resistance.

In prostate cancer, alterations in DNA repair genes such as BRCA1 and BRCA2 indicate benefit from PARP inhibitors, but responses are variable across patient populations. AI can help identify additional molecular dependencies and reveal gene interaction patterns that modify treatment sensitivity. Predicting androgen receptor activity levels using transcriptomic signatures may optimize the use of hormonal therapies.

Muscle invasive bladder cancer demonstrates significant variation in immunotherapy outcomes. AI enabled clustering of tumor molecular profiles supports improved patient selection for checkpoint blockade. Tumor microenvironment analysis through computational pathology can identify immune excluded phenotypes that may respond to combination therapy rather than monotherapy.

Renal cell carcinoma displays intricate immune and metabolic biology. AI tools can discover molecular subsets more likely to respond to VEGF targeted agents or immune checkpoint inhibitors, reducing unnecessary toxicity and improving survival. Multiomic integration helps reveal composite predictors far beyond what single biomarker strategies can achieve.

For rare cancers such as penile carcinoma, small sample sizes hinder traditional analysis approaches. Transfer learning techniques allow models trained on more common cancer datasets to support clinical insights in low incidence diseases, potentially accelerating access to personalized therapies.

By linking molecular complexity to therapeutic opportunity, AI fosters more precise and effective treatment selection across urogenital cancers.

AI Enhanced Surgical and Interventional Planning

Surgery and interventional oncology play primary roles in the management of many urogenital cancers. The quality of local control often determines long term outcomes, especially in diseases such as muscle invasive bladder cancer or testicular cancer. AI has a valuable impact in operative planning, intraoperative decision support, and postoperative evaluation.

Robotic assisted prostatectomy is widely used for

localized disease. AI can support surgeons by predicting optimal nerve sparing strategy based on tumor location and potential extracapsular extension. Preoperative models that incorporate MRI data improve surgical margin outcomes and preserve functional results such as continence and sexual function.

Bladder cancer surgery requires thorough lymph node dissection and precise decision making around urinary reconstruction. Predictive analytics can estimate the likelihood of node involvement and determine when extended dissection is justified. AI can also model postoperative recovery trajectories to personalize counseling and resource planning.

Partial nephrectomy for renal cell carcinoma is technically demanding when tumors are in complex anatomical positions. Algorithms that reconstruct three dimensional kidney vasculature and tumor boundaries can guide approach selection and reduce complications such as ischemia time or renal function loss. Automated evaluation of operative video content provides performance metrics that support surgeon training and continuous improvement.

Interventional techniques such as biopsy targeting and ablative therapies also benefit from computational precision. AI directed targeting minimizes sampling error in heterogeneous prostate tumors and ensures that the

most clinically relevant region is evaluated histologically. Thermal ablation planning guided by tumor behavior models can improve local control in kidney tumors deemed inappropriate for surgery.

These enhancements demonstrate how AI amplifies surgical expertise, reduces procedural variability, and supports optimal outcomes.

AI for Drug Discovery and Adaptive Therapy

Developing new therapies remains critical for patients who progress after standard treatments. AI accelerates drug discovery and development by modeling complex biological pathways, identifying drug targets, and prioritizing candidate molecules. Computational simulations can analyze chemical libraries far faster than traditional laboratory screening, dramatically reducing development timelines.

In metastatic prostate cancer, resistance evolves through diverse pathways involving androgen receptor signaling, neuroendocrine differentiation, and lineage plasticity. AI modeling can reveal pathways that maintain survival despite therapy, highlighting vulnerabilities for next generation treatment strategies. Drug repurposing algorithms may match existing compounds to emerging resistance phenotypes.

Bladder cancer drug discovery benefits from

machine learning in combinational strategy design. Predicting synergy between immune modulation and targeted therapy could lead to safer and more effective regimens. Algorithms that simulate tumor evolution under therapy allow oncology teams to adapt treatments dynamically, maintaining pressure on cancer cells to prevent resistance emergence.

Kidney cancer research faces complexity due to highly variable immune microenvironments. Deep learning analysis across datasets can uncover therapeutic biomarkers that predict sustained response to immune blockade or novel cytokine therapies.

AI guided clinical trial design enhances patient selection and endpoint prediction, ensuring that high potential therapies reach market efficiently. Adaptive trial frameworks supported by real time analytics can modify treatment arms based on interim performance, minimizing exposure to ineffective strategies.

These innovations accelerate therapeutic progress and hold promise for improving survival in patients who urgently need better options.

AI in Digital Pathology and Tumor Microenvironment Assessment

Pathology remains fundamental to cancer diagnosis and staging. Traditional microscopic interpretation is qualitative and subject to

variation among experts. AI transforms pathology into a quantitative science by examining whole slide digital images at granular resolution.

In prostate cancer, computational models can predict Gleason grading with high accuracy, reducing interobserver variability. Algorithms can detect perineural invasion, extraprostatic extension, and other prognostic features automatically, improving report completeness. Predicting tumor aggressiveness from histology alone provides insights that can supplement genomic testing.

Bladder cancer specimens may display heterogeneity that challenges manual evaluation. Deep learning can identify areas of carcinoma in situ, assess lamina propria invasion, and predict risk of recurrence. Tumor microenvironment features, including immune cell density and spatial relationships, can be quantified to guide immunotherapy strategies.

Renal tumor pathology contains diverse histologic subtypes with differing treatment implications. AI can classify rare subtypes with higher accuracy, reducing the risk of therapeutic misdirection. Predictive models may detect sarcomatoid transformation earlier, prompting aggressive management.

Digital pathology offers the ability to standardize global cancer care by making expert level

interpretation available in regions lacking trained specialists. Combining pathology signals with radiologic and genomic data supports comprehensive tumor behavior modeling.

The future of pathology in urogenital oncology relies on AI to enhance diagnostic precision and deepen biological insights that guide therapy decisions.

AI Based Monitoring, Recurrence Detection, and Survivorship

Long term follow up is essential due to the high recurrence risk in many urogenital cancers. Traditional monitoring often relies on periodic imaging and biomarkers that may fail to detect relapse early enough for curative salvage.

Machine learning applied to serial PSA measurements in prostate cancer can predict biochemical recurrence more accurately than simple threshold based approaches. Algorithms detect subtle growth patterns representing early tumor regrowth even before standard triggers are met. Imaging surveillance enhanced by AI improves localization of recurrence, enabling targeted therapies such as metastasis directed treatment.

In bladder cancer, frequent cystoscopy is burdensome for patients. AI enhanced urinary biomarker interpretation may reduce procedure frequency without compromising safety.

Predictive models can individualize surveillance intensity based on risk.

Patients treated for kidney cancer require ongoing evaluation because late recurrence is possible. AI driven interpretation of surveillance imaging reduces misclassification of benign findings and avoids unnecessary interventions.

Beyond recurrence detection, AI tools support symptom reporting and toxicity management. Natural language processing can extract clinically relevant concerns from patient messages or virtual visits, allowing care teams to intervene early when complications arise. Wearable data may identify patterns of fatigue, sleep disruption, or cardiovascular strain linked to treatment effects.

Survivorship also involves psychosocial and lifestyle support. Intelligent coaching platforms tailored to individual needs can improve adherence to exercise and nutrition recommendations, leading to better long term quality of life.

These capabilities provide more personalized, patient centered care throughout recovery and beyond.

Challenges, Limitations, and Ethical Considerations

Integrating AI into clinical workflows for hard

to treat urogenital cancers requires attention to several limitations. Data access and quality are major challenges. Rare disease subtypes lack sufficiently large datasets for high performing models. Data fragmentation across institutions obstructs robust training and validation. Bias may occur if population diversity in the training dataset is limited, potentially widening disparities.

Interpretability remains a significant concern. Clinicians need clear explanations of algorithmic recommendations to trust AI decision support, especially in high stakes situations such as treatment escalation or surgical planning. Collaboration between technologists and clinicians is necessary to design models that align with clinical reasoning.

Regulation and safety governance must evolve to account for systems that update continuously or learn adaptively. Validation standards must ensure consistent performance across settings, and mechanisms for long term monitoring are essential.

Privacy and ethical data use require transparent patient communication about how personal health information contributes to AI performance. Strategies such as federated learning can enable model improvement without compromising privacy.

Workforce impacts also require thoughtful planning. AI aims to assist rather than replace clinicians, enhancing efficiency and allowing more focus on patient interaction. Training health professionals to work with AI tools builds confidence and maximizes benefit.

Addressing these challenges ensures that AI adoption strengthens care while respecting equity, autonomy, and safety.

Future Directions

As AI technology continues to advance, several key trends will shape the future of urogenital cancer care. Multimodal AI models will integrate imaging, genomics, pathology, wearable data, and clinical history into unified predictive frameworks that capture tumor complexity more completely. Real time AI assistance will become increasingly common during diagnostic, surgical, and therapeutic interventions.

Digital twin models representing individual patients may allow clinicians to test virtual treatment strategies and forecast outcomes before applying them in clinical practice. Advances in robotics will combine with AI to enhance precision in minimally invasive surgery. AI powered telemedicine tools will expand access to expert level care for remote or underserved populations, reducing global outcome disparities.

Patient empowerment will grow as AI

democratizes access to medical information and supports shared decision making. Rather than a passive role, patients will become active interpreters of personalized analytics that guide their care journeys.

Scientific collaboration networks leveraging AI will accelerate discovery by sharing knowledge efficiently across institutions and continents. New therapeutic innovations, especially in immuno oncology, will emerge more rapidly through computational modeling.

The success of these future directions relies on maintaining a balance between technological innovation and ethical responsibility. A patient centered focus, continuous evaluation, and inclusive data practices will ensure that AI fulfills its promise in transforming outcomes for patients with hard to treat urogenital cancers.

Conclusion

Hard to treat urogenital cancers remain formidable clinical challenges due to aggressive behavior, high recurrence risk, and limited predictive tools. Artificial intelligence provides pathways to overcome traditional barriers across the entire continuum of cancer care. From early detection and risk stratification to precision therapy selection, surgical optimization, recurrence monitoring, and survivorship enhancement, AI technologies

are driving oncology toward greater accuracy, personalization, and efficiency.

Yet success depends on careful implementation grounded in transparency, validation, ethical conduct, and equitable access. AI must enhance clinician expertise while respecting the complexity of human disease and the lived experiences of patients. By embracing multidisciplinary collaboration and responsible innovation, AI can help shift prognosis and quality of life in favor of individuals facing some of the most difficult urogenital malignancies.

The future holds opportunities for earlier cures, longer survival, and more empowering care journeys. With thoughtful advancement, AI will continue to shape a more hopeful landscape for patients around the world confronting these challenging cancers.

6. AI FOR HARD-TO-TREAT SKIN AND SOFT TISSUE CANCERS

Background

Skin and soft tissue cancers encompass a diverse group of malignancies that arise from the epidermis, dermis, subcutaneous tissues, connective structures, and supporting components of the body. Many are treatable when detected early, particularly common subtypes such as nonmelanoma skin cancer. However, several forms are classified as hard to treat due to their aggressive nature, resistance to conventional therapies, or delayed diagnoses that cause progression to advanced stages. These include malignant melanoma with metastatic spread, advanced sarcomas of connective tissue origin, Merkel cell carcinoma, dermatofibrosarcoma protuberans, and rare cutaneous adnexal tumors. Although each cancer type has unique biological features, they share common challenges that complicate care: significant heterogeneity, frequent misdiagnosis or late detection, limited effective systemic therapies for advanced stages, and a high likelihood of recurrence or spread through lymphatic or hematologic pathways.

The incidence of skin malignancies continues to rise globally due to increased ultraviolet

exposure, aging populations, and environmental factors. Soft tissue sarcomas are less common but account for a disproportionate percentage of cancer mortality due to their difficulty in achieving durable control. Many patients require multimodal treatment approaches involving surgery, radiation therapy, chemotherapy, immunotherapy, or targeted agents. Yet outcomes vary widely even within tumors classified similarly under histopathologic standards. The unpredictable biologic behavior of melanoma or sarcoma can frustrate treatment planning and create uncertainty for both clinicians and patients.

Traditional diagnostic pathways rely on expertise in dermatology, surgical oncology, and pathology. Clinical examination and imaging often fail to identify early aggressive disease, and biopsies may address only a small fraction of a heterogeneous lesion. Moreover, the integration of genomic, proteomic, and radiographic evidence into a single decision making framework remains inconsistent in practice. These circumstances create a pressing need for tools capable of uncovering deeper biological insight, predicting outcomes more accurately, and enhancing clinical judgment at every stage of care.

Artificial intelligence represents a transformative approach to meeting these needs. From screening suspicious lesions to predicting metastasis risk, from stratifying soft tissue sarcoma subtypes to

guiding multimodal therapy, AI enables analysis of complex and high dimensional patient data in ways that exceed manual capacity. Machine learning and deep learning are being applied across clinical, radiologic, digital pathology, molecular profiling, and real time monitoring workflows. AI driven solutions show promise for increasing diagnostic speed, reducing variability, tailoring treatment plans, and improving survival for patients who historically have faced limited options.

This chapter explores the applications, advantages, and limitations of AI in the detection, characterization, and management of hard to treat skin and soft tissue cancers, as well as considerations for future implementation in oncology practice.

AI for Early Detection and Screening

Early identification of aggressive skin cancers is crucial for improving survival rates. Delays in recognizing malignant melanoma or rare skin tumors lead to more widespread disease, extensive surgeries, and reduced opportunities for cure. Many patients first detect skin lesions on their own, and general practitioners are frequently the first evaluators. However, visual inspection accuracy varies significantly among clinicians and even among specialists. Artificial intelligence is stepping in to support earlier recognition of

malignancies through automated image analysis and risk modeling.

Deep learning models trained on vast datasets of dermoscopic and clinical skin lesion images can distinguish melanoma from benign nevi with accuracy comparable to or exceeding experienced dermatologists. These algorithms evaluate subtle color variations, asymmetries, border irregularities, and structural patterns that may signal malignancy but are difficult for the human eye to discern consistently. AI enabled smartphone applications extend this capability into community settings, enabling individuals in remote areas to receive prompt screening support and reduce disparities in access to care.

In primary care and telemedicine environments, AI decision support systems help clinicians decide when to refer for biopsy or specialist evaluation. By analyzing medical history, lesion photographs, and symptom descriptions, risk stratification models can identify patients most likely to benefit from expedited diagnostic procedures.

Screening challenges extend beyond melanoma. Merkel cell carcinoma often presents as a firm, painless lesion mistaken for a benign cyst. AI models trained with clinical context may help distinguish these lesions earlier. The same applies to dermatofibrosarcoma protuberans, where nodules develop slowly but can become locally aggressive if overlooked. Likewise, Kaposi sarcoma

in immunocompromised individuals may be more easily flagged through image based risk classifiers that contextualize skin changes alongside patient immune status and viral co factors.

AI based monitoring tools also show potential for surveillance of individuals with genetic predispositions or histories of UV overexposure. Personalized risk scores updated in real time may identify skin transformations long before symptoms develop. These innovations expand the reach of dermatologic care and offer a pathway toward earlier and more equitable detection.

AI in Imaging and Radiomics for Soft Tissue Sarcomas

Soft tissue sarcomas present complex imaging and diagnostic challenges due to their diverse origins, variable patterns of growth, and tendency to infiltrate surrounding tissues. MRI and CT scans are primary modalities for preoperative evaluation, but interpretation requires significant expertise and subjective judgment. Radiomics, supported by AI, provides a powerful method to quantify tumor phenotype through high dimensional feature extraction from medical images.

Machine learning algorithms applied to MRI can assess tumor margins, vascularity, necrosis, and stromal composition. These characteristics correlate with histologic grade and metastatic

potential, informing treatment decisions such as whether to pursue radiation, neoadjuvant chemotherapy, or wide surgical margins. AI helps identify specific imaging signatures associated with dedifferentiated liposarcoma, synovial sarcoma, or leiomyosarcoma, which may otherwise be challenging to distinguish without invasive biopsy.

Inoperable sarcomas or those undergoing systemic therapy can be monitored more precisely using AI models that detect subtle changes in tumor response before visible shrinkage occurs. Predicting non response early can prevent months of ineffective treatment and allow clinicians to pivot toward more promising strategies.

Image guided interventions such as biopsy and localized ablation also benefit from AI enhanced targeting. Algorithms can identify the most biologically active regions of heterogeneous tumors, maximizing diagnostic yield and allowing therapeutic energy delivery where it is needed most. Integration of radiomics with genomics, known as radiogenomics, holds promise in connecting molecular alterations with imaging phenotypes and ultimately supporting a comprehensive understanding of sarcoma biology.

AI Enhanced Dermatopathology and Histologic Interpretation

Pathology plays a central role in diagnosing

skin and soft tissue cancers, yet manual interpretation is time consuming and prone to interobserver variability. The introduction of whole slide digital imaging and convolutional neural networks enables automated analysis with high reproducibility.

AI systems can detect architectural disorganization, mitotic rates, ulceration, tumor infiltrating lymphocyte patterns, and invasion depth in melanoma biopsy specimens. Predictive models link these features to staging and survival outcomes, offering greater precision in selecting appropriate therapy intensity. Algorithms can also flag ambiguous or borderline lesions for more thorough review, reducing the risk of missed melanoma diagnoses.

Soft tissue tumor pathology benefits from similar computational advances. Many sarcomas share overlapping microscopic features, making differentiation difficult even for experts. Deep learning models can distinguish complex subtypes by analyzing cell morphology, extracellular matrix relationships, and vascular characteristics. By integrating immunohistochemistry data, AI aids in identifying relevant biomarkers such as PD L1 levels or lineage specific markers that influence treatment selection.

Automated quantification of tumor infiltrating lymphocytes and other microenvironmental

attributes contributes to immunotherapy response prediction. Digital pathology tools can analyze thousands of features simultaneously, revealing patterns that may be invisible through traditional visual review.

As access to specialized sarcoma pathology remains uneven worldwide, AI supported platforms offer a scalable way to democratize expert interpretation and improve diagnostic accuracy on a global scale.

AI for Genomic Profiling and Precision Oncology

Genomic analysis has become increasingly important in guiding therapy for skin and soft tissue cancers, particularly melanoma and sarcomas where mutation driven pathways play significant roles. However, interpreting genomic data is difficult due to the complex interactions among genes, immune influences, and tumor microenvironment factors. AI facilitates the integration of these multidimensional datasets.

In melanoma, mutations in BRAF, NRAS, and other signaling pathways inform suitability for targeted therapies such as kinase inhibitors. Machine learning models help identify additional actionable alterations hidden within complex mutation profiles. Predictive systems can estimate resistance likelihood and suggest combination strategies to overcome pathway reactivation.

For metastatic disease, immunotherapy holds significant promise, yet only a portion of melanoma patients respond. AI can analyze transcriptomic and proteomic data to reveal immune signatures associated with durable response. Features such as T cell infiltration, antigen presentation capacity, and interferon signaling activity can be quantified and combined into predictive scores that inform clinical decisions.

Soft tissue sarcomas exhibit greater molecular diversity, often requiring broad panel sequencing. Many lack well defined therapeutic targets, but AI methods can identify molecular clusters correlated with therapeutic vulnerabilities. For instance, specific fusion proteins in synovial sarcoma or Ewing sarcoma may predict sensitivity to targeted or epigenetic therapies. Deep learning tools can support discovery of novel biomarkers that recognize shared dependencies across sarcoma subtypes.

AI enabled drug matching systems evaluate the compatibility of available and experimental therapies with individual molecular profiles. This personalized strategy increases the likelihood of meaningful benefit in cancers known for heterogeneous and unpredictable responses.

AI Guided Surgical and Reconstructive Planning

Surgery is a cornerstone of treatment for many skin and soft tissue cancers, especially melanoma with localized disease or sarcomas that are amenable to wide resection. Achieving negative margins is essential yet challenging when tumors infiltrate complex anatomic regions. AI based planning systems use imaging and predictive models to support surgeons in achieving optimal oncologic and functional outcomes.

Three dimensional reconstructions generated from MRI and CT images provide detailed maps of tumor boundaries and their relationships to muscles, nerves, and bones. Machine learning can analyze risk of local recurrence based on planned margin width and help select appropriate resection strategies. For sarcomas adjacent to major neurovascular structures, AI simulations predict outcomes associated with limb preserving surgery versus amputation, enabling informed shared decision making.

Melanoma patients with sentinel lymph node involvement often undergo lymphadenectomy. AI tools can analyze lymphatic drainage imaging to identify specific nodal basins most at risk of harboring disease. This precision can reduce unnecessary surgical morbidity.

Reconstructive planning benefits from predictive modeling of wound healing and tissue viability. Deep learning algorithms can determine which flap strategies will provide best function and

cosmetic outcome while minimizing complication risks.

Intraoperative video analysis supported by AI can guide surgeons in maintaining clear margins and assessing soft tissue planes in real time. Robotic systems enhanced with intelligent navigation have potential to improve mechanical precision and expand the complexity of surgeries that can be performed minimally invasively.

AI in Radiation Therapy and Response Prediction

Radiotherapy is commonly used to treat high risk melanoma after surgery and for many soft tissue sarcomas either before or after resection. AI optimizes treatment planning by improving target delineation and predicting normal tissue sensitivity. Automated segmentation tools decrease planning time and reduce variability introduced by manual contouring.

Machine learning algorithms model dose response relationships using extensive clinical data. These systems inform decisions about dose intensification when attempting to achieve local control in locally advanced disease or reduced dosing when patient specific toxicity risks are high. Predictive models identify patients likely to benefit from hypofractionated regimens, stereotactic radiotherapy, or proton therapy.

For sarcoma, where radiation fields often involve

multiple critical structures, AI enhanced planning reduces exposure to surrounding organs. Tumor motion prediction supports highly conformal treatment while accommodating respiratory or musculoskeletal shifts.

Monitoring response during radiotherapy is crucial for adaptive planning. AI can detect radiographic changes indicating tumor shrinkage or resistance early in treatment. This approach allows radiation oncologists to adjust plans dynamically to maximize therapeutic efficiency.

Emerging research explores integrating radiomics, tumor genomics, and microenvironment markers into comprehensive models that forecast long term local control and patient outcomes.

AI for Drug Discovery and Novel Therapeutic Development

Developing effective systemic therapies for advanced skin and soft tissue tumors remains a significant unmet need. Many sarcomas lack established targets, and aggressive melanoma can become resistant to available agents. Artificial intelligence accelerates drug discovery by analyzing genetic networks, predicting structure activity relationships, and identifying synergistic drug combinations.

Deep learning models screen compound libraries for molecules likely to bind key oncogenic proteins or restore function to mutated pathways.

These approaches can rapidly evaluate millions of chemical structures in silico, narrowing the number needing laboratory validation.

AI identifies drug resistance pathways in melanoma by modeling how cells adapt to BRAF and MEK inhibitors. This helps researchers design combination regimens that preemptively block escape routes. Repurposing strategies also benefit from pattern recognition across clinical trial databases, revealing unexpected anticancer properties of approved drugs.

In sarcoma drug discovery, where patient numbers are small and resources limited, AI helps prioritize targets most likely to translate effectively into therapy. Simulations of tumor evolution support the concept of adaptive therapy, where drug dosing changes dynamically to prevent resistant population dominance.

These methods bring hope for expanding the therapeutic arsenal against cancers that have historically offered few options at advanced stages.

AI Based Real Time Monitoring and Survivorship Care

For many patients, the journey through skin or soft tissue cancer does not end after initial treatment. Surveillance for recurrence requires repeated imaging, physical exams, and sometimes invasive procedures. AI enhances monitoring

efforts by identifying subtle indications of relapse sooner than traditional approaches.

Melanoma survivors depend heavily on self examination and dermatologic follow up. AI assisted mobile applications can track lesion evolution over time and alert patients or clinicians to concerning changes. Patterns of recurrence risk can adjust visit frequency to match individual risk.

Soft tissue sarcoma recurrence is often detected through shear volume growth on imaging. Radiomic analysis powered by AI enables earlier detection of aggressive changes and supports timely salvage therapy.

Treatment related complications such as lymphedema, neuropathy, or radiation induced fibrosis can be monitored using wearable sensors that continuously assess functional mobility and extremity changes. AI translates these signals into actionable insights that prompt early intervention, improving patient outcomes.

Quality of life fluctuates during survivorship. Natural language processing applied to patient journals or digital communications provides clinicians with insights into distress, fatigue, anxiety, and social difficulties. Personalized coaching and supportive care suggestions can be automatically delivered through AI platforms to meet dynamic needs.

By empowering proactive health management, AI supports not only survival but also long term wellness and recovery.

Challenges and Ethical Considerations

Even with remarkable potential, the integration of artificial intelligence into care for skin and soft tissue cancers brings significant challenges. High performing AI requires large, well curated datasets representative of diverse populations. Many rare skin cancers and most sarcoma subtypes suffer from limited data availability. Small datasets can lead to overfitting and poor real world performance.

Bias in training data may impair model accuracy in populations underrepresented in clinical trials or dermatologic image libraries, such as individuals with darker skin tones. This disparity poses a risk of perpetuating or worsening existing healthcare inequalities. Ongoing efforts must ensure that datasets reflect global diversity.

Interpretability remains essential. Clinicians need to understand how an algorithm reaches a conclusion, especially when guiding high stakes decisions like immunotherapy escalation or wide margin surgery. Black box models can erode trust and obscure errors that require human oversight.

Regulatory pathways for continuously learning AI systems are still evolving. Safety monitoring must

be robust, with mechanisms for accountability when AI recommendations contribute to negative outcomes.

Privacy concerns arise when sensitive patient information including images of identifiable skin areas or genomic data is shared for model development. Ethical use requires secure data handling and clear patient consent processes.

Successful implementation demands collaboration between clinicians, data scientists, technologists, regulators, and patient advocates to ensure that innovation aligns with patient centered values and clinical realities.

Future Directions

The future of AI in managing hard to treat skin and soft tissue cancers promises expanded capabilities and deeper integration into personalized care. Multimodal AI systems will combine dermoscopic images, radiologic features, pathology data, and molecular signatures into cohesive models that capture tumor biology comprehensively. Digital twin models representing unique patient characteristics may simulate treatment responses before clinical implementation.

Robotic systems with intelligent vision will refine surgical precision, while augmented reality overlays assist in visualizing hidden tumor margins. AI guided immunotherapy optimization

is expected to grow as models gain deeper understanding of the tumor microenvironment and immune evasion mechanisms.

Teledermatology and remote oncology care will expand, making expert level guidance accessible globally. These tools may form the backbone of preventive care, helping detect malignancies before they pose life threatening risks.

Research collaboration networks powered by AI will speed discovery by enabling real time analysis of clinical outcomes across institutions. More effective therapies will likely emerge as AI accelerates molecular research and adaptive clinical trials.

Despite these advances, maintaining patient trust will be essential. Ensuring transparency, preserving clinician judgment, and anchoring innovation in ethical frameworks will determine whether AI truly transforms outcomes for patients facing aggressive skin and soft tissue cancers.

Conclusion

Hard to treat skin and soft tissue cancers remain among the most challenging diseases in oncology due to biological aggression, limited treatment response, and risk of recurrence. Artificial intelligence offers new tools that reimagine each phase of cancer care. From early screening and improved diagnostic accuracy to precision

radiotherapy, personalized drug selection, enhanced surgery, and ongoing surveillance, AI brings detailed analysis and predictive power to support clinicians and empower patients.

While barriers exist related to data access, fairness, interpretability, regulation, and privacy, the trajectory of innovation is clear. Responsible adoption of AI has the potential to elevate clinical care and provide hope to individuals who historically have faced limited options.

By fostering collaborative development and ensuring equitable design, AI may play a defining role in shifting outcomes and quality of life for patients with hard to treat skin and soft tissue malignancies. Continual progress will bring us closer to a future where early detection is routine, treatments are precise, and survivorship is more secure for all affected individuals.

7. AI FOR HARD-TO-TREAT HEAD AND NECK CANCERS

Background

Hard to treat head and neck cancers represent a group of malignancies originating in the oral cavity, pharynx, larynx, sinonasal region, salivary glands, and other supporting structures. Many are diagnosed late, present with aggressive biological behavior, and require complex treatment strategies involving combinations of surgery, radiation, and systemic therapy. Even when treated with curative intent, patients frequently experience functional impairments involving speech, swallowing, appearance, and respiration. The survival outcomes have improved modestly over time, but advanced or recurrent disease still leads to a high mortality rate.

A major challenge in this field lies in disease heterogeneity. Head and neck squamous cell carcinoma alone encompasses numerous anatomic locations, risk factors, and molecular subtypes that respond differently to therapy. Human papillomavirus associated oropharyngeal cancer demonstrates a more favorable prognosis and different therapeutic sensitivities compared to cancers caused by tobacco and alcohol exposure. Rare tumors of the salivary glands or sinonasal

tract often have unique molecular drivers but suffer from limited research investment and few options for targeted treatments. Precision oncology in this space is advancing but still remains inconsistently applied.

Traditional diagnostic and treatment pathways depend heavily on expert interpretation of imaging, pathology, and clinical examination. These tasks are labor intensive and subject to significant variability, particularly in resource limited settings. There is an urgent need for tools that enhance early detection, improve risk stratification, guide therapy personalization, and support functional recovery following treatment. Artificial intelligence has emerged as a transformative solution capable of filling these gaps.

AI technologies leverage machine learning and deep learning to analyze complex clinical data, recognize patterns beyond human perception, and generate real time decision support. Applications span a wide spectrum: early cancer screening using voice or image analysis, automated evaluation of radiology or digital pathology, multimodal prognosis prediction, radiotherapy optimization, drug discovery, and long term survivorship support. By integrating diverse data sources, AI offers a comprehensive approach to understanding tumor behavior and improving patient outcomes.

This chapter explores the current and emerging roles of artificial intelligence in addressing the many clinical challenges associated with advanced and hard to treat head and neck cancers, as well as the limitations, ethical considerations, and future directions shaping the integration of these technologies into routine care.

AI in Early Detection and Screening

Many head and neck cancers are diagnosed only once they have caused visible or functional symptoms, such as persistent voice changes, dysphagia, or neck masses. Earlier detection dramatically improves survival, yet reliable screening methods remain limited. Artificial intelligence offers innovative solutions in identifying early stage disease where conventional diagnostics may fail.

Computer vision algorithms trained on clinical imagery have improved recognition of suspicious oral lesions. These programs analyze subtle textural or vascular changes on mucosal surfaces that may indicate malignant transformation. Mobile AI tools can extend screening capabilities to primary care or community health environments, enabling early risk identification without requiring immediate access to specialty providers.

Voice analysis is another area of rapid growth. Machine learning models can detect acoustic

changes associated with early laryngeal cancer before visible lesions appear during laryngoscopy. By incorporating patient voice recordings into automated risk scoring systems, these tools serve as non invasive and low cost methods for ongoing monitoring of high risk individuals such as professional voice users or individuals exposed to tobacco smoke.

Artificial intelligence is enhancing radiology based screening as well. CT and MRI scans performed for unrelated reasons sometimes reveal incidental abnormalities in the upper airway or neck. AI models that scan radiology reports and images can flag concerning changes for secondary review, reducing missed opportunities for intervention.

In populations with human papillomavirus risk, models combining demographic data, sexual behavior patterns, and serologic markers can help determine who may benefit most from targeted screening initiatives. As immune profiling technologies advance, AI will further support risk stratification based on the biological predisposition toward viral driven carcinogenesis.

AI systems that integrate multiple signals, including symptom reports, social determinants of health, and clinical history, likely represent the most powerful future approach. By identifying early stage disease and minimizing diagnostic delay, AI driven screening may significantly

improve the prognosis for many patients.

AI Enhanced Imaging and Tumor Characterization

Medical imaging plays a vital role in diagnosing, staging, and monitoring head and neck cancers. Radiologic assessment requires extensive expertise to evaluate intricate anatomical structures and subtle tumor infiltration patterns. Artificial intelligence augments clinical interpretation by providing quantitative radiomic analysis and consistent evaluation.

AI based segmentation tools accurately delineate tumors and organs at risk from CT and MRI scans, supporting precise staging and radiation planning. Radiomics extracts hundreds of spatial and textural features from tumor images, which can be associated with molecular phenotypes and clinical outcomes. These patterns can help differentiate aggressive from indolent disease and identify early therapy resistance.

For lymph node involvement detection, AI models improve accuracy over manual assessment by recognizing minute shape distortions or internal structural differences not readily visible to the human eye. Early identification of nodal spread supports timely multimodal intervention and improves prognosis.

Positron emission tomography integrated with CT or MRI is widely used to assess treatment

response. Machine learning models trained to detect metabolic changes can identify treatment failure long before size changes occur. Rapid recognition of non response enables clinicians to redirect therapy strategies promptly.

Sinonasal and skull base cancers often infiltrate bone and soft tissue in complex ways. AI enhances navigation by generating three dimensional reconstructions that highlight tumor boundaries, allowing surgeons to visualize regions that require particular caution during intervention.

Radiogenomics, which links radiologic features with underlying molecular drivers, has the potential to enable non invasive tumor subtyping. This is especially valuable when biopsy poses high risk or yields inadequate tissue for full genomic analysis.

These advancements transform imaging from a descriptive tool into a predictive platform, guiding individualized therapy planning.

AI in Digital Pathology and Molecular Interpretation

Pathology remains the cornerstone of diagnosis in head and neck oncology. However, variability in interpretation can occur even among experts, especially when dealing with poorly differentiated tumors or limited tissue samples. Digital pathology and deep learning systems enhance classification accuracy and speed.

Whole slide imaging enables large scale histologic review by AI algorithms capable of detecting specific microscopic features linked to prognosis, such as tumor budding, perineural invasion, or patterns of immune cell infiltration. These features may be difficult to quantify manually but hold significant value for predicting outcomes.

HPV status in oropharyngeal tumors influences treatment response and survival. AI assisted analysis of tissue morphology can estimate HPV association even without molecular staining, offering a cost efficient tool for use in low resource settings. Similarly, in salivary gland cancers, which have numerous distinct subtypes, machine learning helps distinguish histologically similar tumors by analyzing pixel level characteristics across entire slides.

Computational pathology models integrate immunohistochemistry data to predict therapeutic targets or eligibility for immunotherapy based on expression profiles. AI quantification of PD L1 expression or other immune checkpoint markers ensures more consistent scoring than manual review, improving the precision of patient selection.

As the integration of multiomic datasets expands, AI will link genomic, transcriptomic, proteomic, and histologic insights into cohesive diagnostic models. These approaches support more accurate tumor classification and refined prognostic

evaluation, essential for guiding therapy decisions in cancers with wide biological variability.

AI for Personalized Treatment Planning

Treatment of hard to treat head and neck cancers often requires balancing aggressive tumor control with preservation of essential functions such as swallowing, speech, and facial expression. AI helps optimize personalized treatment decisions by synthesizing data from multiple diagnostic sources.

Machine learning models can predict which patients will benefit from primary surgery versus definitive chemoradiation based on clinical staging, imaging patterns, and biological features. Predicting the likelihood of organ preservation success allows more tailored recommendation development.

Artificial intelligence assists in selecting appropriate systemic therapies by evaluating tumor genomics and historical treatment response patterns. Models can estimate sensitivity to platinum based chemotherapy, targeted agents, or immunotherapy, reducing exposure to ineffective or harmful regimens.

Functional outcome prediction is an especially valuable application. By analyzing tumor location, likely surgical margin requirements, and nerve involvement, AI tools can estimate expected

impacts on speaking or swallowing ability. These insights support patient counseling and inform reconstructive planning to minimize long term disability.

Adaptive therapy planning represents an emerging innovation. Throughout treatment, AI continuously updates risk models based on patient response, toxicity metrics, and biomarker changes, allowing clinicians to refine therapy intensity dynamically.

The combination of tumor specific precision and functional preservation makes AI an indispensable partner in clinical decision making.

AI Enhanced Radiation Therapy

Radiotherapy is central to treating head and neck cancers, but achieving optimal tumor coverage while sparing critical structures such as salivary glands, optic nerves, and spinal cord is challenging. AI addresses multiple critical planning needs, making treatment safer and more effective.

Automated segmentation systems delineate tumors and organs at risk quickly and consistently, reducing treatment planning time and minimizing variability across providers. Machine learning optimization algorithms design radiation beam arrangements that maximize tumor control probability while limiting side effects like xerostomia, dysphagia, or vision

impairment.

Predictive response models help clinicians identify patients who may benefit from dose escalation or precision approaches such as proton therapy. Similarly, AI toxicity prediction identifies individuals at risk for severe mucositis or long term swallowing dysfunction, allowing supportive interventions to be initiated early.

During radiation therapy, anatomical changes occur as tumors shrink and patients lose weight. AI driven adaptive planning detects these shifts and recalibrates dose distribution to maintain accuracy throughout treatment.

Post therapy surveillance also benefits from AI enhanced imaging analysis, which detects recurrence earlier than traditional assessment methods. Transitioning radiotherapy from a static protocol to a learning system holds significant promise for personalized cancer care.

AI in Surgery and Procedural Guidance

Surgical management plays a crucial role in treating many head and neck cancers, especially oral cavity tumors and select recurrent cases requiring salvage surgery. AI technologies support preoperative planning, intraoperative navigation, and postoperative evaluation.

Three dimensional modeling of tumor anatomy

and adjacent neurovascular structures enhances surgical precision. Predictive models analyze patient specific anatomy and forecast regions where achieving clear margins poses high risk. Surgeons can then prepare more targeted resection strategies or multidisciplinary approaches involving reconstruction specialists.

Intraoperative decision support tools using AI enhanced endoscopy or fluorescence imaging can help distinguish tumor from healthy tissue in real time. This reduces the likelihood of residual disease while minimizing unnecessary removal of functional tissue.

Robotic surgical systems operate with improved accuracy when supported by intelligent navigation algorithms that stabilize movement and provide visual alerts when instruments approach high risk areas. In skull base surgery, where millimeter scale precision is required, AI improves outcomes and reduces complications.

Following surgery, modeling tools predict wound healing patterns and guide interventions that preserve swallowing, speech, and appearance. Tracking subtle postoperative changes through AI enhanced imaging or sensor technologies allows clinicians to address complications promptly.

These capabilities advance surgical standards toward improved oncologic and functional outcomes.

AI for Immunotherapy and Drug Response Prediction

Immunotherapy has revolutionized treatment for some head and neck cancers, but response rates remain modest and unpredictable. Artificial intelligence helps identify patients most likely to benefit and supports the design of combination strategies to increase overall efficacy.

AI models assess immune microenvironment signatures including lymphocyte infiltration, antigen presentation potential, and checkpoint protein expression levels. These integrated biomarkers inform patient selection for immune checkpoint inhibition.

Machine learning can detect early resistance signals from longitudinal blood biomarkers or radiologic changes, prompting timely treatment modification. Genomic and transcriptomic data are analyzed to uncover novel targets for combination immunotherapy that may overcome primary or acquired resistance.

Drug repurposing strategies benefit from computational modeling as well. AI can match existing medications with molecular characteristics of rare head and neck cancers, accelerating therapeutic access for patients with few available options.

As researchers continue to map the complex interplay between tumor and immune system, AI

will play an increasingly vital role in translating this knowledge into practical therapeutic guidance.

AI in Rehabilitation and Survivorship Support

Patients with head and neck cancers frequently face long term challenges related to treatment toxicity and anatomical changes. Swallowing impairment, chronic pain, difficulties with communication, disfigurement, and psychosocial distress can persist well beyond initial treatment. AI technologies support survivorship by enabling proactive and personalized supportive care.

Speech and swallowing rehabilitation benefits from AI powered assessment tools that analyze acoustic signals, tongue motion, and swallowing mechanics using sensors or mobile applications. Personalized exercise programs can be automatically generated and adjusted based on performance data.

Wearable monitors track vital signs and daily activity, detecting fatigue patterns, malnutrition risk, or signs of depression. Early intervention improves quality of life and reduces emergency hospitalizations.

Virtual assistants trained in patient communication facilitate symptom reporting and education, improving adherence to follow up protocols. Natural language processing interprets

patient concerns with clinical relevance and alerts care teams when urgent attention is required.

Cosmetic and functional reconstruction outcomes can be predicted through machine learning models, assisting with decision making and mitigating body image concerns. Social support platforms driven by AI matchmaking can connect patients with shared experiences, fostering resilience and emotional well being.

These technologies reinforce comprehensive care long after primary treatment concludes.

Challenges and Ethical Considerations

The promise of AI in head and neck oncology comes with significant challenges that must be addressed responsibly. Data limitations remain substantial because many rare tumor subtypes lack large curated datasets. Bias can occur if training data underrepresent certain demographic or socioeconomic groups, risking inequity in performance.

Interpretability remains essential. Clinicians must trust AI outputs, and transparency regarding model decision pathways supports appropriate oversight. Regulatory frameworks need to evolve to govern AI systems that continually update their behavior after deployment.

Patient privacy is especially sensitive in this

population because diagnostic images and audio recordings may reveal identity. Ethical AI development requires strong cybersecurity and clear informed consent processes.

Clinical workflow integration also presents challenges. Technology must support rather than burden providers. Multidisciplinary collaboration is crucial to ensure tools address real clinical needs and complement professional judgment.

Continuous evaluation of long term outcomes and vigilant monitoring for unintended harms will shape responsible use of AI in this field. The balance between innovation and ethics will determine whether AI fulfills its potential to improve patient outcomes.

Future Directions

The future of AI in head and neck oncology is defined by deeper integration of multimodal data and real time decision support. Combining radiomics, digital pathology, genomics, and patient reported information into unified models will allow more comprehensive tumor understanding. Digital twin technology may create virtual representations of individual patients to simulate treatment outcomes before implementing clinical decisions.

AI enhanced robotics and augmented reality will continue to expand surgical precision and safety. Predictive analytics for immunotherapy response

and adaptive radiation therapy will allow highly personalized therapeutic pathways.

Efforts to improve health equity will focus on expanding access to AI tools in underserved communities and ensuring that global datasets reflect diverse patient populations. Advances in telemedicine and remote screening supported by AI can bridge access gaps for populations with limited specialist availability.

Drug discovery pipelines will accelerate as AI identifies new therapeutic targets and simulates combination strategies. Early detection tools will evolve into ubiquitous and user friendly applications that empower individuals to seek care sooner.

Collaborative frameworks involving regulatory bodies, technology developers, clinicians, and patients will ensure successful integration grounded in ethical principles and real clinical value.

Conclusion

Hard to treat head and neck cancers pose substantial challenges due to biological heterogeneity, aggressive progression, frequent functional impairment, and high recurrence risk. Artificial intelligence offers powerful solutions to these long standing obstacles by enhancing early detection, improving diagnostic precision, guiding personalized therapy selection,

optimizing interventions, predicting outcomes, and supporting survivorship throughout recovery.

As AI continues to evolve, the most successful implementations will be those that maintain clinician involvement, protect patient privacy, ensure equity, and prioritize meaningful improvements in quality of life. Through careful and collaborative innovation, AI has the potential to shift the paradigm of head and neck cancer care toward earlier cures, longer survival, and greater functional preservation.

By embracing these capabilities responsibly, the field moves closer to a future in which patients facing these difficult cancers can receive timely, tailored, and life enhancing care.

8. AI FOR HARD-TO-TREAT ORAL CANCERS

Background

Oral cancers remain a significant global health challenge due to their aggressive biological behavior, the difficulties associated with early detection, and the functional burden imposed by curative therapies. Classified primarily as squamous cell carcinomas arising from the mucosal surfaces of the mouth, these malignancies can also involve the lip vermilion, tongue musculature, gingiva, buccal mucosa, palate, and floor of mouth. Although they are grouped within the wider spectrum of head and neck cancers, oral cancers have unique features that set them apart, including distinct etiologic patterns, differences in genetic drivers, and specific implications for speech, chewing, swallowing, and appearance. The disease often progresses rapidly and may infiltrate deep tissue planes early in its development, spreading to regional lymph nodes or metastasizing systemically before a diagnosis is confirmed. These tumors are frequently diagnosed at advanced stages when treatment becomes more complex, resource intensive, and less likely to achieve long term control.

A variety of modifiable and non modifiable risk factors contribute to the development of oral cancers. Tobacco and alcohol use remain the most prominent environmental drivers in many regions, particularly when these behaviors coexist and amplify malignant transformation risk. Betel nut chewing contributes substantially to incidence in South Asia and the Western Pacific. Chronic irritants, poor oral hygiene, microbial dysbiosis, and genetic predispositions also play roles in carcinogenesis. Unlike in oropharyngeal cancers, human papillomavirus involvement is generally much lower, which means immunotherapy strategies that have worked effectively elsewhere in the upper aerodigestive tract may be less successful in the oral cavity without identification of more tailored biomarkers.

The global distribution of this disease reveals considerable disparities. Low and middle income countries bear a disproportionate share of incidence and mortality. Socioeconomic factors influence the ability to access dental services, receive routine screenings, and secure specialized cancer care. These barriers lead to late diagnosis in many patients, lowering survival outcomes and increasing the risk of extensive surgical interventions followed by debilitating functional impairment. Even in high income settings where state of the art treatment is accessible, outcomes

remain far from ideal for individuals with locally advanced or recurrent disease.

Traditional oral cancer care relies heavily on human expertise in visual examination, clinical judgment, imaging interpretation, pathology evaluation, and coordination of complex treatment decisions. Yet each of these steps carries inherent limitations in speed, consistency, and sensitivity. Subtle early lesions escape attention because they appear similar to benign ulcers or inflammatory conditions. Imaging may confirm deeper infiltration only after substantial structural damage has occurred. Histopathology can be subject to interpretive variability, particularly in cases involving borderline dysplasia or small biopsy samples that do not fully represent tumor heterogeneity. The time required for multidisciplinary evaluation may delay initiation of therapy, allowing disease to progress.

Artificial intelligence represents a powerful approach to overcoming these limitations. With its ability to recognize patterns within large and complex datasets at speeds impossible for manual evaluation, AI can enhance every stage of the care continuum. It expands access to screening by supporting frontline clinicians and even patients directly through portable devices. It improves diagnostic accuracy by analyzing multimodal data from photographs, imaging

scans, and histologic slides. It contributes to personalized treatment decisions by integrating genomic, immunologic, and clinical variables into predictive models. It augments surgical planning, radiotherapy delivery, rehabilitation, and survivorship monitoring through real time guidance and predictive analytics. These capabilities align closely with the urgent needs present in oral oncology.

This chapter provides an in depth exploration of how AI technologies are reshaping the management of hard to treat oral cancers. It considers opportunities in early detection, diagnosis, staging, surgical and radiologic therapy, systemic treatment personalization, and rehabilitation. It also acknowledges the ethical, regulatory, and practical barriers that must be addressed to ensure equitable implementation. As AI continues to evolve, its role within oral cancer care is likely to expand dramatically, redefining both outcomes and patient experience.

AI in Early Detection and Screening

Early detection represents the single most impactful way to improve survival in oral cancer. The difference in outcome between early stage and late stage disease is profound. However, subtle mucosal lesions are often invisible to untrained observers and can be misdiagnosed even by experienced clinicians. Artificial intelligence

has introduced new approaches to overcoming these diagnostic obstacles by supporting lesion identification, risk stratification, and triaging of patients into appropriate care pathways.

The rapid expansion of computer vision techniques has enabled deep neural networks to evaluate intraoral images with impressive accuracy. By analyzing characteristics such as color progression, keratinization patterns, architectural distortion, and vascular changes, AI can identify abnormalities that warrant further assessment. Unlike conventional screening methods requiring specialized equipment, AI enabled mobile phone applications can be used at the point of care in dental clinics or community health settings, making screening more accessible.

Telemedicine has also found a strengthened role through AI. Dental practitioners or general physicians can photograph a suspicious lesion and receive reliable automated insights that inform whether a referral to oncology is appropriate. Patients in rural or remote communities can be evaluated rapidly without delaying care, helping to close geographic disparities in diagnosis.

Some systems incorporate longitudinal lesion monitoring into their evaluation. When a lesion persists or evolves in concerning ways over time, AI models detect subtle changes that human observers may overlook. In patients with established oral potentially malignant disorders

such as leukoplakia or lichen planus, continuous tracking reduces the risk of late recognition of malignant transformation.

Beyond image analysis, AI can support risk prediction by integrating data on patient demographics, lifestyle habits, past dental records, and medical comorbidities. For example, a model might weigh a history of tobacco exposure and heavy alcohol intake alongside lesion morphology to produce a personalized malignancy likelihood estimate.

These innovations strengthen the first line of defense against oral cancer progression. By improving early recognition and more timely specialist involvement, AI powered screening tools have the potential to shift diagnosis toward earlier stages when treatment is less destructive and survival prospects are significantly higher.

AI in Diagnostic Imaging and Tumor Characterization

Accurate assessment of tumor extent is essential for determining the best course of treatment. Oral cancers can invade anatomical structures that are critical for essential functions. Imaging evaluation is therefore key to planning interventions that balance oncologic control with preservation of quality of life. Yet interpretation of CT, MRI, and PET scans can be challenging because the oral cavity contains a dense network of

muscles, nerves, and bones packed into a small space, creating imaging artifacts and overlapping densities.

Artificial intelligence enhances imaging interpretation through automated segmentation, radiomic analysis, and prediction modeling. Rather than relying solely on human visual expertise, AI extracts quantitative information from each pixel, identifying features associated with depth of invasion, nodal spread, and early mandibular involvement. Radiomics helps uncover correlations between imaging features and aggressiveness, enabling risk stratification beyond conventional tumor size and shape criteria.

The integration of multimodal imaging data further improves precision. For example, MRI derived soft tissue contrast can complement PET metabolic activity maps, while AI models synthesize information from both techniques into a unified interpretation that provides a more holistic understanding of tumor biology. These approaches reduce diagnostic uncertainty and assist clinicians in determining whether surgical, radiotherapeutic, or combined approaches will yield the best outcome.

Another significant benefit lies in monitoring treatment response. After radiation or systemic therapy, inflammation and fibrosis may mimic persistent cancer on imaging. AI pattern

recognition allows earlier and more accurate distinction between active disease and healing changes. This reduces unnecessary biopsies or surgical exploration and helps identify cases requiring prompt treatment modification.

In high complexity regions such as the base of tongue or deep floor of mouth, three dimensional reconstructions created by AI systems support surgeons in evaluating how a tumor encroaches upon critical structures. This assists in planning surgical margins that achieve both complete tumor removal and functional preservation.

These imaging innovations transform radiology into a predictive and dynamic component of oral cancer care.

AI Enhanced Digital Pathology

Pathologic confirmation remains indispensable in the diagnosis of oral cancers. However, tumor heterogeneity and subjective interpretation contribute to variability in grading, staging, and margin assessment. Transitioning from manual microscopy to digital whole slide imaging creates a platform where artificial intelligence can significantly enhance pathology workflows.

Deep learning systems analyze cellular morphology and tissue architecture at a granular level. They evaluate criteria such as nuclear enlargement, pleomorphism, mitotic activity, keratin pearl formation, and immune infiltrate

distribution, detecting microscopic cues that predict behavior more reliably than qualitative evaluation alone. Such models standardize grading decisions, reducing discrepancies between pathologists and ensuring greater confidence in diagnosis.

Margin assessment in surgical specimens benefits tremendously from computational pathology. Manual review may miss isolated tumor cells, particularly when evaluating large resections that require many slide sections. AI rapidly screens entire specimens, highlighting regions requiring targeted human review. This assists surgeons in achieving complete tumor removal and lowers the likelihood of needing re operation.

Predictive pathology extends beyond diagnosis into prognosis. Machine learning models trained on outcome data can estimate expected survival or recurrence probability by integrating histologic features with genetic and clinical context. This informs decisions about adjuvant therapy and follow up intensity.

Digital pathology also supports resource limited settings. AI enabled interpretation can supplement areas where experienced pathologists are scarce, widening access to expert level evaluation through telepathology networks. Such technology democratizes diagnostic accuracy globally and plays a vital role in reducing international disparities in oral cancer care.

AI Guided Personalized Treatment Decision Making

A defining challenge in oral oncology involves tailoring treatment approaches to individual patient needs. Surgery may remove visible tumor, yet if disease is biologically aggressive, systemic therapy or radiation may be warranted to prevent recurrence. Conversely, overtreatment must be avoided to preserve form and function when disease is less threatening. Striking this balance manually can be difficult because clinical presentations are nuanced and response variability is substantial.

Artificial intelligence guides treatment planning by integrating numerous prognostic indicators. Predictive models assess clinical staging, radiomic signatures, histopathology findings, genomic alterations, immune environment features, and patient health status to estimate which therapies will offer the greatest benefit. For example, AI may identify a subset of patients in whom chemoradiation alone will achieve cure without the need for extensive surgery, preserving critical functions such as speech and swallowing.

Systemic therapy selection benefits from AI analysis of molecular characteristics. Although immunotherapy response has been moderate in oral cancer compared to other head and neck sites, AI based biomarker evaluation can define

which specific patients have a tumor immune landscape compatible with durable responses. Decision support tools allow clinicians to simulate how treatments may perform based on real world outcomes drawn from multiple institutions and patient populations.

AI interpretation of toxicity risk enhances shared decision making. For instance, a model might indicate that a particular radiation plan poses a substantial chance of long term xerostomia or osteoradionecrosis in a patient with preexisting dental vulnerabilities. Understanding risks in advance allows for adaptation of modality or intensity before initiating therapy.

Personalized oncology ideally combines outcome prediction with preservation of quality of life, and AI is instrumental in enabling that evolution.

AI in Surgery and Reconstructive Planning

Surgery remains central to the management of many oral cancers, especially when diagnosis occurs at a stage where tumor removal offers the only realistic chance of cure. Yet surgical intervention must minimize post operative dysfunction. The tongue, mandible, and other structures are essential for articulation, mastication, and swallowing, meaning even small resections can have significant impacts.

AI contributes meaningfully to preoperative

planning by analyzing the anticipated results of various surgical strategies. Three dimensional models show how tumor excision will alter anatomy and allow surgical teams to anticipate consequences for mobility and airway protection. Predictive tools estimate postoperative speech intelligibility and swallowing ability, guiding discussions about reconstruction options that preserve these functions.

For cases involving mandibular involvement, AI evaluation of cortical and medullary bone invasion helps determine whether a segmental resection is required. The decision to remove bone has enormous implications for prosthodontic rehabilitation and facial symmetry. Using AI insights, surgeons can optimize surgical margins while preserving structural integrity when safe.

Intraoperatively, real time AI assistance improves precision. Image guided navigation systems enhanced by machine learning differentiate tumor from healthy tissue based on optical or fluorescence cues. This reduces both under treatment and overtreatment. Robotic assistance guided by AI helps maintain stable instrument positioning and reduces fatigue associated with long and technically demanding procedures.

Reconstructive planning benefits from predictive modeling that assesses tissue viability, healing probability, and functional restoration. Whether bone flaps or soft tissue flaps are used, AI

helps match reconstruction type to the specific functional priorities of the patient.

Through these contributions, AI fosters outcomes that preserve dignity, identity, and the essential elements of communication.

AI Enhanced Radiotherapy

Radiation plays a major role in oral cancer care as either a definitive approach for unresectable tumors or as a postoperative treatment to reduce recurrence. However, the close proximity of numerous sensitive anatomical structures challenges the safe delivery of therapeutic doses. Side effects can severely impact quality of life for survivors, sometimes resulting in chronic disability.

AI improves radiotherapy planning and execution by analyzing anatomical and functional relationships between tumor and organs at risk. Automated segmentation tools reduce planning time and minimize variation between planners. Machine learning algorithms evaluate dose distributions to find optimal strategies that protect salivary glands, taste buds, dental arches, and swallowing musculature.

Predictive toxicity modeling allows high risk individuals to receive tailored support even before symptoms emerge. When integrated with imaging during treatment, adaptive radiotherapy techniques utilize AI to modify delivery plans if

the tumor shrinks or patient anatomy changes. This maintains precision and reduces collateral tissue damage.

Together, these advancements strengthen the therapeutic ratio, enhancing control while limiting harm.

AI in Systemic Therapy and Immunotherapy Response Prediction

Oral cancers with advanced local spread or distant metastasis often require systemic therapy to complement local control measures. Yet treatment success remains variable. The complex biology of oral cancer contributes to resistance, and trial and error approaches can expose patients to unnecessary toxicity without benefit.

Artificial intelligence models support therapy selection by predicting tumor susceptibility to chemotherapy, targeted agents, or immunotherapy based on genomic signatures and microenvironmental patterns. When a tumor displays molecular features linked to aggressive progression, AI may recommend more intensive multimodal therapy for a greater chance of long term survival.

Immunotherapy represents a major area of exploration. Response prediction remains challenging due to mixed involvement of immune pathways in oral carcinoma compared to other

sites. AI aids in identifying which patients express markers associated with durable benefit, ensuring that checkpoint inhibition is reserved for those most likely to respond effectively.

AI tools also track treatment response through liquid biopsies, radiomics, or symptom monitoring to detect signs of non response early. Adjusting therapy based on evolving clinical signals represents a shift toward proactive rather than reactive management.

AI Supported Rehabilitation and Survivorship

Cancer survival means little if survivors are left with severe functional deficits, chronic pain, and diminished social participation. The oral cavity plays central roles in nourishment, communication, identity expression, and social interaction. Post treatment rehabilitation must consider each patient's goals and challenges.

AI supports rehabilitation by analyzing speech and swallowing performance data, interpreting subtle limitations in lingual motion or pharyngeal coordination. Personalized exercise programs can be generated automatically and adjusted in real time based on measurable improvements or setbacks. Integrating this technology into home based care ensures continuous support between clinic visits.

Wearable sensors help track nutritional intake,

weight change, and activity levels. AI identifies trends associated with decline and alerts providers to intervene early. Mental health support is another important dimension. Natural language analysis of patient communication can identify emotional distress that may not surface in brief clinical encounters. Targeted counseling can be offered promptly to those at risk of depression or social isolation.

Advanced prosthodontic planning uses AI to anticipate the functional advantages of various inserts or implants following surgical alteration of oral anatomy. These innovations restore confidence and practical ability for eating and speaking.

Survivorship improved by AI emphasizes autonomy, dignity, and long term health, supporting individuals well beyond completion of primary treatment.

Ethical and Operational Considerations

The promise of artificial intelligence brings with it important responsibilities. Data used to train models must reflect the populations most affected by oral cancer, which often include underserved communities where access to high quality care is limited. Without careful dataset curation, AI may inadvertently widen disparities by delivering lower quality recommendations to those whose

characteristics are underrepresented in training material.

Protecting patient privacy is also paramount because oral images and voice data are uniquely identifiable. Robust safeguards are necessary to maintain trust and comply with regional regulations governing health data. Clinicians must understand how AI arrives at a given recommendation so that they can evaluate its appropriateness and explain it to their patients. Transparent design and external validation processes build confidence that AI operates reliably and safely.

Successful integration into clinical practice requires thoughtful workflow design so that the technology reduces burden rather than increasing it. Stakeholder collaboration across dentistry, oncology, radiology, pathology, engineering, and patient advocacy will be necessary to develop solutions that meet practical needs rather than simply fulfilling a technological vision.

Future Directions

As AI continues to mature, multimodal intelligence integrating clinical, pathological, radiological, genomic, and behavioral data will become foundational to oral cancer care. Digital twins that model individual patients could allow clinicians to simulate the outcomes of varied treatment strategies before committing to a

chosen plan. Real time monitoring throughout therapy may lead to fully adaptive care that optimizes outcomes as situations evolve. The extension of AI enhanced mobile health tools into widespread public use may reduce delays that currently drive poor outcomes by empowering individuals to recognize harmful changes early. Globally connected research networks will allow shared learning and continuous improvement of models, bringing advancements to every corner of the world where oral cancer persists.

Conclusion

Oral cancers continue to impose a devastating burden on individuals and healthcare systems, particularly when detected late or when the disease displays aggressive biological behavior. The complexity of the oral cavity, the challenges of early recognition, and the balance required between oncologic control and preservation of essential functions make traditional approaches difficult to optimize consistently. Artificial intelligence presents transformative opportunities to address these difficulties. It enhances early detection, improves diagnostic accuracy, supports precision therapy selection, strengthens surgical and radiotherapy planning, accelerates the discovery of systemic treatments, and provides personalized rehabilitation support for survivors. Responsible implementation grounded in equity, transparency,

and interdisciplinary collaboration will determine the extent to which these technologies fulfill their potential. With continued innovation, AI offers a pathway toward earlier diagnoses, more effective and humane treatments, and improved survivorship for individuals confronting hard to treat oral cancers.

9. AI FOR HARD-TO-TREAT BONE AND MUSCULOSKELETAL CANCERS

Background

Bone and musculoskeletal cancers present some of the most difficult challenges in oncology because of their rarity, biological aggressiveness, and the complex functional consequences of treatment. These cancers include primary bone malignancies such as osteosarcoma, Ewing sarcoma, and chondrosarcoma, as well as a wide range of soft tissue sarcomas affecting muscles, tendons, fat, and connective tissues. In addition to primary tumors, metastatic disease from breast, prostate, lung, kidney, and thyroid often embeds within the skeletal system, creating painful and disabling secondary lesions that complicate care. Although survival outcomes have improved modestly for some subtypes through advances in multidisciplinary treatment, many patients still face high recurrence rates, treatment resistance, and serious impairments in mobility and limb function. The complicated anatomical regions in which these cancers arise, combined with their capacity to infiltrate vital neuromuscular structures, make achieving both durable local control and functional preservation exceedingly difficult.

Despite their clinical importance, bone and musculoskeletal cancers constitute only a small percentage of total cancer incidence. This rarity creates significant obstacles to research progress because it limits availability of large datasets and experienced specialty providers. Many patients are initially evaluated outside of major sarcoma centers, increasing the risk of misdiagnosis and delayed treatment. Moreover, tumor biology can vary dramatically even within the same histological category, resulting in unpredictable responses to therapy. Standard treatment pathways often rely on aggressive surgeries that remove entire bone segments or involve limb amputation when preservation is not feasible. Reconstruction offers hope for maintaining limb function but may require multiple surgeries and prolonged rehabilitation.

Traditional diagnostic techniques cannot always detect these cancers at early stages because initial symptoms resemble common musculoskeletal disorders such as sprains, joint inflammation, and trauma related pain. Imaging interpretation for bone lesions is complex and subtle changes on x rays may precede advanced disease by months or even years. Biopsy pathways are similarly delicate because improper approach can seed tumor cells into compartments where they were not previously present. Achieving accurate diagnosis quickly while protecting functional anatomy

requires skill and coordinated care that is not universally accessible.

Artificial intelligence promises a fundamental transformation in this field by extending expert level diagnostic and therapeutic guidance across a wider landscape of clinical settings. AI based systems can analyze radiographs, CT scans, MRI, digital pathology, and genomic profiles with remarkable detail and speed. They can detect patterns that humans might overlook and extract biologic information hidden within imaging data or microscopic tissue variations. Predictive models support risk assessment for metastasis, local recurrence, chemotherapy response, radiation effectiveness, and functional outcomes following surgery. Robotics and algorithmic navigation help surgeons plan operations that preserve critical structures while still pursuing oncologic cure. Machine learning platforms enhance drug discovery and facilitate more effective clinical trials for rare cancers. Rehabilitation and survivorship also benefit from AI enhanced monitoring and personalized therapy guidance, ensuring that recovery continues long after hospital discharge.

This chapter focuses on the role of artificial intelligence in improving detection, diagnosis, treatment planning, therapy optimization, follow up, and quality of life for patients facing bone and musculoskeletal cancers that have historically

been difficult to treat. Particular attention is given to opportunities for strengthening precision medicine, reducing global inequity in access to specialized care, and enabling functional outcomes that allow survivors to lead fulfilling lives.

AI in Early Detection and Screening

Early detection is crucial for improving outcomes in bone and soft tissue malignancies, yet symptoms frequently mimic common benign conditions. A young athlete with knee pain might assume a sports injury when in fact osteosarcoma is developing beneath the periosteum. Individuals with persistent swelling or unexplained bone fractures might receive delayed imaging or referral. Artificial intelligence offers strategies to reduce diagnostic delays by expanding access to expert level recognition.

Machine learning applied to plain radiographs can identify early tumor associated abnormalities that might be dismissed during routine evaluation. These models evaluate bone texture irregularities, cortical disruption, and subtle periosteal reactions with greater consistency than human review. In combination with patient age, symptom duration, and laboratory markers such as alkaline phosphatase, AI can triage patients more accurately for advanced imaging.

MRI interpretation benefits further from deep

learning because it supplies detailed insights into soft tissue involvement, marrow infiltration, and neurovascular displacement. Automated segmentation and anomaly detection tools reduce oversight risk and strengthen clinical documentation. AI based pattern recognition supports recognition of signature traits for Ewing sarcoma, chondrosarcoma, or metastatic lesions depending on patient history and tumor location.

In community hospitals or regions without highly trained musculoskeletal radiologists, AI screening support could help prevent misclassification of suspicious bone lesions as benign cysts or trauma recovery. Prompt referral to specialized oncology centers may significantly improve prognosis. Because these cancers often strike children, adolescents, and young adults, early intervention prevents growth impairment, disability, and emotional suffering associated with late stage extensive surgery.

Population level analysis is aided by AI tools that examine electronic health record patterns for unusual clinical trajectories. By recognizing recurrent presentations of mysterious pain or repeated emergency visits without clear diagnoses, AI may alert primary providers to consider further oncologic evaluation. Such innovations aim to shorten the path from first symptoms to definitive diagnosis, which remains one of the greatest barriers to timely and effective

treatment.

AI in Diagnostic Imaging and Tumor Characterization

The interpretation of imaging plays a vital role in defining treatment approaches for bone and musculoskeletal cancers. These tumors grow in complex spaces where surgeons must preserve limb function, avoid excessive damage to surrounding tissues, and prevent systemic spread. Understanding tumor boundaries and biological aggressiveness from imaging is therefore crucial.

Radiomics is central to these innovations. Artificial intelligence can extract thousands of quantitative features from imaging scans, including mathematical descriptions of texture, heterogeneity, shape irregularity, and vascular perfusion patterns. These features can predict tumor grade and clinical behavior before biopsy results are available. For instance, an osteosarcoma with highly irregular signal textures may demonstrate aggressive behavior and require intensification of neoadjuvant chemotherapy.

Deep learning integrates multimodal imaging to reveal features not visible through human interpretation alone. PET, MRI, and CT can be fused in ways that reveal metabolic hot spots that indicate aggressive tumor regions. These models assist in biopsy planning by directing sampling

toward areas most likely to reflect true tumor biology.

When tumors lie near the spine or pelvis, neurologic and organ involvement can be difficult to evaluate. AI supported three dimensional modeling reconstructs anatomical relationships and reveals pathways of infiltration that shape surgical strategy. It becomes possible to anticipate whether limb salvage is feasible or whether structural compromise risks catastrophic fracture.

Monitoring treatment response is another essential component. Traditional radiologic criteria rely on visible shrinkage but bone remodeling after therapy may take months, delaying insight into whether systemic treatment is effective. AI can measure subtle internal modifications within tumor mass that reflect cellular death even before structural changes appear. When resistance is detected early, clinicians can adjust regimens and prevent ineffective therapy from continuing.

Advances in imaging interpretation therefore reduce uncertainty and tailor interventions with greater biological precision.

AI in Computational Pathology and Molecular Profiling

Pathology confirmation is indispensable in identifying the correct tumor subtype and grade. Yet bone and soft tissue tumors often show

overlapping features that challenge even expert pathologists. Digital pathology supported by artificial intelligence greatly increases sensitivity and interpretive consistency.

Whole slide image analysis provides a comprehensive view of tumor architecture. Machine learning identifies microscale features such as osteoid production, mitotic density, cellular pleomorphism, and stromal reaction, correlating them with pathologic diagnosis and prognosis. Difficult borderline cases such as low grade osteosarcoma versus benign fibro osseous lesions become easier to differentiate with AI guidance.

Furthermore, AI supports integrated molecular diagnostics. Genomic profiling has revealed actionable insights for targeted therapy, but interpreting complexity is difficult without computational support. Neural networks evaluate fusion genes characteristic of Ewing sarcoma or mutation signatures associated with chondrosarcoma behavior. They can predict which tumors are likely to respond to immunotherapy, kinase inhibitors, or epigenetic treatments.

Predictive pathology additionally forecasts recurrence risk by evaluating tumor margins, necrosis percentage after chemotherapy, and immune infiltration profiles. These variables shape decisions on whether and how to escalate therapy.

The fusion of digital pathology with molecular interpretation creates a more complete picture of tumor biology than traditional morphology alone. AI thus enables treatment personalization earlier in the care continuum.

AI Guided Surgical Planning

Surgery remains crucial for curing many bone and musculoskeletal cancers. Limb preservation has become a preferred objective whenever oncologically safe, but this requires precise planning. Even slight errors in tumor boundary interpretation can lead to local recurrence, while unnecessarily removing functioning structures may result in avoidable disability.

Artificial intelligence expands planning capabilities through high fidelity reconstruction of tumor boundaries and their relationship to blood vessels, nerves, and joints. Predictive surgical simulation allows teams to explore various resection margins and reconstructive techniques before entering the operating room. Understanding how bone resection will impact mechanical strength helps determine whether implants, allografts, or biological reconstructions are best suited.

Intraoperative imaging supported by AI guides real time decisions. For example, optical imaging enhanced with AI can detect residual cancer cells at the resection surface while surgery is underway,

reducing the likelihood of positive margins. Robotic surgery combines algorithmic guidance with enhanced dexterity for tumor removal in anatomically difficult locations.

Functional outcomes are predicted using biomechanical data models that account for patient specific limb usage, bone geometry, and muscle attachments. Anticipating gait changes or joint limitations before surgery supports customized rehabilitation plans and helps patients prepare emotionally for postoperative challenges.

AI based planning reduces complications, improves safety, and makes limb salvage more achievable for a larger proportion of patients.

AI Enhanced Radiotherapy

Radiation therapy plays a significant role in treating Ewing sarcoma and many soft tissue sarcomas as well as palliating metastatic bone disease. The proximity of cancers to critical structures such as spinal cord, growth plates, and major muscles makes precise dose delivery essential. AI improves radiation therapy through better target mapping, dose prediction, and toxicity avoidance.

Automated segmentation systems delineate tumors and adjacent organs with high accuracy, ensuring that treatment is tailored to the individual. Dose optimization algorithms balance local control against risk to structural integrity

and function. When pediatric patients are treated, models assess growth plate sensitivity to reduce the risk of stunting or deformity.

Adaptation during treatment is achieved through AI systems that examine changes in tumor volume or body alignment across sessions. If the target shrinks significantly, plans can be updated to maintain accuracy and limit collateral damage. Predictive models also estimate risk of long term complications such as fracture or fibrosis, enabling early preventive strategies.

Through improved precision and adaptability, AI enhanced radiotherapy contributes to superior clinical outcomes and reduced disability.

AI Accelerated Drug Discovery and Personalized Systemic Therapy

Systemic therapy for bone and musculoskeletal cancers remains an area of unmet need because many tumors develop resistance to current agents and progress despite intensive treatment. Artificial intelligence accelerates discovery of new drug candidates by modeling interactions at the molecular level and predicting compound performance before human trials.

AI driven virtual drug screening reduces research time substantially, allowing millions of molecules to be evaluated computationally in the time that traditional methods evaluate only a small fraction. These models identify agents that are more likely

to overcome resistance mechanisms by targeting pathways implicated in metastatic progression and immune evasion.

Drug repurposing also benefits greatly. AI finds similarities between musculoskeletal tumor genomic landscapes and diseases treated by existing drugs, potentially offering rapid therapeutic alternatives. For example, if a kinase inhibitor used for another cancer targets pathways active in certain sarcomas, AI might flag this agent for further investigation.

Personalized therapy selection is supported through predictive modeling that integrates genomics, immune composition, and response history. AI analysis of circulating tumor DNA during therapy helps identify early resistance and guides changes that preserve treatment momentum.

Altogether, AI contributes to a more dynamic and personalized approach to systemic therapy.

AI Supported Rehabilitation and Survivorship

Survivorship for patients with bone and soft tissue cancers involves significant rehabilitation due to functional losses associated with tumor location and treatment. Limb salvage procedures often require lengthy recovery periods and physical therapy to regain stability and mobility. Amputation survivors rely on prosthetics that

must be tailored carefully to optimize comfort and performance.

AI helps personalize rehabilitation by assessing gait patterns, range of motion, and force distribution during movement. Wearable sensors transmit data to learning algorithms that identify subtle inefficiencies or increasing strain, prompting targeted exercises. Real time monitoring allows continuous progress evaluation and enables early response when recovery slows.

Pain and emotional trauma can persist long after treatment completion. Natural language processing applied to patient communication highlights distress and helps clinical teams intervene with timely psychosocial support. Muscle and bone integrity predictions inform activity recommendations and protect against stress fractures or joint deterioration.

Advances in prosthetic robotics paired with AI enable more natural limb control and adaptation to varied terrains or tasks. The integration of neural and mechanical signals through machine learning expands possibilities for independent living.

Long term survivorship supported by AI emphasizes ability rather than disability and gives survivors greater freedom to pursue fulfilling life goals.

Ethical and Implementation Considerations

Artificial intelligence promises tremendous benefit, but these innovations raise important responsibilities. Data quality and diversity must be prioritized because musculoskeletal cancers disproportionately affect younger populations whose data may be scattered across institutions or incomplete. Underrepresentation of certain demographics risks biased models that fail to serve every patient equally.

Clinician familiarity and trust are essential. AI systems must be interpretable enough that healthcare providers understand and confidently integrate recommendations. Patients should be able to ask questions and receive clear explanations that affirm their autonomy and support shared decision making.

Privacy and data protection are particularly important because imaging and rehabilitation data can reveal identifiable information. Regulatory oversight must ensure that AI development and deployment are carried out under strict ethical frameworks and validated rigorously before clinical implementation.

Most importantly, technological advances must benefit all patients, not only those treated at elite academic centers. Accessibility and broad integration into diverse healthcare environments

remain crucial goals.

Future Directions

The future of AI in bone and musculoskeletal cancer care involves tighter integration across specialties. Digital twins that create virtual patient models may allow clinicians to simulate treatment outcomes before choosing a plan. Multimodal AI systems will link radiologic imaging with pathology and molecular modeling to produce up to the minute adaptive care strategies. Robotics will expand surgical possibilities with increased safety and precision. Virtual rehabilitation programs will become more sophisticated, giving patients continuous support in their homes.

Global collaboration will expand knowledge sharing and improve rare cancer data availability, strengthening predictive accuracy and broad access to innovation. AI will increasingly support public health initiatives by recognizing environmental exposures and emerging risk trends.

The ethical imperative will be to harness these advancements responsibly and inclusively.

Conclusion

Bone and musculoskeletal cancers impose severe burdens on patients through pain, disability, and uncertainty. Traditional diagnostics and treatments, while essential, do not always provide

timely insight or preserve long term function. Artificial intelligence offers new pathways to reduce diagnostic delays, improve surgical and radiologic precision, accelerate therapy development, and support survivors throughout recovery. When deployed thoughtfully within multidisciplinary care, AI can transform outcomes and quality of life for individuals facing these difficult cancers. Commitment to ethical implementation, equitable distribution, interpretability, and clinician partnership will determine how fully this technology fulfills its potential in redefining care for bone and musculoskeletal cancers.

10. AI FOR THE DIAGNOSIS AND TREATMENT OF UNKNOWN-ORIGIN CANCERS

Background

In oncology, identifying the tissue of origin of a malignancy is fundamental to selecting effective therapy. Yet a subset of patients presents with metastatic cancer lacking any detectable primary site, classified as cancers of unknown primary, or CUP. CUP accounts for approximately 2 to 5 percent of all malignancies and is consistently associated with poor outcomes. Without an identified primary, patients are deprived of site specific treatment options and face significantly worse prognoses. Conventional empirical therapies demonstrate limited efficacy in this setting, which underscores the urgent need for new diagnostic approaches to guide management. Recently, artificial intelligence has emerged as a promising tool, with machine learning models capable of predicting tumor origins with high accuracy and providing additional support to clinicians.

CUP represents a relatively rare but clinically significant entity that contributes disproportionately to cancer related mortality despite its relatively low incidence. Although

incidence has gradually declined with advances in imaging and pathology, CUP remains a persistent diagnostic and therapeutic challenge. Historically, patients underwent exhaustive investigations and, when no primary was found, were treated with empiric broad spectrum chemotherapy. Over time, classification systems stratified CUP cases into prognostic subsets. Around 15 to 20 percent of patients present with clinicopathological patterns suggestive of a specific primary, often referred to as a favorable subset, and may benefit from site directed therapy, whereas the remaining 80 to 85 percent form an unfavorable subset with poor responses to empiric regimens and markedly worse outcomes. Biologically, CUP is highly heterogeneous and encompasses diverse tumor lineages and genomic profiles that reflect multiple potential tissues of origin and complex evolutionary pathways.

Persistent diagnostic challenges stem from the limitations of conventional modalities. Even with advanced imaging techniques and comprehensive histopathological evaluation, CUP often remains a diagnosis of exclusion. Immunohistochemistry can identify a presumptive origin in only a proportion of cases and is particularly unreliable for poorly differentiated tumors, where staining patterns are ambiguous or non specific. Molecular classifiers based on gene expression, methylation profiling, or sequencing

show promise in predicting tissue of origin but lack fully standardized validation and have yet to consistently demonstrate survival benefits in large randomized trials. These limitations often lead to reliance on empiric chemotherapy, leaving most high risk patients with a median survival of only 6 to 10 months and restricting their access to targeted therapies, immunotherapies, or appropriately matched clinical trials.

Artificial intelligence is now being deployed to address these diagnostic gaps. Machine learning classifiers trained on large multi omic datasets can detect tumor specific molecular signatures and have achieved accuracies of approximately 83 to 90 percent in predicting tissue of origin. For example, targeted gene mutation profiling combined with intelligent algorithms has enabled high confidence predictions in a substantial proportion of CUP patients, effectively doubling the number eligible for genomically guided therapy and leading to significantly improved survival for those treated according to artificial intelligence based predictions. Deep learning applied to histopathology has identified primary sites with approximately 80 percent accuracy, while cytology based systems such as newer tumor origin classifiers have shown about 83 percent top one accuracy and have been associated with prolonged survival when treatment was guided by model predictions. Importantly, a

randomized trial demonstrated that use of a 90 gene expression classifier to direct site specific therapy significantly extended progression free survival compared with empiric chemotherapy, providing strong clinical proof of concept that such approaches can change outcomes.

Artificial intelligence enabled clinical decision support systems extend these advances into day to day clinical workflows. By embedding predictive models into oncology practice, clinical decision support tools can classify tumor origin and recommend therapy options, thereby reducing diagnostic uncertainty and improving clinician confidence. Deep learning systems trained on histopathology and cytology already provide structured differential diagnoses that support personalized therapy decisions in challenging cases. Integration with electronic health records enables real time synthesis of multimodal data, including pathology, imaging, laboratory results, and genomics, which streamlines oncologists' ability to make informed treatment choices. Early implementations have shown high clinician satisfaction, and growing evidence suggests that multimodal artificial intelligence integration can improve both decision making and patient outcomes by standardizing assessment and revealing options that might otherwise be missed.

Therapeutically, artificial intelligence is advancing precision strategies in CUP. Machine learning

can integrate molecular and clinical data to recommend targeted treatments or repurpose existing drugs based on tumor specific biomarkers and pathway alterations. Adaptive trial designs now leverage artificial intelligence for response adaptive randomization, dynamically steering patients toward more effective therapies as data accumulate over time. Critically, clinical evidence supports tangible outcome gains. Trials using a 90 gene classifier have demonstrated prolonged progression free survival with site specific therapy compared to empiric chemotherapy, while genomic profiling linked to targeted therapy has produced longer progression free survival than standard regimens in CUP cohorts. These findings highlight the growing potential of artificial intelligence driven therapeutic strategies to improve prognosis in this historically intractable disease and to convert biologic insights into practical clinical benefit.

Despite the significant progress to date, further innovations are on the horizon to fully realize the potential of artificial intelligence in CUP care. Emerging trends in research include the development of explainable artificial intelligence techniques that increase transparency in how models predict tumor origin, thereby improving clinician and patient trust in artificial intelligence guided recommendations. Alongside explainability, multimodal learning is gaining

traction, in which algorithms concurrently analyze histopathology images, radiology scans, genomic sequences, and clinical data. Such integrated models are expected to yield more robust and accurate predictions than single modality systems. Another frontier is federated learning, which enables artificial intelligence models to be trained on data from multiple institutions without pooling sensitive patient data in a central location. This approach could greatly benefit CUP, a relatively rare cancer, by leveraging large, distributed datasets while preserving patient privacy and respecting data security regulations.

In addition to technical advances, there is a growing focus on ethical and policy considerations for artificial intelligence in oncology. Model developers and clinicians are increasingly aware of the need to mitigate biases in training data that could otherwise lead to unequal performance of artificial intelligence tools across different patient populations. Ensuring that algorithms are audited for bias and fairness is crucial for maintaining patient trust and avoiding the perpetuation of healthcare disparities. Likewise, improving the interpretability of artificial intelligence outputs, for example through user friendly explanations or visualizations of what the model found significant, will be key for clinician acceptance

of artificial intelligence driven recommendations. On the regulatory side, professional societies and agencies have begun outlining frameworks for validation and deployment of artificial intelligence in clinical settings. Consensus recommendations stress rigorous prospective validation of any artificial intelligence diagnostic tool against the current standard of care and the development of guidelines to govern how artificial intelligence advice should be integrated into oncologists' decision making workflows. As these policy frameworks solidify, they will provide much needed guidance on issues of accountability, data governance, and quality control for artificial intelligence systems in medicine.

The long term vision is that artificial intelligence will enable truly personalized treatment for CUP to become standard of care. In the coming years, it is anticipated that every CUP patient's tumor will undergo comprehensive molecular profiling and artificial intelligence based analysis at the outset, yielding an origin profile and a map of targetable vulnerabilities. Clinicians would then use this information to select effective, tailored therapies rather than defaulting to nonspecific chemotherapy. Ideally, CUP would cease to be a diagnosis of therapeutic uncertainty and instead would be managed with a precise, individualized plan comparable to the approach used for cancers of known primary. Achieving this vision

will likely require continued multidisciplinary collaboration, with oncologists, data scientists, pathologists, bioinformaticians, ethicists, and regulators working together, but recent studies have already laid the groundwork. Notably, the success of trials that identify a tissue of origin and treat accordingly suggests that tissue specific and biology driven strategies can improve outcomes, supporting the notion that an artificial intelligence driven, personalized approach may become the new standard of care for CUP in the near future. In summary, the convergence of explainable and multimodal artificial intelligence, ethical best practices, and supportive policy development is poised to transform CUP management and to bring renewed hope for better patient outcomes in this challenging area of oncology.

AI in Early Diagnostic Evaluation

When a patient presents with metastatic disease and no clear primary site, clinicians follow a diagnostic algorithm that includes targeted imaging, biopsies, laboratory tests, and sometimes invasive procedures. This evaluation is resource intensive and may still fail to uncover definitive answers. Artificial intelligence enhances this early diagnostic phase by identifying clues that human interpretation could overlook and by prioritizing tests that are most likely to yield informative results based on the unique characteristics of each

case.

In the first stage of evaluation, radiologic imaging plays a central role. AI assisted interpretation of computed tomography, magnetic resonance imaging, and positron emission tomography improves visualization of subtle lesions that might represent the missing primary tumor. Deep learning models have shown capability in detecting very small primary tumors within the gastrointestinal tract, breast tissue, pancreas, and lungs based on texture irregularities, perfusion signals, or metabolic patterns that fall below typical human threshold recognition. These computational systems learn from thousands of confirmed examples to identify regions deserving additional scrutiny, increasing the chance of identifying the tumor origin early in the diagnostic process.

Artificial intelligence also supports triage decisions by modeling which investigations are most likely to provide diagnostic answers for a specific clinical presentation. For example, if a patient arrives with liver predominant metastasis and limited symptom history, AI may estimate the probability of a primary in the gastrointestinal tract or pancreas and suggest the most informative endoscopic or sampling strategies. This avoids excessive and unnecessary procedures and reduces the time until treatment is initiated.

Suspicion of cancer of unknown origin often

creates emotional distress for patients because of the uncertainty and fear that accompany a diagnosis of advanced malignancy. AI enabled systems can guide clinicians in communicating prognostic and diagnostic expectations more clearly by offering predictive confidence intervals and scenario modeling. This creates a more transparent and supportive experience, even when uncertainty remains.

AI in Imaging Based Primary Site Identification

Medical imaging remains an indispensable tool in the diagnosis and staging of metastatic cancers. When the primary site is unknown, radiology must be interpreted with heightened attention to patterns of spread. Metastatic pathways differ based on tumor lineage and influence lymphatic, hematologic, or transcoelomic dissemination. Artificial intelligence excels in analyzing complex patterns and correlating them with known disease trajectories.

Machine learning models evaluate spatial relationships among metastases, comparing them to large datasets of known tumor origins. For instance, a metastatic lesion in the liver combined with bone involvement could originate from gastrointestinal or prostate primaries, whereas regional lymph node involvement in the cervical region paired with thoracic imaging anomalies

may suggest head and neck lineage. AI identifies these patterns quicker than manual review and generates probable primary sites ranked by likelihood. Even when accuracy is not absolute, narrowing diagnostic range significantly helps clinicians refine further testing.

Radiomics extends this precision by quantifying imaging features such as lesion shape, surface sharpness, heterogeneity, and metabolic profile. Tumors from different organs maintain distinct radiomic signatures even after metastasis. Deep learning can cluster tumors based on these signatures and link them to tissue origin. Artificial intelligence also addresses complex imaging presentations such as peritoneal carcinomatosis or diffuse bone metastases where human interpretation alone may struggle to identify a clear source.

Monitoring disease progression with AI creates additional advantages. When new lesions appear during early therapy response evaluation, models can reassess likelihood of origin based on emerging patterns. Tumors that evolve in specific trajectories over time reveal lineage characteristics through disease kinetics.

By integrating radiomics, clinical features, and staging patterns, AI provides a continually improving system for identifying cancer origin from imaging data alone.

AI Enhanced Pathology and Tissue Classification

Biopsy analysis is fundamental to diagnosing cancer, yet metastatic lesions are often less differentiated than primary tumors and may lose key histologic features. Immunohistochemistry helps refine diagnosis but can leave significant uncertainty. The increasing availability of digital pathology has opened new avenues for artificial intelligence to contribute detailed microscopic evaluation capable of detecting lineage specific traits that remain even when tumors appear morphologically ambiguous.

Computational pathology uses convolutional neural networks to study entire slide images and extract subtle image based biomarkers. Nuclear atypia, stromal composition, and architectural patterns can be linked through machine learning to tissue origin with predictive accuracy that exceeds manual estimation. Sarcomatoid or poorly differentiated carcinomas that once defied clear classification may now reveal hidden lineage associations through AI supported pattern recognition.

One promising area involves prediction of tumor primary based solely on metastatic biopsy images. Studies suggest that when a model is trained on large databases of known primary tissues, it can differentiate metastatic colorectal cancer from

metastatic breast or lung cancer by analyzing features that cannot be articulated easily even by expert pathologists. These discoveries enrich multidisciplinary decision making and reduce reliance on broader empiric treatments.

Molecular interpretation builds on pathology by integrating AI at the genomic level. Gene expression signatures, mutational landscapes, and epigenetic markers vary by tissue type. Machine learning methods evaluate countless data points simultaneously to identify combinations that best predict tumor origin. For example, a panel of microRNA signatures can guide classification of carcinoma origin more accurately when enriched by AI clustering algorithms that reflect tumor behavior rather than isolated markers.

AI enhanced tissue diagnostics remove guesswork by enabling a more comprehensive and biologically grounded understanding of metastatic tumor identity.

AI for Precision Systemic Therapy

Once a likely primary is identified or a molecular phenotype becomes clearer through AI analysis, treatment selection becomes more precise. Historically, therapy for unknown origin cancers has consisted of empiric chemotherapy with modest efficacy. Artificial intelligence redefines systemic therapy strategy by enabling personalized variability in biologic targeting.

Pharmacogenomics and treatment history data inform AI systems that predict drug responsiveness for metastatic cancers of uncertain origin. These models can estimate benefit from immunotherapy by evaluating immune profile markers such as tumor mutational burden, T cell infiltration patterns, and inflammatory gene expression. If AI suggests a high probability of immunotherapy response, clinicians gain a stronger rationale for selecting these agents earlier in treatment rather than pursuing cytotoxic chemotherapy first.

Targeted therapy gains greater relevance when AI identifies druggable pathways even without knowing the primary site. For instance, activating mutations in tyrosine kinase receptors or aberrant signaling in PI3K and MAPK pathways can suggest treatment courses normally associated with specific primary tumors but now justified by molecular features. AI supports this precision by comparing rare or unusual metastatic profiles against global databases of therapeutic response.

Adaptive decision support models continue to refine therapy as treatment progresses. Data from imaging, circulating tumor DNA, and symptom monitoring informs AI about whether a treatment is working. If no response is detected early, algorithmic evaluation prompts timely therapy transitions without waiting for visible clinical deterioration.

The goal of AI guided treatment is not only to extend survival but also to avoid unnecessary adverse effects and improve individualized quality of life.

AI Supported Symptom Management and Patient Monitoring

Unknown origin cancers often require intensive follow up because disease behavior is unpredictable. Patients may experience rapid progression or unexpected shifts in metastasis patterns. Artificial intelligence assists by monitoring health data in real time and identifying subtle signs of worsening disease.

Digital health technologies including wearable devices and remote patient reporting systems feed continuous data into machine learning models that evaluate mobility limitations, breathing patterns, nutritional changes, and pain experiences. These changes can signal disease flare earlier than standard clinical appointments would detect. Clinicians using AI alerts can intervene before functional decline becomes irreversible.

Psychological symptoms are also prevalent in unknown origin cancer because the lack of definitive answers amplifies anxiety and fear. Natural language processing can analyze communication during clinic visits or digital check ins to identify emotional distress indicators

that call for timely involvement of supportive care services.

AI applied to follow up imaging further refines detection of recurrence or new metastatic foci. Algorithms identify small lesions that require action before they cause symptomatic burden or structural instability. When bone metastases threaten fracture, early intervention can preserve independence. When central nervous system involvement emerges, rapid screening helps prevent severe neurological compromise.

Through these applications, AI supports a model of proactive care rather than reactive response to deterioration.

Ethical and Implementation Considerations

Artificial intelligence must be implemented with care in the context of unknown origin cancers because the stakes are high for vulnerable patients facing diagnostic uncertainty. Interpretability remains essential. Patients deserve clear communication about how AI contributes to decision making, what level of certainty exists, and how data will influence treatment strategy. Clinicians must maintain responsibility for confirming AI supported insights.

Data availability and equity are critical considerations. Because unknown origin cancers are rare, datasets can be fragmented and skewed

toward high income countries. If AI systems are trained without adequate diversity, diagnostic accuracy may be uneven across populations. This risks entrenching disparities in an area that already disproportionately affects groups with limited access to care. Collaborative data sharing and global partnerships are necessary to achieve representative model training.

Privacy is another central concern. AI depends on sensitive patient information including imaging data and genomic details. Safeguards must ensure confidentiality and prevent discriminatory use of genetic information.

Workforce training is crucial to ensure AI tools are used effectively. Clinicians must understand AI model outputs and integrate them into broader clinical perspectives without overreliance. Technology should augment expertise rather than overshadow clinical judgment.

When addressed proactively, these ethical challenges can strengthen trust and adoption in a meaningful and patient centered manner.

Future Directions

The future of cancer diagnosis and treatment increasingly depends on computational advances in biology, imaging, and clinical decision support. Unknown origin cancers are poised to benefit greatly because they represent the frontier of uncertainty. As data sets expand and models grow

more sophisticated, AI will be able to classify previously unclassifiable tumors based on unique genetic and phenotypic signatures. Digital twin models that simulate a patient's disease trajectory could allow clinicians to virtually test treatment scenarios before exposing patients to potential toxicity. Integration across institutions will allow continuous improvement as models evolve with real time clinical feedback from around the world.

The boundaries between known and unknown origin cancers may eventually blur as AI reveals underlying biological truths common across multiple tumor lineages. Patterns of evolution, immune evasion mechanisms, and metastatic tropism all provide clues that AI can piece together into actionable knowledge. With growing emphasis on patient centric care, AI will also help personalize treatment goals to reflect individual priorities, whether longevity, symptom reduction, or functional independence.

As these transformations unfold, the hope is that fewer patients will be forced to confront metastatic cancer without a clear diagnosis. The phrase unknown origin may become obsolete as artificial intelligence unlocks levels of diagnostic insight once thought unattainable.

Conclusion

Cancers of unknown origin represent a unique crisis in modern oncology. They remove the

foundation upon which most treatment decisions are built and leave both patients and clinicians navigating an uncertain path without clear guidelines. Artificial intelligence is reshaping that experience by uncovering hidden diagnostic signals, supporting precise and targeted treatment choices, guiding surveillance with real time analysis, and improving communication and care coordination.

By leveraging the strengths of machine learning in pattern recognition, data synthesis, and predictive modeling, AI has the ability to replace uncertainty with informed confidence. Yet successful implementation requires attention to ethics, data diversity, clinical integration, and patient empowerment. With responsible development, AI can provide answers where none previously existed, transforming the care of unknown origin cancers from a desperate guessing game into a scientifically informed journey.

REFERENCES

1. Alenezi AM. Artificial Intelligence in Breast Cancer Diagnosis and Surgical Decision-Making: An Updated and Comprehensive Overview of Precision and Personalization in Current Evidence. Cancer Manag Res. 2025;17:2261-75.

2. Alikarami M, Faraj TA, Hama NH, Hosseini AS, Habibi P, Samiei Mosleh I, et al. Artificial intelligence in advancing optical coherence tomography for disease detection and cancer diagnosis: A scoping review. Eur J Surg Oncol. 2025;51(9):110188.

3. Alis D, Onay A, Colak E, Karaarslan E, Bakir B. A Narrative Review of Artificial Intelligence in MRI-Guided Prostate Cancer Diagnosis: Addressing Key Challenges. Diagnostics (Basel). 2025;15.(11)

4. Alsallal M, Habeeb MS, Vaghela K, Malathi H, Vashisht A, Sahu PK, et al. Artificial intelligence in gastric cancer: a systematic review of machine learning and deep learning applications. Abdom Radiol (NY). 2025.

5. Altobelli E, Angeletti PM, Ciancaglini M, Petrocelli R. The Future of Breast Cancer Organized Screening Program Through Artificial Intelligence: A Scoping Review. Healthcare (Basel). 2025;13.(4)

6. Alvarez-Torres MDM, Fu X, Rabadan R. Illuminating the Noncoding Genome in Cancer Using Artificial Intelligence. Cancer Res. 2025;85(13):2368-75.

7. Andras D, Lazar AM, Crețoiu D, Berghea F, Georgescu DE, Grigorean V, et al. Analyzing postoperative complications in colorectal cancer surgery: a systematic review enhanced by artificial intelligence. Front Surg. 2024;11:1452223.

8. Aneja S, Parikh RB. Cancer Informatics: Novel Methods and Applications of Artificial Intelligence in Cancer Care Delivery. Yearb Med Inform. 2024;33(1):99-101.

9. Ang XL, Oh CC. The Use of Artificial Intelligence for Skin Cancer Detection in Asia-A Systematic Review. Diagnostics (Basel). 2025;15.(7)

10. Antony A, Mukherjee S, Bhinder K, Murlidhar M, Zarrintan A, Goenka AH. Artificial Intelligence-Augmented Imaging for Early Pancreatic Cancer Detection. Visc Med. 2025:1-9.

11. Araújo ALD, Sperandio M, Calabrese G, Faria SS, Cardenas DAC, Martins MD, et al. Artificial intelligence in healthcare applications targeting cancer diagnosis-part I: data structure, preprocessing and data organization. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025;140(1):79-88.

12. Araújo ALD, Sperandio M, Calabrese G,

Faria SS, Cardenas DAC, Martins MD, et al. Artificial intelligence in healthcare applications targeting cancer diagnosis-part II: interpreting the model outputs and spotlighting the performance metrics. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025;140(1):89-99.

13. Asadi F, Rahimi M, Ramezanghorbani N, Almasi S. Comparing the Effectiveness of Artificial Intelligence Models in Predicting Ovarian Cancer Survival: A Systematic Review. Cancer Rep (Hoboken). 2025;8(3):e70138.

14. Aswathy R, Chalos VA, Suganya K, Sumathi S. Advancing miRNA cancer research through artificial intelligence: from biomarker discovery to therapeutic targeting. Med Oncol. 2024;42(1):30.

15. Au RC, Jenjitranant P, Cool DW, Izawa J, Inman B, Ward A, et al. Artificial intelligence may enhance the role of magnetic resonance imaging in prostate cancer focal therapy. Prostate Cancer Prostatic Dis. 2025.

16. Ayasa Y, Alajrami D, Idkedek M, Tahayneh K, Akar FA. The Impact of Artificial Intelligence on Lung Cancer Diagnosis and Personalized Treatment. Int J Mol Sci. 2025;26.(17)

17. Azhdarimoghaddam A, Mohammad Bigloo A, Soleimani Meigoli MS, Abdelbaset M, Narimani M, Dadkhah Tehrani F, et al. Artificial intelligence at the gut-oral microbiota frontier: mapping machine learning tools for gastric cancer risk

prediction. Biomed Eng Online. 2025.

18. Babu B, Singh J, Salazar González JF, Zalmai S, Ahmed A, Padekar HD, et al. A Narrative Review on the Role of Artificial Intelligence (AI) in Colorectal Cancer Management. Cureus. 2025;17(2):e79570.

19. Bai G, Huo S, Wang G, Tian S. Artificial intelligence radiomics in the diagnosis, treatment, and prognosis of gynecological cancer: a literature review. Transl Cancer Res. 2025;14(4):2508-32.

20. Bari RZA, Usman M, Huda NU, Javed MA, Tamulevičius S, Zhang X. Advanced artificial intelligence combined with SERS platforms for diagnosis and therapeutic effects of cancer in clinical applications. Spectrochim Acta A Mol Biomol Spectrosc. 2025;348(Pt 1):127053.

21. Behzadi M, Azinfar A, Alshakarchi HI, Khazaei Y, Gataa IS, Ferns GA, et al. The Potential Diagnostic Application of Artificial Intelligence in Breast Cancer. Curr Pharm Des. 2025;31(29):2305-14.

22. Benbow JH, Kim ES. Harnessing Artificial Intelligence to Transform Clinical Trials and Cancer Care: Opportunities and Challenges. Cancer J. 2025;31.(6)

23. Bhalla K, Xiao Q, Luna JM, Podany E, Ahmad T, Ademuyiwa FO, et al. Radiologic imaging biomarkers in triple-negative breast cancer: a literature review about the role of

artificial intelligence and the way forward. BJR Artif Intell. 2024;1(1):ubae016.

24. Bhange M, Telange D. Convergence of nanotechnology and artificial intelligence in the fight against liver cancer: a comprehensive review. Discov Oncol. 2025;16(1):77.

25. Bhujel R, Enkmann V, Burgstaller H, Maharjan R. Artificial Intelligence-Driven Strategies for Targeted Delivery and Enhanced Stability of RNA-Based Lipid Nanoparticle Cancer Vaccines. Pharmaceutics. 2025;17.(8)

26. Broggi G, Maniaci A, Lentini M, Palicelli A, Zanelli M, Zizzo M, et al. Artificial Intelligence in Head and Neck Cancer Diagnosis: A Comprehensive Review with Emphasis on Radiomics, Histopathological, and Molecular Applications. Cancers (Basel). 2024;16.(21)

27. Bukhari I, Li M, Li G, Xu J, Zheng P, Chu X. Pinpointing the integration of artificial intelligence in liver cancer immune microenvironment. Front Immunol. 2024;15:1520398.

28. Cai C, Hu W, Zhou H, Zhang X, Ren R, Liu Y, et al. Artificial intelligence-assisted radiation imaging pathways for distinguishing uterine fibroids and malignant lesions in patients presenting with cancer pain: a literature review. Front Oncol. 2025;15:1621642.

29. Camps J, Jiménez-Franco A, García-Pablo

R, Joven J, Arenas M. Artificial intelligence-driven integration of multi-omics and radiomics: A new hope for precision cancer diagnosis and prognosis. Biochim Biophys Acta Mol Basis Dis. 2025;1871(6):167841.

30. Cannarozzi AL, Biscaglia G, Parente P, Latiano TP, Gentile A, Ciardiello D, et al. Artificial intelligence and whole slide imaging, a new tool for the microsatellite instability prediction in colorectal cancer: Friend or foe? Crit Rev Oncol Hematol. 2025;210:104694.

31. Caraka RE, Supardi K, Gondhowiardjo SA, Isnaniawardhani V, Gio PU, Chen RC, et al. Artificial Intelligence in Cancer Oncology Through Comprehensive Bibliometric Mapping of Global Trends Impact and Conceptual Structures. J Healthc Leadersh. 2025;17:591-621.

32. Cece A, Agresti M, De Falco N, Sperlongano P, Moccia G, Luongo P, et al. Role of Artificial Intelligence in Thyroid Cancer Diagnosis. J Clin Med. 2025;14.(7)

33. Chadha S, Mukherjee S, Sanyal S. Advancements and implications of artificial intelligence for early detection, diagnosis and tailored treatment of cancer. Semin Oncol. 2025;52(3):152349.

34. Chamouni G, Lococo F, Sassorossi C, Atuhaire N, Ádány R, Varga O. Ethical and legal concerns in artificial intelligence applications

for the diagnosis and treatment of lung cancer: a scoping review. Front Public Health. 2025;13:1663298.

35. Chen L, Zhao J, Liu Z, Kong L, Zhou D, Wang F. Global research hotspots and trends in the application of artificial intelligence in gastric cancer: a bibliometric analysis from 2005 to 2024. Front Oncol. 2025;15:1591655.

36. Chen S, Ding P, Guo H, Meng L, Zhao Q, Li C. Applications of artificial intelligence in digital pathology for gastric cancer. Front Oncol. 2024;14:1437252.

37. Chen Y, Sun Y, Chen Y, Zhang J, Zhang H, Liu K, et al. Artificial intelligence-assisted PET imaging for predicting neoadjuvant chemotherapy response in breast cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2025.

38. Cheng CH, Shi SS. Artificial intelligence in cancer: applications, challenges, and future perspectives. Mol Cancer. 2025;24(1):274.

39. Cheng CH, Wong CC. The role of artificial intelligence-based foundation models and "copilots" in cancer pathology: potential and challenges. J Exp Clin Cancer Res. 2025.

40. Cherukuri SP, Kaur A, Goyal B, Kukunoor HR, Sahito AF, Sachdeva P, et al. Artificial Intelligence-Enhanced Liquid Biopsy and Radiomics in Early-Stage Lung Cancer Detection:

A Precision Oncology Paradigm. Cancers (Basel). 2025;17.(19)

41. Chia JLL, He GS, Ngiam KY, Hartman M, Ng QX, Goh SSN. Harnessing Artificial Intelligence to Enhance Global Breast Cancer Care: A Scoping Review of Applications, Outcomes, and Challenges. Cancers (Basel). 2025;17.(2)

42. Chierici A, Lareyre F, Iannelli A, Salucki B, Goffart S, Guzzi L, et al. Applications of artificial intelligence in liver cancer: A scoping review. Artif Intell Med. 2025;169:103244.

43. Ciancia M, Moro F, Bertoni M, Baldassari G, Schips P, Fanfani F, et al. Role of artificial intelligence applied to ultrasound in endometrial cancer: a systematic review. Int J Gynecol Cancer. 2025;35(11):102653.

44. Ciccone V, Garofano M, Del Sorbo R, Mongelli G, Izzo M, Negri F, et al. Improving Early Prostate Cancer Detection Through Artificial Intelligence: Evidence from a Systematic Review. Cancers (Basel). 2025;17.(21)

45. Dalboni da Rocha JL, Lai J, Pandey P, Myat PSM, Loschinskey Z, Bag AK, et al. Artificial Intelligence for Neuroimaging in Pediatric Cancer. Cancers (Basel). 2025;17.(4)

46. Dankwa-Mullan I, Ndoh K, Akogo D, Rocha HAL, Juaçaba SF. Artificial Intelligence and Cancer Health Equity: Bridging the Divide or Widening the Gap. Curr Oncol Rep. 2025;27(2):95-111.

47. De Luca GR, Diciotti S, Mascalchi M. The Pivotal Role of Baseline LDCT for Lung Cancer Screening in the Era of Artificial Intelligence. Arch Bronconeumol. 2025;61(6):359-67.

48. Debellotte O, Dookie RL, Rinkoo F, Kar A, Salazar González JF, Saraf P, et al. Artificial Intelligence and Early Detection of Breast, Lung, and Colon Cancer: A Narrative Review. Cureus. 2025;17(2):e79199.

49. Derbal Y. Adaptive Treatment of Metastatic Prostate Cancer Using Generative Artificial Intelligence. Clin Med Insights Oncol. 2025;19:11795549241311408.

50. Desai M, Desai B. Evolution and integration of artificial intelligence across the cancer continuum in women: advances in risk assessment, prevention, and early detection. Cancer Causes Control. 2025;36(11):1343-60.

51. Di Mauro A, Berretta M, Santorsola M, Ferrara G, Picone C, Savarese G, et al. Towards Post-Genomic Oncology: Embracing Cancer Complexity via Artificial Intelligence, Multi-Targeted Therapeutics, Drug Repurposing, and Innovative Study Designs. Int J Mol Sci. 2025;26.(16)

52. Dimopoulos P, Mulita A, Antzoulas A, Bodard S, Leivaditis V, Akrida I, et al. The role of artificial intelligence and image processing in the diagnosis, treatment, and prognosis of

liver cancer: a narrative-review. Prz Gastroenterol. 2024;19(3):221-30.

53. Dommalapati L, Guenter R, Golivi Y, Ganji SP, Sandhya T, Nagaraju GP, et al. Advances in artificial intelligence for spatial transcriptomics in cancer: Special focus on Yin Yang 1 (YY1) and Raf kinase inhibitor protein (RKIP). Biochim Biophys Acta Rev Cancer. 2025;1880(6):189456.

54. Donatello D. An overview of the use of cutting-edge artificial intelligence (AI) modeling to produce synthetic medical data (SMD) in decentralized clinical machine learning (ML) for ovarian cancer(OC) and ovarian lymphoma(OL). J Ultrasound. 2025;28(2):483-92.

55. Duan C, Sheng J, Ma X. Innovative approaches in colorectal cancer screening: advances in detection methods and the role of artificial intelligence. Therap Adv Gastroenterol. 2025;18:17562848251314829.

56. Duranti L, Tavecchio L, Rolli L, Solli P. New Perspectives on Lung Cancer Screening and Artificial Intelligence. Life (Basel). 2025;15.(3)

57. Ejaz ZH, Shaikh RH, Fatimi AS, Khan SR. Unlocking artificial intelligence, machine learning and deep learning to combat therapeutic resistance in metastatic castration-resistant prostate cancer: a comprehensive review. Ecancermedicalscience. 2025;19:1953.

58. Elahi R, Karami P, Amjadzadeh M, Nazari M.

Radiomics-based artificial intelligence (AI) models in colorectal cancer (CRC) diagnosis, metastasis detection, prognosis, and treatment response prediction. Abdom Radiol (NY). 2025.

59. Elsaigh M, Baqar S, Awan B, Saleh OS, Hesham Gamal M, Abara N, et al. Comparative Effectiveness of Artificial Intelligence Versus Conventional Methods for Detecting Peritoneal Metastasis in Colorectal Cancer: A Systematic Review. Cureus. 2025;17(10):e95484.

60. Farhoudian A, Heidari A, Shahhosseini R. A new era in colorectal cancer: Artificial Intelligence at the forefront. Comput Biol Med. 2025;196(Pt C):110926.

61. Fatima SH, Faisal SJ, Batool SV, Faisal M, Aamir T, Shahid ZUA, et al. Evaluating the combined efficacy of Telisotuzumab Vedotin and artificial intelligence in the treatment of non-squamous non-small cell lung cancer: a narrative review focusing on pharmaceutical and technical insights. Front Oncol. 2025;15:1673586.

62. Felici A, Peduzzi G, Pellungrini R, Campa D. Artificial intelligence to predict cancer risk, are we there yet? A comprehensive review across cancer types. Eur J Cancer. 2025;222:115440.

63. Feng K, Yi Z, Xu B. Artificial Intelligence and Breast Cancer Management: From Data to the Clinic. Cancer Innov. 2025;4(2):e159.

64. Firuzpour F, Heydari M, Aram C, Alishvandi

A. The role of artificial intelligence in enhancing breast cancer screening and diagnosis: A review of current advances. Bioimpacts. 2025;15:30984.

65. Fogli S, Barberis A, Re MD, Crucitta S, Ruglioni M, Luculli G, et al. Artificial intelligence-based pharmacological approach in non-small cell lung cancer in the precision medicine era. Cancer Treat Res Commun. 2025;45:101023.

66. Freitas V, Ghai S, Au F, Muradali D, Kulkarni S. The Transformative Power of Digital Breast Tomosynthesis and Artificial Intelligence in Breast Cancer Diagnosis. Can Assoc Radiol J. 2025;76(2):302-12.

67. Fu M, Xu J, Lv Y, Jin B. Artificial intelligence in advanced gastric cancer: a comprehensive review of applications in precision oncology. Front Oncol. 2025;15:1630628.

68. Fuster-Matanzo A, Picó-Peris A, Bellvís-Bataller F, Jimenez-Pastor A, Weiss GJ, Martí-Bonmatí L, et al. Prediction of oncogene mutation status in non-small cell lung cancer: a systematic review and meta-analysis with a special focus on artificial intelligence-based methods. Eur Radiol. 2025.

69. Galani A, Zikopoulos A, Moustakli E, Potiris A, Paraskevaidi M, Arkoulis I, et al. Cervical Cancer Screening in the HPV-Vaccinated and Digital Era: Reassessing Strategies in Light of Artificial Intelligence and Evolving Risk. Cancers (Basel).

2025;17.(19)

70. Gao Y, Chen J, Fu T, Gu Y, Du W. Quantitative analysis of studies that use artificial intelligence on thyroid cancer: a 20-year bibliometric analysis. Front Oncol. 2025;15:1525650.

71. Garcia-Atutxa I, Villanueva-Flores F, Barrio ED, Sanchez-Villamil JI, Martínez-Más J, Bueno-Crespo A. Artificial intelligence for ovarian cancer diagnosis via ultrasound: a systematic review and quantitative assessment of model performance. Front Artif Intell. 2025;8:1649746.

72. Ge KK, Jin X, Zhong JG, Sun XY, Xie HS, Peng SB, et al. [Applications of artificial intelligence in the diagnosis and treatment of lung cancer]. Zhonghua Zhong Liu Za Zhi. 2025;47(11):1057-65.

73. Geppert J, Asgharzadeh A, Brown A, Stinton C, Helm EJ, Jayakody S, et al. Software using artificial intelligence for nodule and cancer detection in CT lung cancer screening: systematic review of test accuracy studies. Thorax. 2024;79(11):1040-9.

74. Ghane G, Karimi R, Chekeni AM, Darvishi M, Imani R, Vafaeinezhad FZ. Pain Management in Cancer Patients With Artificial Intelligence: Narrative Review. Scientifica (Cairo). 2025;2025:6888213.

75. Ghasemi A, Hashtarkhani S, Schwartz DL, Shaban-Nejad A. Explainable artificial intelligence

in breast cancer detection and risk prediction: A systematic scoping review. Cancer Innov. 2024;3(5):e136.

76. Goh S, Goh RSJ, Chong B, Ng QX, Koh GCH, Ngiam KY, et al. Challenges in Implementing Artificial Intelligence in Breast Cancer Screening Programs: Systematic Review and Framework for Safe Adoption. J Med Internet Res. 2025;27:e62941.

77. Gonçalves N, Chaves J, Marques-Sá I, Dinis-Ribeiro M, Libânio D. Early diagnosis of gastric cancer: Endoscopy and artificial intelligence. Best Pract Res Clin Gastroenterol. 2025;75:101979.

78. Grapă C, Mocan T, Mocan LP, Motofelea A, Stănciulescu R, Crăciun R, et al. Turning the Tide-Artificial Intelligence in the Evolving Landscape of Liver Cancer. Cancers (Basel). 2025;17.(18)

79. Grunhut J, Newland JJ, Brown RF. Implications of Artificial Intelligence for Colorectal Cancer in Young Populations. J Surg Oncol. 2025;131(7):1368-72.

80. Guo Y, Li T, Gong B, Hu Y, Wang S, Yang L, et al. From Images to Genes: Radiogenomics Based on Artificial Intelligence to Achieve Non-Invasive Precision Medicine in Cancer Patients. Adv Sci (Weinh). 2025;12(2):e2408069.

81. Hachache R, Yahyaouy A, Riffi J, Tairi H, Abibou S, Adoui ME, et al. Advancing personalized oncology: a systematic review on the

integration of artificial intelligence in monitoring neoadjuvant treatment for breast cancer patients. BMC Cancer. 2024;24(1):1300.

82. Hagen J, Hornung L, Barham W, Mukhopadhyay S, Bess A, Contrera K, et al. Artificial Intelligence in Head and Neck Cancer: Towards Precision Medicine. Cancers (Basel). 2025;17.(18)

83. HaghighiKian SM, Shirinzadeh-Dastgiri A, Vakili-Ojarood M, Naseri A, Barahman M, Saberi A, et al. A Holistic Approach to Implementing Artificial Intelligence in Lung Cancer. Indian J Surg Oncol. 2025;16(1):257-78.

84. Hamamoto R, Komatsu M, Yamada M, Kobayashi K, Takahashi M, Miyake M, et al. Current status and future direction of cancer research using artificial intelligence for clinical application. Cancer Sci. 2025;116(2):297-307.

85. Haque F, Simon BD, Özyörük KB, Harmon SA, Türkbey B. Generative Artificial Intelligence in Prostate Cancer Imaging. Balkan Med J. 2025;42(4):286-300.

86. Hardacre C, Hibbs T, Fok M, Wiles R, Bashar N, Ahmed S, et al. Predicting Surgical Difficulty in Rectal Cancer Surgery: A Systematic Review of Artificial Intelligence Models Applied to Pre-Operative MRI. Cancers (Basel). 2025;17.(5)

87. Hasan MR, Ibraheem N, Rahman ME, Tamanna R. Artificial Intelligence Across

the Prostate Cancer Pathway: Screening, Imaging, Pathology, and Biomarkers. Cureus. 2025;17(11):e96226.

88. Hashem H, Sultan I. Revolutionizing precision oncology: the role of artificial intelligence in personalized pediatric cancer care. Front Med (Lausanne). 2025;12:1555893.

89. Hashim HT, Alhatemi AQM, Daraghma M, Ali HT, Khan MA, Sulaiman FA, et al. Artificial intelligence versus radiologists in detecting early-stage breast cancer from mammograms: a meta-analysis of paradigm shifts. Pol J Radiol. 2025;90:e1-e8.

90. Hassan C, Bisschops R, Sharma P, Mori Y. Colon Cancer Screening, Surveillance, and Treatment: Novel Artificial Intelligence Driving Strategies in the Management of Colon Lesions. Gastroenterology. 2025;169(3):444-55.

91. Haue AD, Hjaltelin JX, Holm PC, Placido D, Brunak SR. Artificial intelligence-aided data mining of medical records for cancer detection and screening. Lancet Oncol. 2024;25(12):e694-e703.

92. Hays P. Artificial intelligence in cytopathological applications for cancer: a review of accuracy and analytic validity. Eur J Med Res. 2024;29(1):553.

93. He S, Li X, Xie Y, Hou J, Han B, Nie S. [Artificial intelligence in predicting pathological

complete response to neoadjuvant chemotherapy for breast cancer: current advances and challenges]. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2025;42(5):1076-84.

94. Hengky A, Lionardi SK, Kusumajaya C. Can artificial intelligence aid the urologists in detecting bladder cancer? Indian J Urol. 2024;40(4):221-8.

95. Hilbers D, Nekain N, Bates A, Nunez JJ. Patient Attitudes Toward Artificial Intelligence in Cancer Care: Scoping Review. JMIR Cancer. 2025;11:e74010.

96. Hofman P, Ourailidis I, Romanovsky E, Ilié M, Budczies J, Stenzinger A. Artificial intelligence for diagnosis and predictive biomarkers in Non-Small cell lung cancer Patients: New promises but also new hurdles for the pathologist. Lung Cancer. 2025;200:108110.

97. Howard HR, Hasanova M, Tiwari A, Ghose A, Winayak R, Nahar T, et al. The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation. ESMO Open. 2025;10(9):105557.

98. Huang C, Shen Y, Galgano SJ, Goenka AH, Hecht EM, Kambadakone A, et al. Advancements in early detection of pancreatic cancer: the role of artificial intelligence and novel imaging techniques. Abdom Radiol (NY).

2025;50(4):1731-43.

99. Huang D, Li Z, Jiang T, Yang C, Li N. Artificial intelligence in lung cancer: current applications, future perspectives, and challenges. Front Oncol. 2024;14:1486310.

100. Huang L, Wu X, You J, Jin Z, He W, Sun J, et al. Artificial Intelligence Can Predict Personalized Immunotherapy Outcomes in Cancer. Cancer Immunol Res. 2025;13(7):964-77.

101. Huang R, Jin X, Liu Q, Bai X, Karako K, Tang W, et al. Artificial intelligence in colorectal cancer liver metastases: From classification to precision medicine. Biosci Trends. 2025;19(2):150-64.

102. Hussain MS, Ramalingam PS, Chellasamy G, Yun K, Bisht AS, Gupta G. Harnessing Artificial Intelligence for Precision Diagnosis and Treatment of Triple Negative Breast Cancer. Clin Breast Cancer. 2025;25(5):406-21.

103. Ichimasa K, Kudo SE, Kouyama Y, Takashina Y, Chung H, Maeda Y, et al. Artificial Intelligence-Assisted Whole Slide Image Analysis for Lymph Node Status Prediction in Early Colorectal and Gastric Cancer. Dig Endosc. 2025.

104. Imani S, Li X, Chen K, Maghsoudloo M, Jabbarzadeh Kaboli P, Hashemi M, et al. Computational biology and artificial intelligence in mRNA vaccine design for cancer immunotherapy. Front Cell Infect Microbiol. 2024;14:1501010.

105. Ingman WV, Britt KL, Stone J, Nguyen TL, Hopper JL, Thompson EW. Artificial intelligence improves mammography-based breast cancer risk prediction. Trends Cancer. 2025;11(3):188-91.

106. Javanmard Z, Zarean Shahraki S, Safari K, Omidi A, Raoufi S, Rajabi M, et al. Artificial intelligence in breast cancer survival prediction: a comprehensive systematic review and meta-analysis. Front Oncol. 2024;14:1420328.

107. Jeong S, Choi HI, Yang KI, Kim JS, Ryu JW, Park HJ. Artificial Intelligence in the Diagnosis of Tongue Cancer: A Systematic Review with Meta-Analysis. Biomedicines. 2025;13.(8)

108. Jerjes W, Stevenson H, Ramsay D, Hamdoon Z. Enhancing Oral Cancer Detection: A Systematic Review of the Diagnostic Accuracy and Future Integration of Optical Coherence Tomography with Artificial Intelligence. J Clin Med. 2024;13.(19)

109. Ji J, Duan F, Liao Q, Wang H, Liu S, Liu Y, et al. Artificial Intelligence-Based Pathology to Assist Prediction of Neoadjuvant Therapy Responses for Breast Cancer. Cancer Med. 2025;14(15):e71132.

110. Jiang CQ, Li XJ, Zhou ZY, Xin Q, Yu L. Imaging based artificial intelligence for predicting lymph node metastasis in cervical cancer patients: a systematic review and meta-analysis. Front Oncol. 2025;15:1532698.

111. K RU, Elango AP, Subramanian R, Ks

S. The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and Artificial Intelligence- Based Screening and Treatment. Curr Treat Options Oncol. 2025;26(7):622-37.

112. Kadir A, Asaduzzaman M, Kundu J, Rahman MA, Rabbany MG, Shemanto MU, et al. Integrating Genetic Insights and Artificial Intelligence for Enhanced Oral and Maxillofacial Cancer Care. Methods Mol Biol. 2025;2952:107-24.

113. Kagan S, Huynh L, Strickland C, Wang A, Kwan JYY, Ng TL, et al. Survival prediction in metastatic breast cancer using artificial intelligence: a scoping review. Curr Opin Support Palliat Care. 2025;19(4):279-89.

114. Kaidar-Person O, Pfob A, Valentini V, Aznar M, Dekker A, Meattini I, et al. Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study. Breast. 2025;83:104537.

115. Karimzadhagh S, Ghodous S, Robati RM, Abbaspour E, Goldust M, Zaresharifi N, et al. Performance of Artificial Intelligence in Skin Cancer Detection: An Umbrella Review of Systematic Reviews and Meta-Analyses. Int J Dermatol. 2025.

116. Karuppan Perumal MK, Rajan Renuka R, Kumar Subbiah S, Manickam Natarajan P. Artificial intelligence-driven clinical decision support systems for early detection and precision therapy

in oral cancer: a mini review. Front Oral Health. 2025;6:1592428.

117. Kedar P, Bhattacharya S, Kanugo A, Prajapati BG. Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses. Curr Med Chem. 2025;32(35):7752-76.

118. Kemna R, Zeeuw JM, Ziesemer KA, Ali M, Bereska JI, Marquering H, et al. From Development to Implementation: A Systematic Review on the Current Maturity Status of Artificial Intelligence Models for Patients with Colorectal Cancer Liver Metastases. Oncology. 2025:1-10.

119. Khalid U, Gurung J, Doykov M, Kostov G, Hristov B, Uchikov P, et al. Artificial Intelligence Algorithms and Their Current Role in the Identification and Comparison of Gleason Patterns in Prostate Cancer Histopathology: A Comprehensive Review. Diagnostics (Basel). 2024;14.(19)

120. Khosravi M, Jasemi SK, Hayati P, Javar HA, Izadi S, Izadi Z. Transformative artificial intelligence in gastric cancer: Advancements in diagnostic techniques. Comput Biol Med. 2024;183:109261.

121. Khosravi P, Fuchs TJ, Ho DJ. Artificial Intelligence-Driven Cancer Diagnostics: Enhancing Radiology and Pathology

through Reproducibility, Explainability, and Multimodality. Cancer Res. 2025;85(13):2356-67.

122. Kim SJ, Clark V, Hancock JT, Rawassizadeh R, Liu H, Taylor EA, et al. Leveraging artificial intelligence-mediated communication for cancer prevention and control and drug addiction: A systematic review. Transl Behav Med. 2025;15.(1)

123. Kotoulas SC, Spyratos D, Porpodis K, Domvri K, Boutou A, Kaimakamis E, et al. A Thorough Review of the Clinical Applications of Artificial Intelligence in Lung Cancer. Cancers (Basel). 2025;17.(5)

124. Krengli M, Kruszyna-Mochalska MM, Pasqualetti F, Malicki J. Can Advances in Artificial Intelligence Strengthen the Role of Intraoperative Radiotherapy in the Treatment of Cancer? Cancers (Basel). 2025;17.(19)

125. Kumar A, Goel S, Chaudhary A, Dutt S, Mishra VK, Kumar R. Artificial Intelligence-Based Wearable Sensing Technologies for the Management of Cancer, Diabetes, and COVID-19. Biosensors (Basel). 2025;15.(11)

126. Kumar Verma K. Artificial intelligence models for lung cancer diagnosis: A comprehensive review. Curr Probl Diagn Radiol. 2025.

127. Kuppanda PM, Janda M, Soyer HP, Caffery LJ. What Are Patients' Perceptions and Attitudes Regarding the Use of Artificial Intelligence in

Skin Cancer Screening and Diagnosis? Narrative Review. J Invest Dermatol. 2025;145(8):1858-65.

128. Lei C, Sun W, Wang K, Weng R, Kan X, Li R. Artificial intelligence-assisted diagnosis of early gastric cancer: present practice and future prospects. Ann Med. 2025;57(1):2461679.

129. Leonard S, Patel MA, Zhou Z, Le H, Mondal P, Adams SJ. Comparing Artificial Intelligence and Traditional Regression Models in Lung Cancer Risk Prediction Using A Systematic Review and Meta-Analysis. J Am Coll Radiol. 2025;22(6):675-90.

130. Leszczyńska A, Obuchowicz R, Strzelecki M, Seweryn M. The Integration of Artificial Intelligence into Robotic Cancer Surgery: A Systematic Review. J Clin Med. 2025;14.(17)

131. Li G, Shi Q, Wu Q, Sui X. Target identification of natural products in cancer with chemical proteomics and artificial intelligence approaches. Cancer Biol Med. 2025;22(6):549-97.

132. Li K, Wu S, Zhang Y, Zhu B, Qi Z, Hou S, et al. The Usability and Experience of Artificial Intelligence-Based Conversational Agents in Health Education for Cancer Patients: A Scoping Review. J Clin Nurs. 2025.

133. Li R, Li J, Wang Y, Liu X, Xu W, Sun R, et al. The artificial intelligence revolution in gastric cancer management: clinical applications. Cancer Cell Int. 2025;25(1):111.

134. Li W, Hu R, Zhang Q, Yu Z, Deng L, Zhu X, et al. Artificial intelligence in prostate cancer. Chin Med J (Engl). 2025;138(15):1769-82.

135. Liao W, Xu X. Progress in the application research of cervical cancer screening developed by artificial intelligence in large populations. Discov Oncol. 2025;16(1):1282.

136. Lin X, Zhang Z, Zhou T, Li J, Jin Q, Li Y, et al. The Role of Computed Tomography and Artificial Intelligence in Evaluating the Comorbidities of Chronic Obstructive Pulmonary Disease: A One-Stop CT Scanning for Lung Cancer Screening. Int J Chron Obstruct Pulmon Dis. 2025;20:1395-406.

137. Lin Y, Cheng M, Wu C, Huang Y, Zhu T, Li J, et al. MRI-based artificial intelligence models for post-neoadjuvant surgery personalization in breast cancer: a narrative review of evidence from Western Pacific. Lancet Reg Health West Pac. 2025;57:101254.

138. Liu J, Fu R, Su Y, Li Z, Huang X, Wang Q, et al. Applications of artificial intelligence in cancer immunotherapy: a frontier review on enhancing treatment efficacy and safety. Front Immunol. 2025;16:1676112.

139. Liu J, Zhang H, Woon DTS, Perera M, Lawrentschuk N. Predicting Biochemical Recurrence of Prostate Cancer Post-Prostatectomy Using Artificial Intelligence: A Systematic Review. Cancers (Basel). 2024;16.(21)

140. Liu JY, Sun RH, Li C. [Advances in the application of artificial intelligence technology in the surgical diagnosis and treatment of thyroid cancer]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2025;60(1):80-6.

141. Liu L, Pei Q, Qadir J, Chen Y, Li J, Luo Y, et al. Application of artificial intelligence-based stemness index in cancer. Front Oncol. 2025;15:1608712.

142. Liu M, Li L, Rais-Bahrami S, Hemal AK, Atala A, Zhang Y. Artificial intelligence in prostate cancer: navigating the new frontier of precision uro-oncology. Am J Clin Exp Urol. 2025;13(5):348-59.

143. Lococo F, Ghaly G, Flamini S, Campanella A, Chiappetta M, Bria E, et al. Artificial intelligence applications in personalizing lung cancer management: state of the art and future perspectives. J Thorac Dis. 2024;16(10):7096-110.

144. Long X, Sun K, Lai S, Liu Y, Su J, Chen W, et al. Artificial intelligence and anti-cancer drugs' response. Acta Pharm Sin B. 2025;15(7):3355-71.

145. Luan WY, Zhao Q, Zhang Z, Xu ZX, Lin SX, Miao YD. Multidimensional decoding of colorectal cancer heterogeneity: Artificial intelligence-enabled precision exploration of single-cell and spatial transcriptomics. World J Gastrointest Oncol. 2025;17(10):110661.

146. Lukac S, Putz F, De Micheli G, Corti C,

Janni W, Tolaney SM, et al. Artificial intelligence as treatment support in breast cancer: current perspectives. Breast. 2025;83:104564.

147. Lv M, Chen F, Li Q, Xue M, Wang J. Comparative diagnostic accuracy of different artificial intelligence models for early gastric cancer: a systematic review and meta-analysis. Front Oncol. 2025;15:1670843.

148. Ma X, Zhang Q, He L, Liu X, Xiao Y, Hu J, et al. Artificial intelligence application in the diagnosis and treatment of bladder cancer: advance, challenges, and opportunities. Front Oncol. 2024;14:1487676.

149. Macheka S, Ng PY, Ginsburg O, Hope A, Sullivan R, Aggarwal A. Prospective evaluation of artificial intelligence (AI) applications for use in cancer pathways following diagnosis: a systematic review. BMJ Oncol. 2024;3(1):e000255.

150. Maggi M, Chierigo F, Fallara G, Jannello LMI, Tozzi M, Pellegrino F, et al. Shaping the Future of Personalized Therapy in Bladder Cancer Using Artificial Intelligence. Eur Urol Focus. 2025.

151. Mănuc M, Duței CA, Mănuc TE, Chifulescu AE, Grama FA. Could artificial intelligence-powered colonoscopies change the future of colorectal cancer screening? World J Gastroenterol. 2025;31(42):111291.

152. Marouf AA, Rokne JG, Alhajj R. Integrating Multi-Omics and Medical Imaging in Artificial

Intelligence-Based Cancer Research: An Umbrella Review of Fusion Strategies and Applications. Cancers (Basel). 2025;17.(22)

153. Martella S, Cusumano G, Senevirathne TH, Stylianakis D, Palmas E, Denaro N, et al. Evolutionary Overview and Future Perspectives: ESR1 Mutations, Liquid Biopsy, and Artificial Intelligence for a New Era of Personalized Medicine in ER+ Breast Cancer. Mol Diagn Ther. 2025;29(6):773-87.

154. Mashekova A, Zhao MY, Zarikas V, Mukhmetov O, Aidossov N, Ng EYK, et al. Review of Artificial Intelligence Techniques for Breast Cancer Detection with Different Modalities: Mammography, Ultrasound, and Thermography Images. Bioengineering (Basel). 2025;12.(10)

155. Mastella E, Calderoni F, Manco L, Ferioli M, Medoro S, Turra A, et al. A systematic review of the role of artificial intelligence in automating computed tomography-based adaptive radiotherapy for head and neck cancer. Phys Imaging Radiat Oncol. 2025;33:100731.

156. Mastroleo F, Marvaso G, Jereczek-Fossa BA. Artificial intelligence in muscle-invasive bladder cancer: opportunities, challenges, and clinical impact. Curr Opin Urol. 2025;35(5):543-8.

157. Megat Ramli PN, Aizuddin AN, Ahmad N, Abdul Hamid Z, Ismail KI. A Systematic Review: The Role of Artificial Intelligence in Lung Cancer

Screening in Detecting Lung Nodules on Chest X-Rays. Diagnostics (Basel). 2025;15.(3)

158. Mehri-Kakavand G, Mdletshe S, Wang A. A Comprehensive Review on the Application of Artificial Intelligence for Predicting Postsurgical Recurrence Risk in Early-Stage Non-Small Cell Lung Cancer Using Computed Tomography, Positron Emission Tomography, and Clinical Data. J Med Radiat Sci. 2025;72(3):280-96.

159. Mela E, Tsapralis D, Papaconstantinou D, Sakarellos P, Vergadis C, Klontzas ME, et al. Current Role of Artificial Intelligence in the Management of Esophageal Cancer. J Clin Med. 2025;14.(6)

160. Miao KH, Miao JH, Finkelstein M, Chatterjee A, Oto A. Next-Generation Advances in Prostate Cancer Imaging and Artificial Intelligence Applications. J Imaging. 2025;11.(11)

161. Migliorelli A, Manuelli M, Ciorba A, Stomeo F, Pelucchi S, Bianchini C. Role of Artificial Intelligence in Human Papillomavirus Status Prediction for Oropharyngeal Cancer: A Scoping Review. Cancers (Basel). 2024;16.(23)

162. Mirfendereski P, Li GY, Pearson AT, Kerr AR. Artificial intelligence and the diagnosis of oral cavity cancer and oral potentially malignant disorders from clinical photographs: a narrative review. Front Oral Health. 2025;6:1569567.

163. Mishra A, Sharma S, Pandey SK. The Present State and Potential Applications of

Artificial Intelligence in Cancer Diagnosis and Treatment. Recent Pat Anticancer Drug Discov. 2025;20(3):287-305.

164. Moglia V, Johnson O, Cook G, de Kamps M, Smith L. Artificial intelligence methods applied to longitudinal data from electronic health records for prediction of cancer: a scoping review. BMC Med Res Methodol. 2025;25(1):24.

165. Montazer F, Mehdikhani B, Noroozi N, Nezameslami R, Nezameslami A, Shahbazi A, et al. GPU-Accelerated Artificial Intelligence Applications in Cancer Diagnosis, Imaging, and Treatment Planning. Asian Pac J Cancer Prev. 2025;26(8):2725-39.

166. Moradi Kashkooli F, Bhandari A, Gu B, Kolios MC, Kohandel M, Zhan W. Multiphysics modelling enhanced by imaging and artificial intelligence for personalised cancer nanomedicine: Foundations for clinical digital twins. J Control Release. 2025;386:114138.

167. Morelli I, Banini M, Greto D, Visani L, Garlatti P, Loi M, et al. Integrating Radiomics and Artificial Intelligence (AI) in Stereotactic Body Radiotherapy (SBRT)/Stereotactic Radiosurgery (SRS): Predictive Tools for Tailored Cancer Care. Cancers (Basel). 2025;17.(17)

168. Murray K, Oldfield L, Stefanova I, Gentiluomo M, Aretini P, O'Sullivan R, et al. Biomarkers, omics and artificial intelligence for

early detection of pancreatic cancer. Semin Cancer Biol. 2025;111:76-88.

169. Mushcab H, Al Ramis M, AlRujaib A, Eskandarani R, Sunbul T, AlOtaibi A, et al. Application of Artificial Intelligence in Cardio-Oncology Imaging for Cancer Therapy-Related Cardiovascular Toxicity: Systematic Review. JMIR Cancer. 2025;11:e63964.

170. Naderian S, Soleimanzadeh F, Nikniaz L, Sanaie S, Sadeghi-Ghyassi F, Samad-Soltani T. A Systematic Review of Artificial Intelligence-Based Clinical Decision Support Systems in Prostate Cancer Management. Healthc Technol Lett. 2025;12(1):e70026.

171. Naemi A, Tashk A, Sorayaie Azar A, Samimi T, Tavassoli G, Bagherzadeh Mohasefi A, et al. Applications of Artificial Intelligence for Metastatic Gastrointestinal Cancer: A Systematic Literature Review. Cancers (Basel). 2025;17.(3)

172. Najar Najafi N, Hajihassani H, Azimzadeh Irani M. The Impact of Artificial Intelligence on Cancer Diagnosis and Treatment: A Review. Cancer Inform. 2025;24:11769351251371273.

173. Nasr E, Al-Hamid Z, Younan MH, Omran M, Sarsam M, Abdellatif M. Modernizing Colorectal Cancer Care With Artificial Intelligence: Real-Time Detection, Radiomics, and Digital Pathology. Cureus. 2025;17(10):e95178.

174. Nayana M, Avinash J, Jayachandra MY,

Bhat PK, Kumar S, Bhuyan L. Diagnostic Accuracy of Artificial Intelligence in Detecting Oral Potentially Malignant Disorders and Oral Cancer: A Meta-Analysis of Imaging-Based Studies (2015-2024). J Int Soc Prev Community Dent. 2025;15(5):391-401.

175. Ng XJK, Mohd Khairuddin AS, Liu HC, Loh TC, Tan JL, Khor SM, et al. Artificial intelligence-assisted point-of-care devices for lung cancer. Clin Chim Acta. 2025;570:120191.

176. Nguyen MH, Le MHN, Bui AT, Le NQK. Artificial intelligence in predicting EGFR mutations from whole slide images in lung Cancer: A systematic review and Meta-Analysis. Lung Cancer. 2025;204:108577.

177. Nguyen THT, Jeon S, Yoon J, Park B. Global mapping of artificial intelligence applications in breast cancer from 1988-2024: a machine learning approach. Breast Cancer. 2025;32(6):1244-54.

178. Ni HM, Kouzy R, Sabbagh A, Rooney MK, Feng J, Castillo SP, et al. The state of the art in artificial intelligence and digital pathology in prostate cancer. Nat Rev Urol. 2025.

179. Noei Teymoordash S, Zendehdel H, Norouzi AR, Kashian M. Diagnostic accuracy of artificial intelligence algorithms to predict remove all macroscopic disease and survival rate after complete surgical cytoreduction in patients with ovarian cancer: a systematic review and meta-

analysis. BMC Surg. 2025;25(1):27.

180. Norouzkhani N, Mobaraki H, Varmazyar S, Zaboli H, Mohamadi Z, Nikeghbali G, et al. Artificial intelligence networks for assessing the prognosis of gastrointestinal cancer to immunotherapy based on genetic mutation features: a systematic review and meta-analysis. BMC Gastroenterol. 2025;25(1):310.

181. Novellino T, Masciocchi C, Tudor AM, Casà C, Chiloiro G, Romano A, et al. Artificial Intelligence and Rectal Cancer: Beyond Images. Cancers (Basel). 2025;17.(13)

182. O'Connor O, McVeigh TP. Increasing use of artificial intelligence in genomic medicine for cancer care- the promise and potential pitfalls. BJC Rep. 2025;3(1):20.

183. O'Dowling AT, Rodriguez BJ, Gallagher TK, Thorpe SD. Machine learning and artificial intelligence: Enabling the clinical translation of atomic force microscopy-based biomarkers for cancer diagnosis. Comput Struct Biotechnol J. 2024;24:661-71.

184. Ohannesian VA, Falcão L, Ishizuka BM, Menezes IR, Han ML, Suruagy-Motta RFO, et al. The diagnostic accuracy of artificial intelligence models in detecting lymph node metastases in lung cancer using endobronchial ultrasound (EBUS) images: A bivariate meta-analysis. Clin Imaging. 2025;128:110633.

185. Oldan JD, Anugu A, Islam MZ, Amindarolzarbi A, Werner RA, Pomper MG, et al. Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types. Diagn Interv Imaging. 2025;106(12):413-20.

186. Paiboonborirak C, Abu-Rustum NR, Wilailak S. Artificial intelligence in the diagnosis and management of gynecologic cancer. Int J Gynaecol Obstet. 2025;171 Suppl 1(Suppl 1):199-209.

187. Pallumeera M, Giang JC, Singh R, Pracha NS, Makary MS. Evolving and Novel Applications of Artificial Intelligence in Cancer Imaging. Cancers (Basel). 2025;17.(9)

188. Patil MR, Bihari A. Role of artificial intelligence in cancer detection using protein p53: A Review. Mol Biol Rep. 2024;52(1):46.

189. Pawar M, Pingale S, Kadam K, Jadhav A, Kaul-Ghanekar R. Artificial intelligence-driven screening, early diagnosis, and treatment strategies for cervical cancer: an overview. Infect Agent Cancer. 2025.

190. Pesapane F, Nicosia L, D'Amelio L, Quercioli G, Pannarale MR, Priolo F, et al. Artificial Intelligence-Driven Personalization in Breast Cancer Screening: From Population Models to Individualized Protocols. Cancers (Basel). 2025;17.(17)

191. Pfob A, Pinker K, Vaz-Luis I, Di Meglio A, Cardoso MJ, Curigliano G, et al. The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer-a multidisciplinary consensus. Lancet Oncol. 2025;26(12):e694-e706.

192. Pham TD, Teh MT, Chatzopoulou D, Holmes S, Coulthard P. Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions. Curr Oncol. 2024;31(9):5255-90.

193. Picchio V, Pontecorvi V, Dhori X, Bordin A, Floris E, Cozzolino C, et al. The emerging role of artificial intelligence applied to exosome analysis: from cancer biology to other biomedical fields. Life Sci. 2025;375:123752.

194. Pourakbar N, Motamedi A, Pashapour M, Sharifi ME, Sharabiani SS, Fazlollahi A, et al. Effectiveness of Artificial Intelligence Models in Predicting Lung Cancer Recurrence: A Gene Biomarker-Driven Review. Cancers (Basel). 2025;17.(11)

195. Pourmadadi M, Shabestari SM, Abdouss H, Rahdar A, Fathi-Karkan S, Pandey S. Artificial intelligence-driven intelligent nanocarriers for cancer theranostics: A paradigm shift with focus on brain tumors. Semin Oncol. 2025;52(6):152429.

196. Pramatya SH, Sastri DM, Kencono Wungu

CD, Setiawan HW, Amin IM, Zufar MF, et al. The future of immunotherapy: Can artificial intelligence predict the survival of lung cancer patients? A systematic review and meta-analysis. Respir Med. 2025;250:108492.

197. Purohit L, Kiamos A, Ali S, Alvarez-Pinzon AM, Raez L. Incidental Pulmonary Nodule (IPN) Programs Working Together with Lung Cancer Screening and Artificial Intelligence to Increase Lung Cancer Detection. Cancers (Basel). 2025;17.(7)

198. Ramchandani R, Guo E, Biglou SG, Sabbah SG, Mostowy M, Mahiny D, et al. Representation and Bias in Artificial Intelligence Models for Thyroid Cancer: A Systematic Review. Thyroid. 2025.

199. Ramírez LVH, Forero HE, Grosso MPN, Rincón EHH. Advances in artificial intelligence for the early detection of cervical cancer in adult women: a scoping review. Rev Bras Ginecol Obstet. 2025;47.

200. Ramos R, Moura CS, Costa M, Lamas NJ, Castro LPE, Correia R, et al. Heterogeneity of Lung Cancer: The Histopathological Diversity and Tumour Classification in the Artificial Intelligence Era. Pathobiology. 2025;92(4):239-50.

201. Ran D, Li J, Zhao M, Du L, Zhang Y, Zhu J. Artificial intelligence integrates multi-omics data for precision stratification and drug

resistance prediction in breast cancer. Front Oncol. 2025;15:1612474.

202. Riaz IB, Khan MA, Osterman TJ. Artificial intelligence across the cancer care continuum. Cancer. 2025;131(16):e70050.

203. Rizkala T, Menini M, Massimi D, Repici A. Role of Artificial Intelligence for Colon Polyp Detection and Diagnosis and Colon Cancer. Gastrointest Endosc Clin N Am. 2025;35(2):389-400.

204. Roche JJ, Seyedshahi F, Rakovic K, Thu AW, Le Quesne J, Blyth KG. Current and future applications of artificial intelligence in lung cancer and mesothelioma. Thorax. 2025;80(12):957-65.

205. Rodriguez NG, Mercado NC, Panjiyar K, Kunwor R. Artificial intelligence versus radiologists in predicting lung cancer treatment response: a systematic review and meta-analysis. Front Oncol. 2025;15:1634694.

206. Romeo M, Dallio M, Napolitano C, Basile C, Di Nardo F, Vaia P, et al. Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)? Diagnostics (Basel). 2025;15.(3)

207. Ruini C. [In vivo reflectance confocal microscopy and keratinocyte skin cancer : Reflectance confocal microscopy and

artificial intelligence]. Dermatologie (Heidelb). 2025;76(11):688-96.

208. Safarian A, Mirshahvalad SA, Nasrollahi H, Jung T, Pirich C, Arabi H, et al. Impact of [(18)F]FDG PET/CT Radiomics and Artificial Intelligence in Clinical Decision Making in Lung Cancer: Its Current Role. Semin Nucl Med. 2025;55(2):156-66.

209. Sahoo K, Lingasamy P, Khatun M, Sudhakaran SL, Salumets A, Sundararajan V, et al. Artificial Intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine. Epigenetics Chromatin. 2025;18(1):35.

210. Sahoo RK, Sahoo KC, Dash GC, Kumar G, Baliarsingh SK, Panda B, et al. Diagnostic performance of artificial intelligence in detecting oral potentially malignant disorders and oral cancer using medical diagnostic imaging: a systematic review and meta-analysis. Front Oral Health. 2024;5:1494867.

211. Salama V, Godinich BM, Lilly PM, Pifer PM, Duckworth AL, Hall SJ, et al. Artificial Intelligence and Machine Learning in Sexual Health and Dysfunction Across the Cancer Care Continuum: A Systematic Review. Cancers (Basel). 2025;17.(18)

212. Samathoti P, Kumarachari RK, Bukke SPN, Rajasekhar ESK, Jaiswal AA, Eftekhari Z. The role of nanomedicine and artificial intelligence in cancer health care: individual applications and

emerging integrations-a narrative review. Discov Oncol. 2025;16(1):697.

213. Sampieri C, Peretti G. Democratizing cancer detection: artificial intelligence-enhanced endoscopy could address global disparities in head and neck cancer outcomes. Eur Arch Otorhinolaryngol. 2025;282(5):2739-43.

214. Sarvepalli S, Vadarevu S. Role of artificial intelligence in cancer drug discovery and development. Cancer Lett. 2025;627:217821.

215. Scalia IG, Pathangey G, Abdelnabi M, Ibrahim OH, Abdelfattah FE, Pietri MP, et al. Applications of Artificial Intelligence for the Prediction and Diagnosis of Cancer Therapy-Related Cardiac Dysfunction in Oncology Patients. Cancers (Basel). 2025;17.(4)

216. Schito L, Rey-Keim S. Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence. Trends Cancer. 2025;11(2):88-90.

217. Šebestová G, Klinger T, Švajdler M, Jr., Daum O, Jirásek T. Utilization of Artificial Intelligence Algorithms for the Diagnosis of Breast, Lung, and Prostate Cancer. Cesk Patol. 2025;61(2):70-90.

218. Selvaraj C, Cho WC, Langeswaran K, Alothaim AS, Vijayakumar R, Jayaprakashvel M, et al. Artificial intelligence in cancer care: revolutionizing diagnosis, treatment, and

precision medicine amid emerging challenges and future opportunities. 3 Biotech. 2025;15(10):355.

219. Seth L, Ladbury C, Amini A. Artificial Intelligence and Machine Learning Approaches in Designing Immunotherapy in Cancer. Cancer Treat Res. 2025;129:17-32.

220. Sguanci M, Palomares SM, Cangelosi G, Petrelli F, Sandri E, Ferrara G, et al. Artificial Intelligence in the Management of Malnutrition in Cancer Patients: A Systematic Review. Adv Nutr. 2025;16(7):100438.

221. Shahzad K, Abu-Zanona M, Elzaghmouri BM, AbdelRahman SM, Fadol Osman AA, Al-Khateeb A, et al. USING ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING APPROACHES TO ENHANCE CANCER THERAPY AND DRUG DISCOVERY: A NARRATIVE REVIEW. J Ayub Med Coll Abbottabad. 2024;36(1):183-9.

222. Shaktah LA, Carrero ZI, Hewitt KJ, Gustav M, Cecchini M, Foersch S, et al. Application of artificial intelligence and digital tools in cancer pathology. Lancet Digit Health. 2026:100933.

223. Shen K, Tan M, Liu Y, Xu X, Yang S. From data to Diagnosis: How artificial intelligence is revolutionizing preoperative assessment of thyroid nodules and cancer. Eur J Surg Oncol. 2025;51(9):110191.

224. Shi J, Chen J, He G, Peng Q. Artificial intelligence in high-dose-rate brachytherapy

treatment planning for cervical cancer: a review. Front Oncol. 2025;15:1507592.

225. Shirzad M, Salahvarzi A, Razzaq S, Javid-Naderi MJ, Rahdar A, Fathi-Karkan S, et al. Revolutionizing prostate cancer therapy: Artificial intelligence - Based nanocarriers for precision diagnosis and treatment. Crit Rev Oncol Hematol. 2025;208:104653.

226. Silveira JA, da Silva AR, de Lima MZT. Harnessing artificial intelligence for predicting breast cancer recurrence: a systematic review of clinical and imaging data. Discov Oncol. 2025;16(1):135.

227. Silvestre-Barbosa Y, Castro VT, Di Carvalho Melo L, Reis PED, Leite AF, Ferreira EB, et al. Worldwide research trends on artificial intelligence in head and neck cancer: a bibliometric analysis. Oral Surg Oral Med Oral Pathol Oral Radiol. 2025;140(1):64-78.

228. Smiley A, Reategui-Rivera CM, Villarreal-Zegarra D, Escobar-Agreda S, Finkelstein J. Exploring Artificial Intelligence Biases in Predictive Models for Cancer Diagnosis. Cancers (Basel). 2025;17.(3)

229. Soghli N, Khormali A, Mahboubi D, Peng A, Miguez PA. Recent advancements in artificial intelligence-powered cancer prediction from oral microbiome. Periodontol 2000. 2025.

230. Song B, Liang R. Integrating artificial

intelligence with smartphone-based imaging for cancer detection in vivo. Biosens Bioelectron. 2025;271:116982.

231. Song J, Gao Y, Liu W, Sun X, Chen C, Wu IX. Effectiveness of Artificial Intelligence-Assisted Examination for Cancer Detection in Medical Imaging: A Systematic Review and Meta-Analysis. J Am Coll Radiol. 2025.

232. Stevenson E, Esengur OT, Zhang H, Simon BD, Harmon SA, Turkbey B. An overview of utilizing artificial intelligence in localized prostate cancer imaging. Expert Rev Med Devices. 2025;22(4):293-310.

233. Sultany A, Chikatimalla R, Rao A, Omar MA, Shaar A, Ali H, et al. Real-Time Artificial Intelligence Versus Standard Colonoscopy in the Early Detection of Colorectal Cancer: A Systematic Review and Meta-Analysis. Healthcare (Basel). 2025;13.(19)

234. Sun K, Wang Y, Qu R, Yang Q, Luo R, Jiang Z, et al. Comprehensive application of artificial intelligence in colorectal cancer: A review. iScience. 2025;28(7):112980.

235. Sun L, Zhang R, Gu Y, Huang L, Jin C. Application of Artificial Intelligence in the diagnosis and treatment of colorectal cancer: a bibliometric analysis, 2004-2023. Front Oncol. 2024;14:1424044.

236. Sun Y, Guo X, Liu X, Liu H, Wang

X. Advances in artificial intelligence-based radiogenomics for lung cancer precision medicine. Prog Biomed Eng (Bristol). 2025;8.(1)

237. Tabataba Vakili S, Haywood D, Kirk D, Abdou AM, Gopalakrishnan R, Sadeghi S, et al. Application of Artificial Intelligence in Symptom Monitoring in Adult Cancer Survivorship: A Systematic Review. JCO Clin Cancer Inform. 2024;8:e2400119.

238. Taha HA, Zeilani RS, Haddad RH, Abdalrahim MS. Artificial intelligence and machine learning techniques for predicting neuropathic pain in patients with cancer: A systematic review. Digit Health. 2025;11:20552076251358315.

239. Takahashi T, Kobayashi Y, Sakurai R, Matsuoka K, Akatsuka J, Kisu I, et al. A Systematic Review of the Application of Artificial Intelligence in Colposcopy: Diagnostic Accuracy for Cervical Intraepithelial Neoplasia and Cervical Cancer. Clin Med Insights Oncol. 2025;19:11795549251374908.

240. Takamatsu M. Transforming histologic assessment: artificial intelligence in cancer diagnosis and personalized treatment. Br J Cancer. 2025.

241. Tang C, Xu Z, Duan H, Zhang S. Advancements in artificial intelligence for ultrasound diagnosis of ovarian cancer:

a comprehensive review. Front Oncol. 2025;15:1581157.

242. Tang X, Zhou H, Liu Y, Gao S, Zhou Y. Diagnostic performance of the ultrasound -based artificial intelligence diagnostic system in predicting cervical lymph node metastasis in patients with thyroid cancer: A systematic review and meta-analysis. Sci Prog. 2025;108(2):368504251346906.

243. Tarhini AA, Dave P, El Naqa I. General artificial intelligence for the diagnosis and treatment of cancer: the rise of foundation models. BJR Artif Intell. 2025;2(1):ubaf015.

244. Tayyil Purayil AL, Joseph RM, Raj A, Kooriyattil A, Jabeen N, Beevi SF, et al. Role of Artificial Intelligence in MRI-Based Rectal Cancer Staging: A Systematic Review. Cureus. 2024;16(12):e76185.

245. Thalambedu N, Balla M, Sivasubramanian BP, Sadaram P, Malla KP, Vasipalli KP, et al. Integrating artificial intelligence with circulating tumor DNA for non-small cell lung cancer: opportunities, challenges, and future directions. Front Med (Lausanne). 2025;12:1612376.

246. Tiwari A, Ghose A, Hasanova M, Faria SS, Mohapatra S, Adeleke S, et al. The current landscape of artificial intelligence in computational histopathology for cancer diagnosis. Discov Oncol. 2025;16(1):438.

247. Toumaj S, Heidari A, Jafari Navimipour N. Leveraging explainable artificial intelligence for transparent and trustworthy cancer detection systems. Artif Intell Med. 2025;169:103243.

248. Tun HM, Rahman HA, Naing L, Malik OA. Artificial intelligence utilization in cancer screening program across ASEAN: a scoping review. BMC Cancer. 2025;25(1):703.

249. Uchikov P, Khalid U, Dedaj-Salad GH, Ghale D, Rajadurai H, Kraeva M, et al. Artificial Intelligence in Breast Cancer Diagnosis and Treatment: Advances in Imaging, Pathology, and Personalized Care. Life (Basel). 2024;14.(11)

250. Urso L, Badrane I, Manco L, Castello A, Lancia F, Collavino J, et al. The Role of Radiomics and Artificial Intelligence Applied to Staging PSMA PET in Assessing Prostate Cancer Aggressiveness. J Clin Med. 2025;14.(10)

251. Usmani S, Al Riyami K, Kheruka S, Numani SP, Al Sukaiti R, Ahmed M, et al. Deep learning (DL)-based advancements in prostate cancer imaging: Artificial intelligence (AI)-based segmentation of (68)Ga-PSMSA PET for tumor volume assessment. Precis Radiat Oncol. 2025;9(2):120-32.

252. Utti V, Bikia V, Agarwal AA, Daneshjou R. Integrating Artificial Intelligence in Dermatological Cancer Screening and Diagnosis: Efficacy, Challenges, and Future Directions. Annu Rev Biomed Data Sci. 2025;8(1):591-603.

253. Uwimana A, Gnecco G, Riccaboni M. Artificial intelligence for breast cancer detection and its health technology assessment: A scoping review. Comput Biol Med. 2025;184:109391.

254. Vardasca R, Mendes JG, Magalhaes C. Skin Cancer Image Classification Using Artificial Intelligence Strategies: A Systematic Review. J Imaging. 2024;10.(11)

255. Vasquez VM, Jr., McCabe M, McKee JC, Siby S, Hussain U, Faizuddin F, et al. Transforming Cancer Care: A Narrative Review on Leveraging Artificial Intelligence to Advance Immunotherapy in Underserved Communities. J Clin Med. 2025;14.(15)

256. Verma H, Mistry S, Jayam KV, Shrestha P, Adkins L, Liang M, et al. Artificial Intelligence in Oncology: A 10-Year ClinicalTrials.gov-Based Analysis Across the Cancer Control Continuum. Cancers (Basel). 2025;17.(21)

257. Vidiyala N, Parupathi P, Sunkishala P, Muppavarapu CS, Gujja A, Kanagala P, et al. Artificial intelligence: a new era in prostate cancer diagnosis and treatment. Int J Pharm. 2025;683:126024.

258. Vinay V, Jodalli P, Chavan MS, Buddhikot CS, Luke AM, Ingafou MSH, et al. Artificial Intelligence in Oral Cancer: A Comprehensive Scoping Review of Diagnostic and Prognostic Applications. Diagnostics (Basel). 2025;15.(3)

259. Viviana Cortlana M, Kennedy Itodo B, Yan Leyfman M, Jenna Ghazal B, Vraj JigarKumar Rangrej M, Adhith T, et al. Artificial Intelligence in Cancer Care: Addressing Challenges and Health Equity. Oncology (Williston Park). 2025;39(3):105-10.

260. Vyas A, Kumar K, Sharma A, Verma D, Bhatia D, Wahi N, et al. Advancing the frontier of artificial intelligence on emerging technologies to redefine cancer diagnosis and care. Comput Biol Med. 2025;191:110178.

261. Farrokhi M, Taheri F, Moeini A, Farrokhi M, Rabiei S, Farahmandsadr M, et al. Sex and gender differences in the pathogenesis and treatment of diseases. Kindle. 2023;3(1):1-168.

262. Karimian S, Taheri F, Farrokhi M, Farrokhi M, Bayat Z, Zadeh SAM, et al. Digital Health and Wearable Technologies. Kindle. 2024;4(1):1-240.

263. Taheri F, Farrokhi M, Fard AM, Rahmani E, Soltani R, Shamsedanesh S, et al. Role of Micronutrients and Nutrition in Prevention and Treatment of Cancers. Kindle. 2023;3(1):1-102.

264. Farrokhi M, Taheri F, Farrokhi M, Tosi YEK, Ghadirzadeh E, Bagheri M, et al. Nanomedicine: Technologies and Applications. Kindle. 2024;4(1):1-196.

265. Motavaselian M, Farrokhi M, Khouzani PJ, Fard AM, Daeizadeh F, Pourrahimi M, et al. Diagnostic performance of ultrasonography

for identification of small bowel obstruction; a systematic review and meta-analysis. Archives of Academic Emergency Medicine. 2024;12(1):e33.

266. Rahmani E, Amani-Beni R, Hekmatnia Y, Yaseri AF, Ahadiat S-A, Boroujeni PT, et al. Diagnostic accuracy of ultrasonography for detection of intussusception in children; a systematic review and Meta-Analysis. Archives of Academic Emergency Medicine. 2023;11(1):e24.

267. Farrokhi M, Moeini A, Taheri F, Farrokhi M, Khodashenas M, Babaei M, et al. AI-assisted Screening and Prevention Programs for Diseases. Kindle. 2023;3(1):1-209.

268. Rahmani E, Bayat Z, Farrokhi M, Karimian S, Zahedpasha R, Sabzehie H, et al. Monkeypox: a comprehensive review of virology, epidemiology, transmission, diagnosis, prevention, treatment, and artificial intelligence applications. Archives of Academic Emergency Medicine. 2024;12(1):e70.

269. Shayganfar A, Farrokhi M, Shayganfar S, Ebrahimian S. Associations between bone mineral density, trabecular bone score, and body mass index in postmenopausal females. Osteoporosis and sarcopenia. 2020;6(3):111-4.

270. Farrokhi M, Yarmohammadi B, Mangouri A, Hekmatnia Y, Bahramvand Y, Kiani M, et al. Screening performance characteristics of ultrasonography in confirmation of endotracheal intubation; a systematic review and meta-

analysis. Archives of Academic Emergency Medicine. 2021;9(1):e68.

271. Rahmani E, Fayyazishishavan E, Afzalian A, Varshochi S, Amani-Beni R, Ahadiat S-A, et al. Point-of-care ultrasonography for identification of skin and soft tissue abscess in adult and pediatric patients; a systematic review and meta-analysis. Archives of Academic Emergency Medicine. 2023;11(1):e49.

272. Kazemi S-M, Khorram R, Fayyazishishavan E, Amani-Beni R, Haririan Y, Khameneh SMH, et al. Diagnostic Accuracy of Ottawa Knee Rule for Diagnosis of Fracture in Patients with Knee Trauma; a Systematic Review and Meta-analysis. Archives of Academic Emergency Medicine. 2023;11(1):e30.

Proof